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Vaccination is one of the greatest public health achievements of the last century. 
However, vaccine uptake rates worldwide remain sub-optimal. The vaccine 
decision-making process is complex and multifaceted and multiple barriers to 
vaccine uptake have already been identified. However, these barriers are highly 
variable and context specific. Therefore, there is an urgent need to identify and 
address the factors contributing to decreasing vaccine uptake in Ireland. 
Aim 
The aim of this doctoral research was to explore vaccine decision-making in order 
to identify, and address, barriers to vaccine uptake in Ireland. 
Methods 
Multiple approaches were used to address this aim. A comprehensive literature 
review, and subsequent qualitative research, involving parents sought to 
understand if and how microneedle technology could impact vaccine decision-
making and vaccine uptake. In addition, a systematic review and meta-
ethnographic synthesis of the qualitative literature and a series of qualitative 
studies, involving both adolescents and parents, sought to gain an insight into the 
HPV vaccine decision-making process, to identify barriers to vaccine uptake. This 
culminated in the development and evaluation of a theory and evidence-based 





The vaccine decision-making process was explored qualitatively, in a series of 
studies, involving multiple stakeholders. Factors such as perception of disease risk, 
trust in healthcare system, and to a lesser extent, knowledge, interact to impact 
vaccine decision-making, in the midst of variable, yet omnipresent vaccine safety 
concerns.  
Conclusion 
This thesis has provided a comprehensive overview of vaccine decision-making and 
has identified the barriers to vaccine uptake perceived by key stakeholders. These 
identified barriers may be addressed by policy-makers and vaccinators, to enhance 
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Vaccination is one of the greatest public health achievements of the last century 
and is estimated to save up to three million lives per annum worldwide [6]. 
According to the World Health Organisation (WHO) a vaccine is a biological 
preparation that improves immunity to a particular disease [7]. Vaccines act by 
initiating an innate immune response, which in turn activates an antigen-specific, 
adaptive immune response [8]. The latter is characterised by a diverse set of 
specialised cells known as lymphocytes which recognise and eliminate the pathogen 
[8]. The antigens contained in a vaccine can induce cell-mediated immunity by 
activating specific subsets of T lymphocytes, and humoral immunity by stimulating 
antibody production by B lymphocytes [8]. These antibodies persist in circulation 
and memory B cells are generated, that can rapidly and more efficiently reactivate 
upon subsequent exposure to repeat antigenic challenge [8]. This immunological 
memory, mediated by B and T cells, is the basis of long term protection and the 
goal of vaccination [9].  
Vaccination is often regarded as an individual intervention with a wider public 
health impact [10]. By vaccinating one individual, protection can be conferred to a 
wider group, through the phenomenon of ‘herd effect’: the indirect protection of 
unvaccinated individuals, whereby an increase in the prevalence of vaccine 
immunity prevents circulation of pathogens in unvaccinated, susceptible 
populations [11, 12]. There are several groups within society that cannot be safely 
or effectively vaccinated (e.g. infants, immunocompromised, and 
immunosuppressed) [13]. The most effective mode in which these vulnerable 
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individuals can be protected against common infections is through herd protection, 
achieved by high vaccination rates. The threshold required for herd immunity varies 
by disease, but it typically ranges between 80 and 90% vaccination of the target 
population [14, 15].  
Vaccines are generally divided into three main types: live attenuated, inactivated, 
and subunit [16]. Live attenuated vaccines contain pathogens that have been 
weakened, altered or selected to be less virulent than their wild-type counterparts 
[9]. Examples of live attenuated vaccines include; rabies, measles, mumps, 
tuberculosis, yellow fever and vaccinia virus, the latter arguably the most successful 
human vaccine to date, resulting in the eradication of smallpox in 1980 [16, 17]. 
These are highly immunogenic and can induce memory with minimal doses. 
Inactivated vaccines, as the name suggests, are produced by inactivating 
preparations of whole pathogens by heat, radiation, or chemical treatment (e.g. 
formaldehyde). This process destroys the pathogen’s ability to replicate and cause 
disease, but maintains its immunogenicity [9]. Examples of inactivated vaccines 
include typhoid, cholera, plague, whole-cell pertussis (WCP), rabies and hepatitis A 
[9, 16]. Some of these vaccines, such as WCP, are highly immunogenic as they 
retain all of the immune stimulating proteins contained in the virulent form of the 
microbe. Finally, subunit vaccines contain selected fragments of the pathogens, 
presented as antigens. Antigenic fragments include proteins, toxoids, virus-like 
particles (VLP), polysaccharides, and polysaccharide conjugates [9]. Examples of 
subunit vaccines include tetanus toxoid, inactivated split and subunit influenza, 
acellular pertussis, pneumococcal polysaccharide, and VLP human papillomavirus 
(HPV) vaccines [9]. Subunit vaccines require immune stimulants or adjuvants, to 
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enhance the magnitude and duration of the immune response. As the majority of 
childhood vaccines are of the subunit variant, multiple doses are required to 
generate sufficient immunity to disease and may require periodic booster doses to 
counter waning immunity over time. The seasonal influenza vaccine is unique in 
that it requires repeated annual dosing due to changes in circulating pathogens 
each year (i.e. antigenic shift and drift [18]).  
1.2 Immunisation in Ireland 
The substantial protection offered by vaccination has led to recommendations for 
routine immunisation from birth to old age. In Ireland, the Health Service Executive 
(HSE) is responsible for the implementation of the primary childhood and school 
immunisation programmes, outlined in Table 1. An inspection of the immunisation 
schedules shows that the majority vaccines are administered in the first months of 
life. Between birth and 13 months; babies are recommended to get 14 vaccines, 
with additional doses up to the age of five years, including both single and 
combination vaccines ( 
Table 1). Combination vaccines offer protection against multiple diseases in a single 
product (e.g. 6-in-1, MMR) (Table 1). These products have numerous benefits: 
simplified immunisation schedules; fewer injections; reduced trauma; higher rates 
of compliance with complex vaccination schedules [19, 20]; improved vaccine 
coverage [21]; and timely vaccination [21]. Adolescents are recommended to 
receive a booster vaccine (i.e. Tdap), as well as MenC and HPV vaccines. Primary 
childhood and school immunisation programme vaccines are free of charge [22], 
and parental consent is required for children to be vaccinated. In addition, the 
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seasonal influenza vaccine is strongly recommended for children aged six months 
and over with long term health conditions (e.g. chronic respiratory disease, 
diabetes mellitus, and neurodevelopmental disorders) and/or those who are 
immunosuppressed. 
Table 1 Primary childhood and school immunisation programmes 
Programme   Age Vaccine Location 






6 in 1 + MenB + PCV + Rotavirus 
6 in 1 + MenB + Rotavirus 
6 in 1 + PCV + MenC 
MMR + MenB 
Hib (booster)/MenC + PCV 
GP surgery 




MMR + 4 in 1 





6 in 1: Diphtheria, Haemophilus influenza b (Hib), Hepatitis B, acellular Pertussis, inactivated Polio, Tetanus 
MenB: Meningococcal B conjugate 
PCV: Pneumococcal conjugate  
MenC: Meningococcal C conjugate 
MMR: Measles, Mumps, Rubella 
4 in 1: Diphtheria, Tetanus, Pertussis, Polio 
MenC*: From September 2019, the MenC vaccine administered at 12-13 years will be replaced by the 
MenACWY vaccine 
Tdap: Tetanus, low dose diphtheria, low dose pertussis  
HPV: Human papilllomavirus  
#
From September 2019, the HPV vaccine will be offered to both girls and boys in Ireland 
 
While vaccination is recommended, it is voluntary in all cases. Vaccinators in Ireland 
include general practitioners (GPs), GP surgery practice nurses, community health 
doctors and public health nurses. More recently, pharmacists have been introduced 
as vaccinators and can administer influenza, pneumococcal polysaccharide (PPV23) 
and herpes zoster (zoster/shingles) vaccines as a private service.   
The National Immunisation Advisory Committee (NIAC) is an independent 
committee of the Royal College of Physicians in Ireland (RCPI), that produces and 
routinely updates the National Immunisation Guidelines, based on best evidence 
regarding the safety and efficacy of vaccines, the disease burden, and 
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pharmacoeconomic analyses [23]. The committee then provides expert, impartial 
guidance to the Chief Medical Officer in the Department of Health. The Health 
Protection Surveillance Centre (HPSC) is Ireland’s specialist agency for the 
surveillance of communicable diseases, collating data and reporting on the uptake 
of vaccines provided through the primary childhood and school immunisation 
programmes. Immunisation uptake statistics are presented in Figure 1-4. The 
European Region of the WHO recommends that, on a national basis, at least 95% of 
children are immunised against vaccine-preventable diseases and those targeted 
for elimination, or control [24] (e.g. diphtheria, tetanus, pertussis, polio, 
Haemophilus influenza b, measles, mumps and rubella). While a minority of the 
recommended vaccines have reached this 95% target (Figure 2), the uptake of the 
majority remains sub-optimal. In line with the Centre for Disease Control and 
Prevention’s (CDC) Healthy People 2020 recommendations, the national target for 
HPV vaccination in Ireland is 80% [25]. Figure 4 illustrates the significant and rapid 





Figure 1 Immunisation uptake at 12 months of age in Ireland (HPSC) 
 
 

























































Figure 3 Immunisation uptake at 4-5 years of age in Ireland (HPSC) 
 
 
Figure 4 Immunisation uptake at 12-13 years of age in Ireland (HPSC) 
 
1.3 Vaccine decision-making 
Parental vaccine decision-making is complex and multi-dimensional. Experiences, 
emotions, routine ways of thinking, information sources, peers/family, risk 
perceptions, and trust have been shown to inform the decision-making process 


















































the benefits and costs of vaccinating [28]. Vaccination provides both personal and 
societal benefits. Personal benefits include protection and disease prevention [9]. 
The perceived personal benefit depends on the perceived risk, and the personal 
impact of potentially contracting the disease [28]. Societal benefits of vaccination 
include the attainment of herd immunity and reduction in the levels of disease, 
morbidity and mortality, as well as pharmaeconomic & economic benefits [10]. 
However, vaccination generates personal costs, broadly defined to include 
monetary and non-monetary individual costs. Monetary costs include the cost of 
the vaccine [29-31], inconvenient time or place of vaccination [29-31], or perceived 
time pressure [32]. Non-monetary costs include adverse effects [33, 34], safety 
concerns [33, 35], fear of injection [36-38], concerns that the vaccine itself could 
cause the disease [28], and difficulties in accessing vaccine providers due to 
distance or appointment delays [33, 39]. In recent years, informed decision-making 
has garnered much attention in the context of childhood vaccination [40]. Decisions 
are classified as informed when decision-makers have relevant knowledge about 
the subject, and the decision reflects the attitudes of the decision-maker [41]. In 
addition, the consequences of the decision should be deliberated [42]. Parental 
decision on child vaccination is a specific case of health-related decision [43, 44]. 
Research has identified two types of parental decision-making: non-deliberate and 
deliberate [45, 46]. Non-deliberate or automatic decisions are characterised by 
passive adherence [47]. These decisions are made rapidly, under a certain set of 
circumstances: when parents perceive vaccination as routine and comply with 
recommendations; when parents feel that they do not have a choice; and/or when 
parents use social norms as a heuristic (cognitive shortcut) for their decision-
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making [42, 45]. In contrast, deliberate or conscious decisions are characterised by 
enlightened conformism [47] and are made when parents consider the advice or 
experience offered by others; when parents are affected by beliefs about social 
judgement; and/or when parents weigh up the perceived benefits and costs of 
vaccination [45]. Low perceived benefits and/or high costs drive the phenomenon 
known as vaccine hesitancy [28].  
1.4 Vaccine hesitancy: a threat to global public health 
Vaccine hesitancy has been defined as “the delay or refusal of vaccination despite 
the availability of vaccine services” [36, 48]. This definition depolarises the “pro” or 
“anti” vaccine stance [49]. In reality, vaccine-hesitant individuals are a 
heterogeneous group in a continuum, ranging from total acceptance to complete 
refusal [49] (Figure 5).  
 
Figure 5 The continuum of vaccine hesitancy between full acceptance and outright refusal of all vaccines [50] 
 
Figure 5 demonstrates how these hesitant individuals may accept some vaccines, 
while refusing others, delay vaccination, or accept vaccines but remain 
apprehensive [49, 51]. Vaccine hesitancy is “highly variable, and context specific, 
varying across time, place and vaccines involved” [36, 48, 50]. It is a multi-layered 
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phenomenon, related to prior beliefs about vaccines [52, 53], perceived benefits of 
vaccines [54], attitudes towards vaccines [55, 56], previous experiences with 
vaccines [57], socioeconomic status [58], number of children [59], and marital 
status [58]. Peretti-Watel et al have proposed to define vaccine hesitancy as a 
decision-making process, that depends on people’s level of commitment to 
healthism/risk culture and on their level of confidence towards health authorities 
and mainstream medicine [47]. Despite extensive findings, research suggests that 
there are still factors that need to be identified and explored, due to the highly 
variable and context specific nature of the phenomenon [49, 60, 61]. Three key 
drivers of vaccine hesitancy have been identified and include convenience, 
complacency and confidence [48, 50].  
1.4.1 Convenience 
Vaccine convenience is a significant factor when uptake is affected by physical 
availability, affordability and/or willingness to pay, geographical accessibility, ability 
to understand, and appeal of immunisation services [48]. Physical availability, 
affordability and willingness to pay, and geographical accessibility are factors 
associated with vaccination monetary costs, as previously discussed. Vaccine 
availability can be a key issue in low and middle-income countries (LMIC), primarily 
due to issues such as cold storage or administration [62]. In general, recommended 
vaccines are readily available in high-income countries (HIC), such as Ireland. One 
notable exception is the Bacillus Calmette-Guérin (BCG) vaccine. The BCG vaccine 
was introduced in the 1950s, for the prevention of tuberculosis. However, on a 
number of occasions, routine vaccination has had to be temporarily suspended, due 
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to vaccine shortages and inability to secure sufficient supply [63, 64]. In light of the 
ongoing issues with the supply of BCG vaccine, it is imperative that available 
vaccines are used efficiently, for maximal benefit. Due to a decline in national 
tuberculosis incidence, many European countries have ceased universal vaccination 
programmes, the majority moving towards a policy of selective vaccination of 
individuals deemed high risk. This approach reduces demand for the vaccine and 
ensures that those at highest risk of infection are prioritised for immunisation. A 
Health Technology Assessment (HTA) has supported the adoption of selective BCG 
vaccination [65]. Therefore, the HSE has been requested to undertake a review of 
the epidemiology of tuberculosis in Ireland, considering the public health impact of 
protracted BCG shortages. This review will inform an updated recommendation to 
the Department of Health regarding future provision of BCG vaccination.  
Childhood and adolescent vaccine uptake in Ireland remains predominantly 
unaffected by factors such as affordability and willingness to pay. This is due to the 
free provision of vaccines through local health offices, GP surgeries, and schools. 
School-based immunisation programmes take advantage of compulsory school 
attendance, while minimising logistical and time constraints for vaccinators and 
parents alike [66]. Vaccine uptake, however, may be impacted by the ability to 
understand recommendations. This ability depends on both language, and health 
literacy. Health literacy is a multifaceted concept that deals with the capabilities of 
individuals to meet the complex demands of health [67]. According to the Sørensen 
Integrated Model, health literacy is ‘linked to literacy and entails people’s 
knowledge, motivation, and competence to access, understand, appraise, and apply 
health information in order to make judgements and decisions in everyday life, 
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concerning healthcare, disease prevention, and health promotion to maintain or 
improve quality of life’ [68]. Research has demonstrated that limited health literacy 
is associated with undesirable health outcomes, including poorer overall health 
status [69], increased rates of hospitalisations [70], mortality [71], and healthcare 
costs [72]. Limited health literacy has also been associated with reduced adoption 
of preventive behaviours such as immunisation, possibly due to the complexity of 
the information and multiple steps involved [73].  
1.4.1.1 Microneedle technology: addressing ease of administration and vaccine 
availability 
Vaccines are conventionally administered using a hypodermic needle [74]. This 
form of administration provides a rapid and direct method of vaccine delivery. 
Despite familiarity, widespread use and proven efficacy, the hypodermic needle is 
associated with phobia, pain and significant anxiety [75-78]. The fear of needles can 
delay or result in avoidance of medical procedures such as vaccination [79]. 
According to Johnson et al, in a nationally representative population of US adults, 
19% did not receive a pneumococcal vaccine and 20% did not receive a tetanus 
vaccine due to needle dislike [80]. In a survey of 100 US physicians, 71%, 71% and 
69% indicated that needle fear was a contributing factor to avoiding tetanus, 
influenza and pneumococcal immunisation, respectively [80]. In a Canadian study, 
noncompliance with immunisation primarily due to needle fear occurred in 8% of 
children and 7% of parents, and this degree of noncompliance was positively 
associated with the degree of fear [37]. In an Australian study of general practice 
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patients, more than 64% of those with needle fear would avoid influenza 
immunisation, compared with nearly 20% of those without needle fear [81]. 
Although needle fear is acknowledged as a contributor to vaccine hesitancy, there is 
a paucity of research to address this concern [82], in particular the issue of the 
needle itself [83]. One suggested novel approach to replace typical injection 
procedures and mitigate needle fear, involves microneedle technology [79]. 
Microneedles can be 1µm in diameter and range from 50µm to 1000µm in length 
[84]. They  can penetrate the outermost skin barrier layer, the stratum corneum, 
creating transient pathways for minimally invasive transcutaneous delivery [85]. It 
is reported that microneedles can facilitate delivery without stimulating the pain 
receptors and blood vessels that lie beneath, thus being perceived as painless and 
associated with a reduction in bleeding [74, 86, 87]. Other advantages of 
microneedle-mediated delivery include avoidance of first pass metabolism; 
potential for highly targeted administration to individual cells [86, 87]; improved 
patient compliance [88]; dose sparing [89, 90]; and potential for self-administration.  
There are four types of microneedles: solid, coated, hollow, and dissolving. Solid 
microneedles create transient micropores in the stratum corneum, thereby 
increasing permeability of this barrier layer. When the vaccine is applied onto the 
treated surface, it diffuses into the skin (from a loaded patch or semi-solid 
formulation) through the pores created by microneedle pre-treatment. In spite of 
immunogenicity [91, 92], the popularity of solid microneedles has reduced in recent 
years, potentially due to the requirement for a multi-step administration process 
[2]. An advanced iteration of solid microneedles was the development of coated 
devices. Solid microneedles are pre-coated with a vaccine in a formulation suitable 
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for coating and dissolution [74], thus resulting in a one-step delivery process. The 
vaccine coated microneedles are inserted into the skin, where dissolution of the 
vaccine occurs. Hollow microneedles provide a pre-defined conduit for vaccine 
delivery into the skin or other tissue, similar to hypodermic needles. Currently there 
are two hollow microneedle designs: a single microneedle or mini-needle, which 
mimics the conventional hypodermic needle [93] or an array of multiple 
microneedles [89, 94]. The latter permits the application of a vaccine formulation 
over a wider area of the skin. Hollow microneedle-mediated delivery of a bolus can 
result in higher bioavailability and, depending on the volume injected into the skin, 
can increase the likelihood of lymphatic uptake of presented antigens [95]. Vaccines 
may be delivered by passive diffusion through the microneedle. Conversely, a 
syringe may be attached to the microneedle, permitting active vaccine delivery. The 
final, most advanced and complex microneedle is the dissolvable microneedle 
patch. These patches are the most attractive microneedle platform for delivery of 
vaccines. Reasons for this choice include but are not limited to: higher dose-loading 
and improved efficiency of vaccine delivery into skin compared to coated 
microneedles, enhanced stability outside of cold-chain, and lower costs of 
materials. These vaccine delivery systems are based on a patch loaded with vaccine-
containing microneedles. When placed on the skin, the microneedles pierce the 
skin and subsequently dissolve, releasing the vaccine into the body. These 
biodegradable microneedles are manufactured with the vaccine embedded in a 
formulation that permits vaccine stabilization on drying and dissolution on 
application and insertion [74, 96-99]. However, unlike hollow microneedles, a 
limitation is placed on the amount of vaccine that can be incorporated into the 
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system [100]. It is also important to ensure that microneedles rapidly dissociate 
from their adhesive backing so that the vaccine is delivered efficiently, irrespective 
of wear-time [99]. Microneedle technology for immunisation has been shown to 
have greater acceptability when compared to traditional hypodermic injection [101, 
102]. Therefore it may be hypothesised that this increased acceptability could 
improve immunisation compliance and potentially increase vaccine uptake.  
Microneedle technology may also address issues of vaccine availability, especially in 
LMIC, where a cold-chain infrastructure is almost prohibitively expensive, thus 
preventing adequate vaccine distribution [103, 104]. The thermostability of certain 
microneedle platforms eliminates cold-chain requirements [105-107], thus reducing 
logistical costs and potentially improving distribution [105-107]. This 
thermostability would permit stock-piling in regular drug distribution networks, 
combatting the frequently encountered issue of supply shortage [2]. In addition to 
being thermolabile, conventional vaccines often require administration by trained 
personnel. In LMIC countries, there are shortages of medical personnel at all levels 
of training [108]: Africa has 2.3 healthcare workers per 1000 population, compared 
to 24.8 per 1000 in the Americas [109]. Therefore, the potential for self-
administration associated with microneedle technology could further improve 
vaccine coverage and availability in these countries [101, 110-112]. A recent 
narrative review collated the primary scientific literature pertaining to microneedle-
mediated in vivo vaccination programmes [2], compiling vaccination strategies in six 
different models, which tested a wide range of vaccines against viral, bacterial and 
protozoan pathogens. Microneedle-mediated vaccines have demonstrated safety 
and immunogenicity in pre-clinical and clinical settings [2]. However, the adoption 
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of the technology as a tool to improve vaccine uptake and reduce hesitancy, will 
depend on end-user acceptability (e.g. HCPs, vaccinees, parents), which requires 
further investigation. 
1.4.2 Complacency 
Complacency “exists where perceived risks of vaccine-preventable diseases are low 
and vaccination is not deemed a necessary preventive action” [48]. Due to the 
effectiveness of vaccines, health risks associated with vaccine preventable diseases 
are perceived as low, which leads to the cognitive bias against the decision to 
vaccinate [113], and feelings of invulnerability [114]. Refusing a vaccine and 
experiencing no negative repercussions can in turn, reinforce decisions not to get 
vaccinated in the future [115]. If alternative life or health priorities are perceived as 
more important, or if impaired self-efficacy prevails, i.e. the self-perceived or actual 
ability to take action to vaccinate [113], complacency may increase.  
1.4.3 Confidence 
Confidence is defined as; the trust in the effectiveness and safety of vaccines, the 
system that delivers them (i.e. the reliability and competence of the health services 
and healthcare providers (HCPs), and the motivations of policy makers (who 
ascertain vaccine need) [48]. Negative vaccine safety sentiment is a global issue 
[116]. A recent report, conducted by the Wellcome Trust, summarised the results of 
a quantitative survey of public attitudes towards health, including vaccines, in more 
than 140 countries [117]. Globally, 79% of people agree that vaccines are safe 
[117]. In high-income regions this figure is lower: 72% in North America, 73% in 
Northern Europe, 59% in Western Europe, and 50% in Eastern Europe [117]. In 
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France, one in three people disagree that vaccines are safe, the highest percentage 
for any country worldwide [117]. In low-income regions, the proportion tends to be 
much higher, with highs of 95% of people in South Asia and 92% in Eastern Africa. In 
Ireland, 94% of the 1000 respondents had heard of vaccines and 91% agreed that 
vaccines are important for children to have. However, a decreased number (87%) 
agreed that vaccines are effective, and 74% agreed that vaccines are safe. 
Additionally, more than 1000 members of the Irish public were included in the State 
of Vaccine Confidence in the European Union (EU) 2018 report [118] (Table 2). 
Table 2 State of Vaccine Confidence in the EU 2018: results from Ireland [118] 
Vaccine survey statements % of respondents in 





Vaccines are important for children to have 90.4 14 
Vaccines are effective 88.8 12 
Vaccines are safe 84.9 10 
 
While the majority of Irish respondents included in both reports recognised the 
importance of immunisation for their children, a decreased number were confident 
in the safety and efficacy of vaccines [117, 118]. Therefore, an effort is required to 
identify and address safety and efficacy concerns, to improve vaccine confidence.  
Misinformation is a key factor contributing to, and amplifying issues of confidence 
[28, 119]. Misinformation has been categorised into several levels and occurs when 
information is actively shared with the intention to mislead [28]. The most harmful 
of these levels occurs when HCPs (i.e. perceived vaccine experts) propagate 
exaggerated or unfounded vaccine concerns [120]. The most notorious example of 
this level of misinformation was the publication by the now disgraced former 
doctor Andrew Wakefield, purporting to demonstrate a link between autism and 
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the MMR vaccine [121]. Mr Wakefield was found guilty of deliberate fraud, 
undisclosed and serious conflicts of interest [122] and was banned from practicing 
medicine in the UK due to a “callous” disregard for children in the course of his 
research (medical records of at least 10 of the 12 children in the Lancet paper were 
falsely reported) [122-124]. In spite of the publication being retracted and the 
revocation of his medical license, Mr Wakefield persists in his campaign against the 
vaccine [125]. Expert consensus has suggested that his persistence has contributed 
to prevailing vaccine concerns and refusals [125]. In turn, these refusals have 
contributed to gaps in vaccination cover and a reduction in herd immunity. 
Consequently, reported measles cases worldwide spiked in 2017, with multiple 
countries experiencing severe and protracted outbreaks, resulting in an estimated 
110,000 deaths [126]. Based on 2018 data, the WHO has withdrawn the measles-
free status of four European countries (i.e. UK, Greece, the Czech Republic and 
Albania), representing an ongoing cause for concern [127]. Vaccine misinformation 
is emotive and tends to be rapidly disseminated by traditional and digital media 
sources [128]. This spread can lead to a crisis of confidence and vaccine instability, 
where instability is defined as a sudden drop in vaccine coverage, often as a result 
of a vaccine safety scare [115].  
1.4.3.1 Anti-vaccine activism 
Anti-vaccine activism has been in existence for more than 200 years [129]. Online 
tactics used by those who are against vaccination tend to fall into four distinct 
areas: they skew the science; they shift hypotheses; they censor dissent; and they 
attack critics [130]. They tell a highly emotive story, in contrast to the messages 
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from official sources, which tend to be factual, cryptic, and forgettable [131]. First-
person testimonies by alleged victims or their parents are commonly used, 
harnessing the recognised psychological finding that anecdotes about a single 
individual are often more influential that large population statistics [132, 133]. In 
addition, negative experiences are easier to perceive than the main benefits of 
vaccination, the absence of disease [134]. Anti-vaccine groups discredit expert 
authority, sometimes sourcing whistle-blower doctors or vaccine researchers, who 
claim an expansive cover-up of information by pharmaceutical companies 
conspiring with governments [135, 136]. These anti-vaccine stories elicit an 
emotional response, as well as an increased perception of vaccine-related risks 
[119], an increased mistrust of vaccine efficacy, accompanied by a suspicion of 
authority, including health services, HCPs, the pharmaceutical industry and policy-
makers [137]. Even though anti-vaccine websites are of lower quality [138], they 
prominently appear in search-engine results [139]. In addition, the recognition that 
vaccine-hesitant individuals are more active in searching for information on the 
internet than their vaccine-compliant counterparts [36], further confounds the 
issue.  
1.4.3.2 HPV vaccine instability 
HPV is a group of more than 100 viruses, and is one of the most common sexually 
transmitted viral infections worldwide, with initial infections typically occurring 
soon after sexual debut [140, 141]. Although the majority of infections are 
transient, persistent infection is a pre-requisite for pre-cancerous lesions and 
malignancies [142]. HPV is responsible for approximately 4.5% of global cancer 
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disease burden [142, 143]. The infection is also associated with cancers of the 
oropharynx, anus, rectum, penis, vulva and vagina and is responsible for anogenital 
warts in men and women [143]. On average, 538 cases of HPV-related cancers were 
diagnosed in Ireland between 2010 and 2014 [143]. Of these, 75% were in women 
[143]. Overall rates of HPV-related invasive cancers are increasing: in the ten year 
period leading up to 2014, there was a 2% increase in the rate of HPV-related 
invasive cancers per year, for both sexes in Ireland [143]. A recent clinical audit of 
oropharyngeal cancer cases, diagnosed between 2014 and 2018 in Ireland, found a 
37% increase in cases, when compared to data recorded by the National Cancer 
Registry Ireland (NCRI) between 2009 and 2013 [143]. Approximately half of these 
were thought to be attributed to HPV [143]. Furthermore, a significant number of 
pre-cancerous lesions occur in Ireland annually. The most significant pre-cancerous 
lesions are high grade cervical intraepithelial neoplasia (CIN2/3), with 8,885 new 
cases being diagnosed between September 2015 and August 2016 in Ireland [143]. 
In addition, anogenital warts are common, with almost 7,500 cases associated with 
HPV estimated to occur in Ireland each year [143]. Three vaccines are licensed and 
marketed for use to prevent HPV infections and their sequelae: the bivalent vaccine 
Cervarix®, which contains HPV 16 and 18 antigens [144]; the quadrivalent Gardasil®, 
containing HPV 6, 11, 16 and 18 antigens [145] and; the nonavalent Gardasil® 9, 
containing HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 antigens [146]. The vaccines are 
intended to be administered to adolescents, before the onset of sexual activity. The 
reason for this recommendation is two-fold: (i) it ensures that the vaccinee is HPV 
naïve; and (ii) bridging studies demonstrated that adolescents display superior 
immune responses to HPV antigens compared to adults [143]. Since the first license 
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in 2006, more that 270 million doses of HPV vaccines have been distributed globally 
and at least 82 countries have included these vaccines in their national 
immunisation programmes [147]. In Ireland, the HSE has offered the quadrivalent 
vaccine to all girls in the first year of second levels schools, vaccinating more than 
240,000 girls since 2010 [148]. There is high grade evidence that HPV vaccines 
protect against cervical pre-cancer [149], with significant decreases in vaccine-type 
HPV in vaccinated women [150]. A recent systematic review of efficacy 
demonstrated that the quadrivalent Gardasil vaccine is associated with a 90% or 
greater reduction in persistent HPV infection, anogenital warts, CIN, vulvar 
intraepithelial neoplasia (VIN) and vaginal intraepithelial neoplasia (VaIN), in HPV-
naïve women [143]. In addition, HPV vaccines have been shown to reduce abnormal 
screening tests, colposcopies and excisions [151]. This reduction in diagnostic and 
therapeutic procedures not only lowers healthcare expenditure [151, 152] but also 
improves health, whilst reducing negative psychological effects on the women 
involved [153].  
More recently there has been a focus on HPV vaccine safety, linking the vaccines to 
‘new onset chronic diseases’ and ‘medically significant conditions’ [141, 143, 154]. 
Reported chronic diseases and significant conditions include Guillain–Barré 
syndrome, stroke, appendicitis, seizure, syncope, migraine, complex regional pain 
syndrome, postural orthostatic tachycardia syndrome, premature ovarian 
insufficiency, primary ovarian failure and venous thromboembolism, among many 
others [141, 143]. However, the safety of the HPV vaccines is well established [155, 
156], and extensive research has consistently reported that there is no difference in 
the rate of serious adverse events or deaths between individuals who receive the 
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HPV vaccine and participants who receive a placebo or control vaccine [143, 149, 
155, 157-159]. This literature supports the position of the WHO’s Global Advisory 
Committee on Vaccine Safety (GACVS) [160], the European Medicines Agency 
(EMA) [161] and several country-level regulatory agencies in the US [162, 163], the 
UK [164] and pooled data from Denmark and Sweden [165, 166]. Despite the 
availability of extensive reassuring safety data, media attention has continued to 
focus on misinformation. In Ireland, these case reports were broadcast on 
television in December 2015 and propagated extensively on social media [167]. A 
support group was established by parents who believed their daughters had been 
adversely affected by the HPV vaccine (Reactions and Effects of Gardasil Resulting 
in Extreme Trauma; REGRET). Whilst there may have been other contributing 
factors, it is likely that this misinformation was a significant factor in the decrease in 
HPV vaccine uptake across all areas of Ireland to an estimated 51% in 2016/17, 
down from 87% in 2014/15 (Figure 4) [26, 168]. Similar crises have been observed 
in several countries worldwide, including Denmark and Japan. Immediately 
following the vaccine’s launch in Denmark in 2009, the HPV vaccine was received 
positively, with over 90% vaccine uptake [169]. From 2013 onwards, the 
immunisation programme has been challenged by an increase in the number of 
reported suspected adverse events, leading to increased media interest and 
attention. This was further affected by the release of a similar documentary in 
2015, describing a group of girls with a range of disabling symptoms, presumed to 
follow vaccination. After this, vaccination rates declined to 54% [169]. Similarly in 
Japan, the HPV vaccine was included in the national immunisation programme in 
April 2013 [170]. However, just two months later, the Ministry of Health, Labour 
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and Welfare announced a “suspension in the proactive recommendation for routine 
use of the vaccine” [170]. This suspension has not been revoked and HPV vaccine 
uptake decreased from 70% in 2013, to a current rate of  less than 1% [171].  
A reactive response to the HPV vaccine crisis by the National Immunisation Office 
(NIO) in Ireland led to the formation of cross-sectoral alliances. The NIO is 
government funded and is responsible for managing vaccine procurement and 
distribution, and developing training and communication materials for the public 
and HCPs. The HPV Vaccination Alliance was launched, with leadership from the 
NIO. This alliance consists of a group of more than 35 different organisations (e.g. 
Irish Pharmacy Union, Irish Cancer Society, and Irish College of General 
Practitioners), working in a variety of areas (e.g. medicine and health, women’s 
rights, child protection) that are committed to raising HPV vaccine awareness. In 
2017, an information campaign was launched and featured vaccinated adolescents. 
This campaign was supported by the HPV vaccination Alliance, the HSE, the 
Department of Health and the Minister for Health [172]. This collaborative effort is 
likely to have contributed to the increase in the first dose uptake to an estimated 
64% (from 51% in 2016/17) in 2017/18 (Figure 4) [167]. It should be noted 
however, that a substantial variation in uptake is seen by area; ranging from just 
40% uptake in Kerry, to 74% uptake in South Dublin East [172]. This variation 
requires further investigation at local level, to guide intervention development to 
improve vaccine uptake and maintain positive momentum to decrease morbidity 
and mortality from HPV-related infections and sequelae [167]. 
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1.5 Addressing vaccine hesitancy to improve vaccine uptake 
There is an urgent need for the development of interventions to address sub-
optimal vaccination uptake among those experiencing uncertainty about vaccines 
[45, 173-176]. Vaccine hesitancy is receiving unprecedented global attention, 
stimulated by the WHO identifying it as a priority issue [177] and declaring it one of 
the top ten threats to global health in 2019 [178]. It is well established that 
changing behaviour is complex, and a systematic approach is required to 
understand the factors that influence vaccine hesitancy and uptake. In general, 
providing information alone does not change behaviour [179, 180]. Instead, one 
must gain an insight into the knowledge, beliefs, attitudes and current behaviours 
of the target audience, and the environmental context in which they occur [28]. The 
European Centre for Disease Prevention and Control (ECDC) has developed a 
catalogue of 40 interventions, to diagnose and address vaccine hesitancy [181]. 
Diagnostic tools have been designed to measure or monitor vaccine hesitancy e.g. 
the Global Vaccine Confidence Index [182], the Vaccine Confidence Scale [183], and 
the Parent Attitudes About Childhood Vaccines survey [51]. Dialogue-based 
interventions to address vaccine hesitancy include: individual-level interventions 
focusing on parents; interventions focusing on improving HCPs’ confidence and 
communication skills to respond to vaccine hesitant patients; and community-level 
interventions [181]. Determinants targeted include: general vaccine hesitancy, 
misinformation, perceived benefits, safety issues, religious and philosophical views, 
and trust [181].  
Behaviour change has been shown to be more effective when interventions are 
based on principles drawn from evidence and theories of behaviour change [184]. 
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Behaviour change theory is a broad term for a set of pre-specified ideas or 
predications aimed at explaining behaviour [185-187]. These theories have 
emerged from multiple disciplines including psychology, sociology and behaviour 
economics and identify multiple determinants or components of behaviour [188]. A 
substantive body of research, including both primary studies and syntheses, has 
identified the effectiveness of theory-based interventions targeting change in real 
world contexts [189-191]. Examples of such theories include the Health Belief 
Model (HBM), and the Theoretical Domains Framework (TDF). The HBM was 
developed initially in the 1950s by social psychologists to explain widespread under-
participation in programmes to prevent and detect disease [192, 193]. The model 
was later extended to assess individual’s responses to symptoms [194], and their 
behaviours in response to a diagnosed illness, such as medication adherence [195]. 
The HBM contains several primary constructs that predict why an individual will 
take action to prevent, to screen for, or to control an illness or condition: perceived 
susceptibility; perceived severity; perceived benefits; perceived barriers; cue to 
action; and self-efficacy [193]. ‘Perceived susceptibility’ refers to beliefs about the 
likelihood of getting a disease or condition. ‘Perceived severity’ refers to the 
seriousness of contracting an illness or leaving it untreated and includes an 
evaluation of both medical and clinical consequences (e.g. pain, death, and 
disability) and potential social consequences (e.g. impact on social, family and work 
life). ‘Perceived benefits’ refers to the effectiveness of the actions available to 
reduce disease threat. Conversely, ‘perceived barriers’ refers to the negative 
aspects of these available actions. Research has demonstrated that combined levels 
of susceptibility and severity provide the energy, or force, to act and the perception 
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of benefits (minus barriers) provide a preferred path of action [193]. Cue to action 
describes the stimulus needed to trigger the decision-making process to accept a 
recommended health action. These cues can be internal (e.g. symptom) or external 
(e.g. advice from others, and media coverage). Self-efficacy is defined as the 
conviction that one can successfully execute the behaviour required to produce the 
outcome(s) [196] and was added to the model in 1988 [197]. The HBM’s 
effectiveness in predicting and explaining behaviour has been well documented in a 
series of meta-analyses [198-201]. In addition, the model has been used to inform 
the development of interventions to improve health behaviours [202]. However, 
there are several limitations of the HBM, which limit its utility in public health 
interventions: the important roles of impulsivity, habit, self-control, associative 
learning, emotional processing are not addressed [203, 204], contributory factors in 
the vaccine decision-making process.  
The TDF provides a systematic and theoretical basis for understanding and changing 
behaviour. The framework simplifies 33 psychological theories relevant to 
behaviour change into 128 constructs (component parts of theories), that were 
sorted into 14 validated domains [205, 206]. These 14 validated domains are: (1) 
knowledge, (2) skills, (3) social/professional role and identity, (4) beliefs about 
capabilities, (5) optimism, (6) beliefs about consequences, (7) reinforcement, (8) 
intentions, (9) goals, (10) memory, attention and decision processes, (11) 
environmental context and resources, (12) social influences, (13) emotion, and (14) 
behavioural regulation. These domains include individual-level, social, and 
environment and resource factors, prompting the consideration of a wide range of 
influences [207]. The TDF has been applied across a wide range of healthcare 
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settings and clinical behaviours, with a range of objectives e.g. to process 
evaluations of randomised controlled trials (RCT) [208], to guide the identification 
of behaviour change techniques (BCT) [209] and to design broader intervention 
strategies [210]. Several methodological approaches have been used in its 
application including interview [211, 212] and questionnaire studies [213, 214]. 
While the TDF has been used primarily in the context of health to understand 
behaviour at the individual level, it can also be used in a variety of contexts to 
understand behaviour at the organisational and community level and to identify 
external factors influencing behaviours [204]. The capability, opportunity, 
motivation model of behaviour (COM-B) further distils the TDF domains into three 
sources that interact to predict behaviour. These sources are the individual’s 
capability, motivation and opportunity for the behaviour [204] (Figure 6).  
 
Figure 6 Theoretical Domains Framework [204] 
 
The central tenet of the model is that for any behaviour to occur there must be: 
capability to do it, opportunity for the behaviour to occur; and sufficiently strong 
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motivation to undertake the behaviour [204]. Each of these components may be 
divided heuristically into two distinct types. Capability may be physical (i.e. having 
the physical skills, strength, or stamina) or psychological (having the knowledge, 
psychological skills, strength, or stamina). Opportunity may be physical (i.e. what 
the environment facilitates in terms of time, triggers, or resources) or social (i.e. 
interpersonal influences, social cues, or cultural norms). Motivation may be 
reflective (i.e. self-conscious deliberation) or automatic (i.e. processes involving 
desires, impulses, or reflex responses) [204]. These components interact, as 
illustrated in Figure 7.  
 














The COM-B model forms the central component of the Behaviour Change Wheel 
(BCW) [210]. Within 19 frameworks for classifying behaviour change interventions, 
intervention functions and policy categories were discerned to construct the BCW 
(Figure 8).  
 
Figure 8 The Behaviour Change Wheel [204] 
 
Nine intervention functions are specified in the BCW and mapped onto the COM-B 
domains: (1) education, (2) persuasion, (3) incentivisation, (4) coercion, (5) training, 
(6) restriction, (7) environmental restructuring, (8) modelling, and (9) enablement 
[210]. These intervention functions were then linked to seven policy categories: (1) 
communication/marketing, (2) guidelines, (3) fiscal, (4) regulation, (5) legislation, 
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(6) environmental/social planning, and (7) service provision. Definitions of these 
intervention functions and policy categories are provided in Table 3 and Table 4. 
 




Education Increasing knowledge or understanding 
Persuasion Using communication to induce positive or negative feelings or stimulate action 
Incentivisation Creating expectation of reward 
Coercion Creating expectation of punishment or cost 
Training Imparting skills 
Restriction 
Using rules to reduce the opportunity to engage in the target behaviour (or to increase 
target behaviour by reducing the opportunity to engage in competing behaviours 
Environmental 
restructuring 
Changing the physical or social context 
Modelling Providing an example for people to aspire to or imitate 
Enablement Increasing means/reducing barriers to increase capability or opportunity 
 
Table 4 Definitions of policy categories [210] 
Policy categories Definition 
Communication/marketing Using print, electronic, telephonic or broadcast media 
Guidelines Creating documents that recommend or mandate practice  
Fiscal Using the tax system to increase or reduce the financial cost 
Regulation Establishing rules or principles of behaviour or practice 
Legislation Making or changing laws 
Environmental/social planning Designing and/or controlling the physical or social environment 
Service provision Delivering a service 
 
A corresponding Behaviour Change Technique Taxonomy (v1) has also been 
developed, to standardise the content and reporting of intervention studies [204, 
215]. This taxonomy includes 93 BCTs organised into 16 groups [215]. A BCT is 
defined as “an active component of an intervention designed to change behaviour” 
[204]. BCTs have been identified in relation to specific behaviours such as physical 
activity, healthy eating, smoking, and alcohol use [216-219]. Therefore the BCW is 
unique in that it not only identifies which components need to change for the 
target behaviour to occur but its association with the BCTTv1 also provides 
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guidance on the strategies and techniques that can be used to modify the 
behaviour [204, 215]. For this reason, the BCW (and TDF) was chosen to guide 
intervention design in this research.  
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1.6 Thesis aim and objectives 
The previous discussion described how the vaccine decision-making process is 
complex and multifaceted, and that several barriers to vaccine uptake have already 
been identified. However, these barriers are highly variable and context specific. 
Therefore, there is an urgent need to identify and address the factors contributing 
to decreasing vaccine uptake in Ireland. In this doctoral research, I undertook 
multiple approaches to address this need.  
Microneedle-mediated vaccines have demonstrated safety and immunogenicity [2]. 
However, the adoption of the technology as a tool to improve vaccine uptake and 
reduce hesitancy, will depend on end-user acceptability. Therefore, I first sought to 
understand if and how microneedle technology could impact vaccine decision-
making and vaccine uptake. In the process of this qualitative exploration into 
microneedle technology, the issue of HPV vaccine instability spontaneously 
emerged as a discussion point within the parent focus groups. These participants 
would be asked to make a decision about the HPV vaccine within several years and 
their concern was palpable. The 2015 conduct of this research coincided with the 
downturn of HPV vaccine uptake and the broadcast of a documentary on a popular 
national television station. The participants in this documentary argued that their 
children not only presented with postural orthostatic tachycardia syndrome (POTS) 
and complex regional pain syndrome (CRPS), but with many other cluster 
symptoms, including seizures, chronic pain, syncope, sleep disorders, menstrual 
disorders, ovarian cysts, pancreatitis, and premature ovarian failure [220]. Similar 
confidence crises were observed in several countries worldwide including Japan 
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[221], Denmark [222], and France [223]. Therefore I reactively responded to the 
research findings and sought to gain an insight into the HPV vaccine decision-
making process, in a series of stakeholders, to explore and identify barriers to 
vaccine uptake.  
Aim 
 To explore vaccine decision-making in order to identify, and address, barriers to 
vaccine uptake in Ireland. 
Objectives 
Three specific objectives were defined in order to achieve this aim: 
1. To generate an evidence-base, describing the perception and acceptability of 
vaccination. 
 Review the literature on the perception, acceptability and suitability of 
microneedle technology for paediatric immunisation (Chapter 2). 
 Systematically review the qualitative literature on the views of parents 
regarding HPV vaccination (Chapter 4). 
2. To ascertain the knowledge, attitudes and beliefs of key stakeholders to 
elucidate vaccine decision-making and to identify barriers to vaccine uptake in 
Ireland. 
 To investigate the knowledge, attitudes and beliefs of parents about 
microneedle-patch vaccines (Chapter 3). 
 To investigate the knowledge, attitudes and beliefs of female 
adolescents about HPV vaccination (Chapter 5). 
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 To investigate the knowledge, attitudes and beliefs of parents of female 
adolescents about HPV vaccination (Chapter 6). 
3. To design, develop and evaluate a theory-based intervention to improve 
knowledge and intention to vaccinate. 
 To evaluate participants’ baseline knowledge (Chapter 7). 
 To assess the impact of the intervention on participants’ knowledge and 
intention to vaccinate (Chapter 7). 
 To assess participants’ satisfaction with the intervention (Chapter 7). 
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1.7 Methodological justification 
A mixed methods approach was chosen for this research based on the overall aim 
of the thesis and the complexity of the topic of interest [224]. Mixed methods 
research has been defined as an approach or methodology: focussing on research 
questions that call for real-life contextual understandings, multi-level perspectives, 
and cultural influences; employing rigorous quantitative research assessing 
magnitude and frequency of constructs and rigorous qualitative research exploring 
the meaning and understanding of constructs; utilising multiple methods (e.g. 
interviews and intervention trials; intentionally integrating or combining these 
methods to draw on the strengths of each; and framing the investigation within 
philosophical and theoretical positions [225]. It was determined that neither the 
positivist, quantitative approach nor the constructivist or post-positivist, qualitative 
approach alone, is adequate to develop multiple perspectives and a complete 
understanding of the current research question [225, 226]. Quantitative research is 
deductive, associated with a belief that reality can be measured and observed 
directly. Strengths of quantitative research include its procedures to minimise 
confounding and its ability to generate generalisable findings, if samples involved 
are sufficiently large and representative. However this quantitative approach is less 
suited to generating hypotheses to explain complex social or cultural phenomena 
[226]. Qualitative research is inductive, associated with a belief that there are 
multiple realities shaped by personal viewpoints, context and meaning. It provides 
a rich description of views and beliefs and permits hypotheses to emerge from the 
data [226]. High quality qualitative research can generate robust theory that is 
62 
 
applicable to contexts both within and without the study area, guiding practitioners 
and policy-makers [227]. However, for research that aims to direct impact practice 
and policy, qualitative research findings can be limited by small sample sizes 
necessary for in-depth exploratory work and the subsequent lack of generalisability 
[226]. Mixed methods research has the ability to harness the strengths and 
counterbalance the limitations of both approaches [226, 228-231]. Research has 
identified several advantages of this approach: it enables researchers to 
simultaneously address exploratory and confirmatory research questions, 
evaluating and generating theory at the same time; it enables researchers to 
provide more robust inferences than a single method or reality; and it provides an 
opportunity to produce a greater assortment of divergent and/or complimentary 
views [231]. In mixed methods research, methodological issues arise that must be 
anticipated [225]. Because multiple forms of data are being collected and analysed, 
mixed methods research requires extensive time and resources to carry out the 
multiple steps involved [225]. For exploratory sequential design, sampling issues 
arise, related to deciding what results from the initial phases to include in the 
follow-up phases, choosing samples and estimating reasonable sample sizes for 
both phases, and interpreting results from both phases [232, 233]. However, 
evidence in the published literature attests to the current use of mixed methods 
approaches in health-related research, such as cardiology [234], pharmacy [235], 
and public health [236].  
This methodological approach is in keeping with the research paradigm of 
pragmatism that served as the philosophical approach to this thesis. A pragmatic 
perspective draws on using the most appropriate research method, using diverse 
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approaches, and giving primacy to the importance of the research problem and 
question, valuing both objective and subjective knowledge [237, 238].  
The primary purpose of using mixed methods in this thesis was development i.e. 
using results from one method to inform the use of the other [226]. The overall aim 
of this thesis was to explore vaccine decision-making to identify and address 
barriers to vaccine uptake in Ireland. As with other areas of healthcare research, its 
undertaking is inherently complex, and to generate sufficient understanding, mixed 
methods are required [224]. An exploratory sequential design was adopted, 
beginning with a qualitative exploration followed by a quantitative follow-up [225]. 
The first step in this research involved a narrative (Chapter 2), and systematic 
(Chapter 4), review of the literature, to identify the current evidence base and to 
identify knowledge gaps that should be addressed in this thesis. The findings in 
these reviews informed the development of the individual studies that formed the 
thesis. Qualitative research methods (focus groups and interviews) were used to 
investigate the knowledge, attitudes and beliefs of stakeholders: parents and 
adolescents (Chapters 3, 5 and 6). The findings of this exploratory qualitative data 
collection were used to design a quantitative instrument, which was administered 
to a sample of the population, in a feasibility study (Chapter 7).  
While the research design uses a mixed methods approach, a ‘composite analysis’ 
approach is applied to discussing the findings [239]. This approach recognises that 
the analysis is composed of independent parts, but that the whole is greater than 
the sum of these parts [239]. Therefore the qualitative and quantitative studies are 
presented and published independently, and their key findings are inter-related in 
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the discussion, in a manner that respects their unique characteristics, and exploits 
their potential to yield complementary insights [239].  
1.8 Thesis outline 
This thesis consists of eight chapters, which provide a thorough and detailed 
investigation on vaccine decision-making in an Irish setting. Figure 9 provides an 
overview of the thesis and demonstrates how the aim and objectives are addressed 
by the individual studies undertaken as part of this doctoral research. 
Chapter 1 This chapter introduces the research topic and defines the overall aim 
and objectives of the thesis. 
Chapter 2 This chapter presents the findings of a narrative literature review on the 
perception, acceptability and suitability of microneedle technology for paediatric 
immunisation (Paper 1). 
Chapter 3 This is a qualitative, focus group study undertaken with parents to 
explore the knowledge, attitudes and beliefs about microneedle-patch vaccines for 
paediatric immunisation (Paper 2).   
Chapter 4 This chapter presents the findings of a systematic review on the views of 
parents regarding HPV vaccination (Paper 3). 
Chapter 5 This is a qualitative, focus group study undertaken with female 
adolescents to explore the knowledge, attitudes and beliefs about HPV vaccination 
(Paper 4). 
Chapter 6 This chapter presents the findings of a qualitative, interview study 
undertaken with parents of female adolescents to explore their knowledge, 
attitudes and beliefs about HPV vaccination.  
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Chapter 7 This chapter describes the design of a theory and evidence-based 
intervention to improve vaccine knowledge and intention to vaccinate. It also 
presents an evaluation of the intervention.  
Chapter 8 The final chapter of this thesis presents the overall discussion, taking into 
consideration the key findings from each study that comprises the thesis (Chapters 

















Aim: to explore vaccine decision-making in order to 
identify, and address, barriers to vaccine uptake in Ireland. 
 
 
1. To generate an evidence-base describing 
the perception and acceptability of 
vaccination. 
 Review the literature on the 
perception, acceptability and 
suitability of microneedle technology 
for paediatric immunisation  
 Systematically review the qualitative 
literature on the views of parents 
regarding HPV vaccination 
 
3. To design, develop and evaluate a theory 
and evidence-based intervention to 
improve knowledge and intention to 
vaccinate. 
 To evaluate participants’ baseline 
knowledge 
 To assess the impact of the 
intervention on participants’ 
knowledge and intention to vaccinate 
 To assess participants’ acceptability of 
the intervention 
2. To ascertain the knowledge, attitudes and 
beliefs of key stakeholders to elucidate 
vaccine decision-making and to identify 
barriers to vaccine uptake in Ireland. 
 To investigate the knowledge, 
attitudes and beliefs of parents about 
microneedle-patch vaccines 
 To investigate the knowledge, 
attitudes and beliefs of female 
adolescents about HPV vaccination 
 To investigate the knowledge 
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Figure 9 Thesis outline 
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Chapter 2 Microneedle technology for 
immunisation: perception, acceptability 
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Paediatric populations have been identified as desirable end-users of microneedle 
technology.  
Aim 
The aim of this literature review was to examine published research which explores 
the perceptions and acceptability of microneedle technology in both patients and 
HCPs.  
Methods 
A series of keywords and their synonyms were combined in various combinations 
and permutations using Boolean operators to sequentially search four databases 
(PubMed, Web of Science, EMBASE and CINAHL). Following removal of duplications 
and irrelevant results, 12 research articles were included in the final literature 
review.  
Results 
The opinions of patients, parents, children and HCPs were collated. A positive 
perception and a high level of acceptability predominated.  
Conclusion 
Microneedle technology research has been focussed on demonstrating efficacy 
with minimal focus on determining HCP/public perception and acceptability for 
paediatric use, exemplified by the paucity of studies presented in this review. 
Commercial viability will depend on HCP/public acceptability of microneedle 
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technology. An effort must be made to identify the barriers to acceptance and to 
overcome them by increasing awareness and education in stakeholder groups 




Since its invention in 1853 [240, 241], the hypodermic needle has become the most 
widely used medical device [242], with an estimated 16 billion injections 
administered worldwide [243]. This form of administration permits rapid delivery of 
plasma levels, careful titration of narrow therapeutic index drugs and 
administration of those exhibiting poor oral bioavailability by avoiding first pass 
metabolism and the degradative environment of the enteral system. Despite 
efficacy and widespread use, conventional hypodermic needles are associated with 
hazardous waste, accidental needle-stick, nosocomial infection as well as phobias, 
pain and significant anxiety in both adult and paediatric populations alike [76, 78, 
242, 244]. Guided by these concerns, research has been focused on the 
development of alternate drug delivery methods. One such method that has 
emerged is delivery via microneedle technology. Microneedles are designed 
specifically to target the outermost, rate-limiting, skin barrier layer, the stratum 
corneum, creating transient pathways for transcutaneous delivery [85]. It is 
reported that microneedles can facilitate drug delivery through stratum corneum 
interruption without stimulating the pain receptors or blood vessels that lie 
beneath [86] thus being perceived as completely painless and devoid of bleeding. 
This technology has been used in a wide variety of pharmaceutical applications 
including the delivery of drugs [111, 245-247] and macromolecules, namely 
vaccines, proteins and peptides [74, 89, 93, 105-107, 248-253]. The major 
microneedle approaches employed in order to achieve facilitated delivery are solid, 
coated, hollow, dissolvable and swellable devices [254]. Solid microneedles are 
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primarily used for skin pre-treatment [74], whereby the needles puncture the skin, 
temporarily increasing permeability. This facilitates the passive diffusion of drug 
from a reservoir, typically in the form of a patch [254]. Coated microneedles pierce 
the stratum corneum, the drug layer dissolves and the active is deposited in the skin 
[74, 254]. Dissolvable microneedles are polymer based; the drug is incorporated 
into the formulation and is released as the system dissolves [74, 254]. Hollow 
microneedles facilitate drug diffusion [74], via a method of intradermal injection 
that is similar to that of conventional parenteral delivery. Finally swellable 
microneedles rapidly take up interstitial fluid upon skin insertion to form 
continuous, unblockable, hydrogel conduits from attached patch-like drug 
reservoirs to the dermal microcirculation [255]. In spite of promising results, the 
commercial success of microneedle technology will depend on end-user 
acceptability. Acceptability refers to determining how well an intervention will be 
received by the target population and the extent to which a new intervention or its 
components may meet the needs of the target population and organisational 
setting [256]. Interventions can often be developed without sufficient 
understanding of how the target population will embrace its activities [256]. A 
formulation with poor patient acceptability will affect compliance, prescribing 
practices and ultimately commercial viability [257] thus the European Medicines 
Agency (EMA) has recommended that acceptability studies form an integral 




The aim of this literature review was to examine published research which explores 
the perceptions and acceptability of microneedle technology in both patients and 
HCPs. A particular focus was placed on the amenability of this technology for use in 
the paediatric population, as children have been identified as desirable end-users 
[86]. 
2.4 Methods 
2.4.1 Search strategy 
Keywords and their synonyms or related terms were chosen which define the 
important concepts of the search. These included ‘acceptability’; ‘acceptance’; 
‘perception’; ‘microneedle’; ‘paediatric’; ‘child’; ‘children’; ‘vaccination’; 
‘immunisation’; ‘healthcare’; ‘public’; ‘parent’ and ‘guardian’. These keywords were 
combined in a variety of different permutations and combinations using the 
Boolean operators AND/OR. The same search was applied to four databases 
(PubMed; Web of Science; EMBASE and CINAHL), using Google as a search engine. 
No restrictions or advanced search filters were applied to the database searches. 
The search was repeatedly conducted from 6th October 2014 to 16th January 2015.  
2.5 Results 
The initial search across the chosen databases yielded 61 results. Following removal 
of duplications; 34 results remained.  
 




Table 5 Literature search inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Related to the perception and acceptability of 
microneedle technology 
Published in English language 
Human subjects 
Not related to the perception and acceptability of 
microneedle technology 
Related only to microneedle  technology 
No abstract available 




Eleven of these results were excluded based on the irrelevance of their title and/or 
abstract. The remaining 23 results were assessed in full and their relevance to the 
query was determined. This process returned nine relevant results and revealed a 
further three results that had not been included in the initial search. Therefore, the 
final literature review included 12 results (Figure 10).  
 
 




The purpose of this review was to collate the literature which examined the 
perception and acceptability of microneedle technology for use in paediatrics. The 
literature search yielded 12 results directly related to the research query. Eight of 
the search results involved the actual administration of microneedle technology 
while the remaining four involved the hypothetical discussion of the technology. 
There are several methods to assess acceptability, both qualitative and 
quantitative. Popular and effective qualitative research methods include interviews 
and focus groups. These provide considerable opportunity for discussion between 
the researcher(s) and the target population. They also permit the researcher to 
probe topics as they emerge naturally in conversation, resulting in an in-depth 
understanding of forces that may impede or facilitate the intervention. During an 
interview, the interviewer engages an individual in a discussion about the proposed 
intervention. The individual may represent a member of the target population or an 
organisational representative with the experience to knowingly assess the 
acceptability of the intervention. Focus groups have been described as one of the 
most widely used qualitative research tools in the applied social sciences [256, 258], 
useful for designing healthcare interventions, pre-testing intervention materials, 
and establishing acceptable intervention implementation procedures. Interview 
techniques were used in three of the research papers presented here [84, 259, 260] 
and focus group methods were used in a further three [84, 86, 261]. Focus groups 
are advantageous as they permit and facilitate a collective brainstorming, resulting 
in a “synergistic group effect” [256]. In addition, focus groups are more cost 
effective in both time and resources. Quantitative research methods, to determine 
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acceptability, were also used in several of the research papers presented here. The 
primary method of quantitative research was the use of questionnaires [85, 86, 
101, 259, 260, 262-266]. Several of the papers employed previously validated 
questionnaires, for example Modified Theory of Reasoned Action [101], Vaccinees’ 
Perception of Injection [266] and McGill Pain Questionnaire-Short Form [85], while 
the remainder developed questionnaires for the purpose of their research. 
2.6.1 Perception and acceptability of microneedle technology 
Eleven of the studies reported a positive response to microneedles with only one 
study reporting the contrary [262]. Several recurring themes emerged which 
appeared to positively guide acceptability. These included; a perceived or actual 
reduction in pain associated with microneedle technology [84-86, 101, 259-261, 
263-266]; ease and convenience of administration [86, 101, 259-261, 263-265]; 
potential for self-administration [86, 101, 261] and attractive visual appearance [84, 
86, 261, 263, 265]. Conversely, several barriers to acceptability were identified; 
unfamiliarity with the technology [84, 86, 261]; allergic potential [84, 261] and the 
inclusion of the term ‘needle’ in the name of the product [261]. Research and 
development, particularly for paediatric markets, should focus on these barriers 
and strive to remove them through patient education, the development of a 
hypoallergenic delivery system and the adoption of novel nomenclature e.g. 
ImmuPatch®, to eliminate the negative connotations associated with the term 
‘needle’. 
It is also important to consider HCP acceptability of microneedles. It has been 
demonstrated that the majority of patients will reserve the ultimate healthcare 
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decision for their HCP [84]. Five of the papers presented in this literature review 
included the opinions of 711 HCPs [86, 259, 260, 264, 265]. 90.65% (n=644) of those 
HCPs included declared a positive response to microneedle technology, with 
76.37% (n=543) expressing preference for microneedle technology over 
conventional administration. Perceived benefits were similar to those mentioned 
by the general public, such as increased patient acceptability, especially in the 
needle-phobic [86, 264, 265] but HCPs acknowledged additional benefits such as 
improved immunogenicity and seroprotection [264, 265] and a reduced risk of 
needle-stick injury [86]. However, several barriers to acceptability were 
acknowledged by HCPs: risk of cross-contamination and an inability to ensure 
accurate delivery on microneedle application [86]. Significant efforts have been 
made to address these concerns with devices based on biodegradable dissolving 
formulations receiving increased attention. Once inserted into the skin, these 
polymeric systems will either rapidly dissolve or undergo such morphological 
changes that disable effective skin penetration if applied to another individual [267, 
268], thus preventing intentional or accidental cross contamination. An effort must 
be made to formulate the inclusion of a delivery indicator without significantly 
increasing the cost of production. 
2.6.2 Perception and acceptability for use in immunisation 
Vaccines are a key contributor to public health [269]. Despite repeatedly 
demonstrating cost-effectiveness, the WHO has estimated that vaccine spending 
accounts for only 2–3% of the total pharmaceutical market. Total costs of providing 
immunisation services are divided into capital and recurrent costs [270, 271]. 
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Capital costs are identified as items that last longer than one year and are therefore 
incurred every few years rather than annually. Important capital costs for 
immunisation services are associated with cold chain equipment vehicles. Recurrent 
costs are those items consumed during the year, warranting regular purchase. 
Recurrent costs include the vaccines themselves and training activities [270]. In 
recent years, the global vaccine market has undergone rapid growth. The impetus 
for this changing status is a combination of improved profitability with the 
development of ‘blockbuster vaccines’, defined as those with US sales of at least 
one billion dollars [272], such as Pfizer’s Prevnar7® and Prevnar 13®, GSK’s Rotarix® 
and MSD’s Rotateq®, new funding opportunities with government grants and 
public–private partner-ships [269], and new manufacturing techniques, namely 
microneedle technology. 
Vaccine delivery to the skin is a logical approach [254]. The skin is an immunogenic 
organ, housing a high concentration of professional antigen presenting cells [90]. 
This permits the induction of a strong immune response upon antigenic challenge 
[90]. For this reason, microneedles are especially attractive for immunisation. They 
have demonstrated a compatibility with live, inactivated and subunit vaccines [111, 
247], the ability to induce comparable and, in some cases, improved 
immunogenicity when compared to conventional vaccination [89, 93, 253, 273], 
coupled with significant dose sparing characteristics [89, 90]. Microneedle-
mediated vaccination could potentially reduce both the capital and recurrent costs 
associated with conventional immunisation programmes: their thermostability 
eliminates cold-chain transportation requirements [105-107] and their potential for 
self-administration could reduce the requirement for trained personnel to 
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administer the vaccine. There are currently 12 clinical trials at various stages 
involving the delivery of vaccines using microneedle technology. Ten of these have 
been completed; one is actively recruiting, while the other has completed 
recruitment. Eleven of the 12 clinical trials involve vaccine delivery using hollow 
microneedles (Soluvia®, MicronJet®), while the remaining trial involves delivery 
using a dissolvable microneedle patch. Vaccine targets under trial include varicella 
zoster, polio and influenza [274]. It is not possible to discuss vaccination without 
mentioning influenza. It is estimated that 5–10% of adults and 20–30% of children 
are infected with influenza globally per annum. Influenza vaccination is one of the 
most effective methods to prevent infection or complications from illness, 
providing approximately 70–90% protection against clinical disease in healthy 
adults aged 18–59, provided there is good correlation between the vaccine antigens 
and circulating viral strains [255]. The requirement for re-vaccination on an annual 
basis as a result of viral antigenic shift and drift explains the popularity and 
commercial advantage of influenza vaccine development. This review presents the 
results of a first-in-humans study of microneedle patch acceptability for self-
vaccination against influenza [101]. In this study, etched, stain-less steel 
microneedles were mounted on adhesive foam backing. When this self-
administered microneedle patch was offered to participants as an alternative to 
conventional vaccination, intention to vaccinate increased from 44% at baseline to 
65%. This review also highlights the success of Intanza®, a trivalent, inactivated 
influenza vaccine that is delivered intradermally with the world’s first proprietary 
microinjection system, Soluvia®. This system features a 30 gauge hollow 
microneedle designed for perpendicular administration into the intradermal space. 
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The microneedle is pre-attached to a delivery system that limits the depth of 
insertion to 1.5 mm from the skin’s surface. The needle is attached to a glass 
syringe prefilled with the vaccine dose and a needle shielding system that covers 
the needle post injection [275]. The hollow microneedle within this system is 10–16 
times shorter and 40% thinner than the conventional needles used for IM 
vaccinations [275]. In addition, the microinjection system allows the precise 
administration of 0.1ml [275]. The integrated needle-shielding system is manually 
activated immediately after vaccination, minimising the risk of needle-stick injury, 
contamination and illicit re-use [275]. Comparable acceptability studies of Intanza® 
have been undertaken in European countries such as the United Kingdom, France, 
Germany, Belgium, Spain, Czech Republic and Turkey as well as Australia and 
Argentina, compiling the opinions of 13,518 participants and 680 general 
physicians. Of the 10,740 adults that were vaccinated by Intanza®, 96.6% (95–98%) 
declared they were “satisfied” or “very satisfied” and 93.7% (85–99%) indicated 
that they would prefer to be vaccinated by this method, if given a future choice. 
The latter statistic is particularly significant as it provides an indication of potential 
uptake associated with microneedle-mediated influenza vaccination. Vaccination 
rates remain below the targeted coverage rate of 75% as recommended by the 
European Centre for Disease Prevention and Control. Many reasons have been 
hypothesised to explain this low vaccination uptake, including a low perception of 
risk, a general lack of accurate information about influenza and vaccination, a fear 
of possible and perceived side effects and issues of cost, availability and 
convenience. This literature review has highlighted how microneedle technology 
using either a patch system [101] or  the microinjection system Soluvia®, has the 
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ability to ameliorate several of these concerns, exemplified by the fact that 30% of 
previously unvaccinated participants were willing to be vaccinated when offered 
this technology [101]. 
2.6.3 Perception and acceptability for use in paediatrics 
In their exploratory study, Birchall et al. captured the views of the eventual end-
users of microneedle technology [86]. Focus groups comprising members of the 
public and HCPs were convened. In all seven focus groups, microneedle technology 
was identified as being “good for children”. Questionnaires were further used to 
substantiate the outputs from the qualitative focus groups. This questionnaire 
revealed that 92% of public respondents agreed that microneedles would be ideal 
for the administration of medicines to children. Three of the papers presented in 
this review explored the use of microneedles in the paediatric population [84, 261, 
262]. One study explored children’s views on microneedle use as an alternative to 
blood sampling and reported a positive response [261]. Similarly, a second study 
assessed the views of parents of premature babies on microneedle-mediated 
monitoring as an alternative to blood sampling and once again reported a positive 
response [84]. A third study explored parent’s attitudes toward multiple 
vaccinations at a single visit, with several alternate methods, including a 
microneedle device. This study reported that the microneedle device, MicronJet®, 
was not perceived as better than the conventional syringe [262]. While this system 
is composed of four 0.6 mm hollow silicon microneedles, it is attached to a 
standard syringe barrel thus resembling a conventional vaccine system. This 
arrangement may explain the reduced acceptability reported in this study. 
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Vaccination is one of the most common causes of iatrogenic pain in the paediatric 
population [276]. This pain is a source of distress for children and their guardians 
and can lead to pre-procedural anxiety, needle phobia in later life, mistrust in HCPs 
and healthcare avoidance, including non-adherence with vaccination schedules 
[277]. While several techniques have been employed with varying success to 
manage pain during paediatric injections (topical anaesthetic, music distraction, 
oral distraction in infants, positioning techniques and pH alteration), the ability of 
microneedles to eliminate pain on injection is a significantly desirable attribute [84]. 
In Ireland, the Health Service Executive (HSE) recommends 15 vaccinations (16 for 
females), to be administered from birth to approximately 14 years of age. Current 
vaccination practices typically involve administration of two or three vaccines 
concomitantly at a single visit. Research has demonstrated that the most notable 
reason influencing a guardian’s comfort level with the maximum number of 
injections per visit for their child was avoiding too much pain and discomfort [278, 
279]. Therefore, there is a considerable commercial market for microneedle-
mediated childhood immunisation. However, similar to other areas of medical 
research, the industry remains hesitant to invest in paediatric vaccines given the 
significant ethical implications associated with this special population. While the 
development of microneedle-mediated childhood vaccination programmes is a 
logical goal, microneedle technology could also be used in specific subgroups of the 
paediatric population to reduce treatment burden. For example, Gupta et al. 
concluded that insulin delivery using hollow microneedles in children with Type 1 
diabetes was less painful and had a more rapid onset of action compared to 
conventional administration [248, 280]. Similarly Norman et al. demonstrated that 
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intradermal insulin delivery using a hollow microneedle device resulted in less 
insertion pain and faster onset and offset of action in children and adolescents, 
suggesting that this reduction in pain may improve compliance with insulin delivery 
[88]. Therefore, while the benefits of microneedle technology are multi-fold, their 
dose sparing characteristics, thermostability and reduced potential for needle-stick, 
pale in comparison to their ability to reduce pain when considering the paediatric 
population. 
2.7 Conclusion 
The purpose of this publication was to review the perception and acceptability of 
microneedle technology. Research in recent years has focussed on demonstrating 
the development and potential efficacy of the technology with little published focus 
on determining acceptability, as demonstrated by this review. The benefits of 
microneedle technology in vaccination, especially in the paediatric population are 
glaringly apparent. However, commercial viability will depend on acceptability of 
this technology by parents and HCPs who are key stakeholders who will decide the 
vaccination method. Therefore, research ought to focus on increasing awareness of 
the technology and promoting education in these stakeholder groups. 
2.8 Chapter conclusion and context within thesis 
This chapter presented the findings of a narrative literature review on the 
perception, acceptability and suitability of microneedle technology for paediatric 
immunisation, therefore addressing the first objective of this doctoral research i.e. 
to generate an evidence-base. This evidence-base identified parents as key 
stakeholders in the vaccine decision-making process and informed the design of the 
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qualitative research study, outlined in Chapter 3. This research has been published 
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Vaccines incorporated into microneedle-based patch platforms offer advantages 
over conventional hypodermic injections. However, the success and clinical utility 
of these platforms will depend on its acceptance among stakeholders. Minimal 
focus has been placed on determining parents’ acceptability of microneedle-patch 
vaccines intended for paediatric use.  
Aim 
The aim of this qualitative study was to probe the perceived acceptability of 
microneedle technology for paediatric vaccination in a parent population. 
Methods 
Focus groups (n = 6) were convened through purposive sampling of Cork city 
primary schools. Discussions were audio-recorded, transcribed verbatim, 
anonymised, independently verified and analysed by thematic analysis, with 
constant comparison method applied throughout. 
Results 
The opinions of 32 parents were included. All participants declared that their 
children were fully vaccinated. Five core themes were identified and defined as: 
concern, suitability for paediatric use, potential for parental administration, the role 
of HCPs and special populations. Drivers for acceptance include; concerns with 
current vaccines and vaccination programmes; attributes of microneedle-patch 
(reduced pain, bleeding, fear and increased convenience) and endorsement by a 
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HCP. Barriers to acceptance include; lack of familiarity, concerns regarding 
feasibility and suitability in paediatrics, allergic potential, inability to confirm 
delivery and potential reduction in vaccine coverage. 
Conclusion 
This is the first study to explore parental acceptance of microneedle-patch vaccines. 
Capturing the opinions of parents, the ultimate decision-makers in paediatric 
vaccination, is crucial in the understanding of the eventual uptake of microneedle 
technology and therefore adds to literature currently available. This study has 
revealed that even “vaccine-acceptors”; parents who agree with, or do not question 
vaccination, will question the safety and efficacy of this novel method. Participants 
in this study remained tentative. However, the study has also revealed that HCP 
endorsement could reduce this tentativeness, thereby identifying the role of HCPs 
in disseminating information and providing support to parents. An increased 
awareness of developments in microneedle technology is needed to permit 




Microneedles are micron-sized needles, designed to achieve the efficacy of the 
conventional hypodermic injection with the simplicity of a skin patch [74, 110]. 
Incorporating vaccines into microneedle-based patch platforms offer the possibility 
of reducing costs associated with current vaccination programmes: (i) their 
thermostability eliminates cold-chain transportation requirements, thereby 
reducing distribution costs [105-107] (ii) their potential for self-administration 
would reduce reliance on trained personnel, reducing administration costs [101, 
110-112] and (iii)  their potential dose-sparing characteristics would permit a 
reduction in vaccine antigen per dose, reducing production costs [89, 281, 282]. In 
addition, microneedles may be fabricated using dissolving polymers, eliminating the 
biohazardous sharps waste associated with conventional vaccination methods [111, 
283]. These dissolving microneedle-patches have been developed to successfully 
incorporate vaccines in vivo for multiple disease indications [2]. The ability to 
penetrate the skin with minimal trauma, in the absence of pain and bleeding [110] 
has been identified by healthcare users as an important factor in their eventual 
clinical use [85, 284]. 
Despite these desirable characteristics for HCPs and vaccinees, the success and 
commercial viability of this technology will depend on its acceptance among these 
stakeholders. It is widely accepted that obtaining and evaluating public opinion on 
developing scientific, technological and medical innovation and policy is important 
[285, 286]. The European Medicines Agency (EMA) recommends that evaluation of 
patient acceptability should be an integral component of pharmaceutical and 
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clinical development. In their exploratory research study, Birchall et al., captured 
the perceived advantages of, and concerns with microneedles, through the 
convening of focus groups comprising public participants and HCPs [86]. A high 
percentage of participants suggested that microneedles would be ‘ideal’ for the 
administration of medicines to children [86]. In another study, children expressed a 
favourable viewpoint, suggesting that microneedle-based blood monitoring could 
offer an attractive alternative to conventional methods [261]. This research was 
expanded to include parental perception of microneedle-mediated blood 
monitoring of their infants and, once again, support for the microneedle was 
evident [84]. Research thus far has focussed on demonstrating safety and efficacy 
of microneedle-mediated delivery and assessing the acceptability of microneedle 
technology in general, with minimal focus on determining the acceptability of 
microneedle-patch vaccine delivery, in particular those intended for paediatric use. 
3.3 Aim 
The aim of this qualitative study was to probe the perceived acceptability of 
microneedle technology for paediatric vaccination in a population of parents. 
3.4 Methods 
The acceptability of microneedle-patch vaccines was explored through a series of 
focus groups. Focus groups were chosen as they can provide insights into attitudes 
and beliefs that underlie behaviour and give context and perspective that enable 
experiences to be understood more holistically [287]. These attitudes, feelings and 
beliefs may be partially independent of a group or its social setting but are more 
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likely to be revealed via the social gathering and the interactions entailed within a 
focus group.  
A list of primary schools in Cork city, Ireland (n=50), detailing address, principal 
name and contact details was compiled using information freely available from the 
Irish Department of Education and Skills. A recruitment poster, a copy of the 
informed consent form and a cover letter detailing study overview, addressed to 
each principal, were sent via post. A follow-up email detailing the same information 
was sent one week later. With the permission of the principal, contact was made 
with the Parent Association of those schools that expressed willingness to 
participate and focus group participants were recruited, using purposive sampling. 
Inclusion criteria included self-declared satisfactory English language and parent or 
guardian of a child or children less than 12 years of age, with no limitation placed 
on age or gender of participant. Focus groups took place within the grounds of the 
school, often coinciding with pre-arranged Parent Association meetings, to enhance 
convenience for participants. Written informed consent to take part in the study 
and to be audio-recorded was obtained from participants prior to each focus group. 
Information detailing gender, age, highest level of education achieved (according to 
International Standard Classification of Education (ISCED)) [288], number of 
children less than 12 years of age in their care and the vaccination status of their 
children was obtained for each participant. 
A brief description of microneedle-patch vaccines, explaining their ability to disrupt 
the outer skin barrier layer and deliver a vaccine, without impinging on the 
underlying pain receptors and blood vessels, was provided by the moderator. This 
was considered necessary given the likely unfamiliarity of participants with 
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microneedle technology. However, to mitigate against risk of introduction of bias, 
information relayed was of a factual nature only. A research prototype, placebo 
microneedle-patch was passed around the groups and a magnifying glass was 
provided, to permit visualisation of the individual microneedles, to act as a 
focussing exercise to stimulate discussion and to reduce bias by enabling the 
independent formation of opinions (Figure 11).  
 
Figure 11 Prototype, placebo microneedle-patch & magnifying glass given to participants at the outset of 
focus groups 
 
A topic guide with a semi-structured design was used during each focus group, 
constructed based on a comprehensive literature search [1], providing general 
probes in an open-questioning style (Table 6). Ethical approval was obtained from 
the Social Research Ethics Committee, University College Cork.  
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Table 6 Focus group topic guide 
Opinions of vaccines  
What are your opinions on current paediatric vaccination programmes? 
Do you agree with current paediatric vaccination programmes? 
What are the benefits of vaccination programmes? 
What are your concerns about vaccination programmes? 
What are the problems with current vaccination programmes? 
Are you happy for your children to be vaccinated? 
Do you have any issues with current vaccination methods? 
Do you think cost is a major consideration with vaccination programmes? 
Opinions of microneedle-patch vaccines 
Before today, had you ever heard of a microneedle-patch vaccine? 
What is your initial opinion of the microneedle-patch vaccine? 
Do you believe that the microneedle-patch vaccine is as effective as other vaccination methods? 
Would you trust this vaccination method? 
Do you think there are any advantages of the microneedle-patch vaccine? 
What do you like about the microneedle-patch vaccine? 
Do you think there are any disadvantages of the microneedle-patch vaccine? 
What do you dislike about the microneedle-patch vaccine? 
Would you have any concerns in relation to the use of a microneedle-patch vaccine? 
Would you allow your child or a child in your care to be vaccinated using a microneedle-patch vaccine? 
Do you think the microneedle-patch vaccine could change opinions of vaccination? 
What would children think of the microneedle-patch vaccine? 
Do you think people would be nervous of the microneedle-patch vaccine? 
If given a choice, which method of vaccination would you prefer? 
Who do you think should administer the microneedle-patch vaccine? 
Do you think you would be able to self-administer the microneedle-patch vaccine? 
Would you be willing to administer the microneedle-patch vaccine to your child or a child in your care? 
Would you be comfortable with administering the microneedle-patch vaccine to your child or a child in your 
care? 
Is there any way you think the microneedle-patch vaccine could be improved? 
What do you think of the design of the microneedle-patch vaccine? 
Is there any way you think the design of the microneedle-patch vaccine could be improved? 
Do you think the Health Service Executive (HSE) should endorse and invest in the microneedle-patch vaccine? 
 
Audio-recorded sessions, using a Dictaphone (OLYMPUS Digital Voice Recorder VN-
731PC), were fully transcribed verbatim within one week of each focus group. Data 
were entered into QSR International’s NVivo V.11 software to assist analysis. Each 
participant was assigned an anonymised identifier. Transcripts were verified against 
audio-recordings with a random sample verified by an independent researcher. 
Focus groups transcripts were independently coded by co-investigators. Disparities 
were identified and resolved through discussion. Data were analysed by thematic 




Six focus groups were completed from 3rd November 2015 to 12th January 2016, 
representing an uptake rate of 12%. The opinions of 32 participants (29 female) 
were compiled. The most commonly reported age range was 30-39 years (46.88%), 
highest education level was Higher Education (ISCED level ≥ 4) (68.75%) and the 
number of child(ren) under 12 years in their care was two (46.88%). All participants 
declared that their children were fully vaccinated, to the best of their knowledge. A 
summary of participant demographics, including their anonymised identifier is 






Table 7 Participant demographics 













ISCED level 3 
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ISCED level ≥4 
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ISCED level 3 
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*Highest education level 
 ISCED level 1: Primary education, equivalent to 8 years official State education 
 ISCED level 2: Lower secondary education: Irish Junior/Inter Certificate, equivalent to 11 years official State 
education   
 ISCED level 3: Upper secondary education: Irish Leaving Certificate, equivalent to 14 years official State 
education 
 ISCED level ≥4:  Higher Education including post-secondary non-tertiary education, short-cycle tertiary 
education, Bachelor (or equivalent), Master (or equivalent) and Doctoral (or equivalent) 
 
 
Two of the six participating schools were included in the Delivering Equality of 
Opportunity in Schools (DEIS) programme, that is part of the Department of 
Education and Skills action plan which focusses on addressing and prioritising the 
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educational needs of children from disadvantaged communities. Focus group 
duration ranged from 27 to 42 minutes (Table 8). 
Table 8 Focus groups: DEIS status, gender breakdown and duration 
 DEIS* Male (n) Female (n) Duration (mins) 
FG1 No 0 4 33 
FG2 Yes 0 5 42 
FG3 Yes 1 5 37 
FG4 No 0 5 27 
FG5 No 0 5 29 
FG6 No 2 5 33 
 
*DEIS = Delivering Equality of Opportunity in Schools 
 
  
Focus groups transcripts were analysed by thematic analysis, with constant 
comparison method applied throughout. Five core themes were identified and 
defined as: concern, suitability for paediatric use, potential for parental 
administration, the role of the HCP and special populations (Table 9). A pictorial 
representation of these themes, sub-themes and associated exemplar quotes is 
seen in Figure 12. 
Table 9 Themes and sub-themes and their occurrence in each focus group 
 Focus group 





























Suitability for paediatric use 
Practicality 
Child-friendly design 
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Benefits of parental administration 
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Figure 12 Themes, sub-themes and associated exemplar quotes
•Current vaccines 
•Vaccine hesitancy 




•Transfer of acceptability 
Suitability for 
paediatric use 
•Benefits of parental administration 





•Source of healthcare information 






“No one likes looking at a needle, no matter how brave you are” 
“I don’t think it’s the patch at all or the needles, I just think some people are just against 
vaccines no matter what” 




“You would have to monitor a child a lot more to make sure they keep it on and everything” 
“What about making them more child-friendly, like with Disney princesses or superheroes?” 
“But if it becomes an accepted norm for adults, then they’ll more easily put it on their kids 
 
“This is more casual and relaxed. Just like putting on a band aid” 
“You’d need to be told or shown first…before you did it yourself” 
 “But even something that when you put it on and then when it changed colour or did 
something, 100%, you know it’s done” 
 
 
“I think if my doctor recommended this patch and trusted it, I would be happy with it” 
 
 
“Could kids be allergic to it? To the plaster part. People are allergic to plasters aren’t they?” 





Concern emerged as a theme in all focus groups. Participants expressed concerns 
regarding current vaccination methods and programmes, such as unattractive visual 
appearance and hysteria associated with in-school programmes. In addition, 
participants discussed personal negative experiences with vaccines such as fear, 
parental and paediatric trauma, pain and side effects:  
P31 “No one likes looking at a needle, no matter how brave you are” 
P29 “Mass fainting, hysterical crying, nightmare to deal with, this is why 
I’m not sure these in-school vaccine sessions are a good idea. I think 
it creates chaos” 
Some participants alluded to the behavioural phenomenon of vaccine hesitancy, 
despite declaring that all children in their care were fully vaccinated. 
P11 “Is it still as important today as it was 10 years ago to get these 
vaccinations?...if you listen to some media, people have gotten sicker 
because of these vaccinations and some people blame these 
vaccinations…my small one is after having the mumps even after 
getting the vaccine…is it really important to get them when you say it 
prevents these things but it’s still not preventing them”  
P11 “I don’t think it’s the patch at all or the needles, I just think some 
people are just against vaccines no matter what” 
Evidence of safety and efficacy was of paramount importance to parents, with all 
focus groups requiring reassurance that microneedle-patch vaccines would be as 
safe and efficacious as conventional vaccines.  
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P3 “So they have done controls comparing with injection with needle 
and syringe to the patch?” 
P7 “I actually, I love the idea of it in theory being able to give it but at 
the same time, before I’d give it to my child I’d want it to be tested in 
hundreds of thousands of people across the world for ideally at least 
10 years”  
 P32 “Well I think it sounds great, if it’s as good as the normal vaccine” 
P30 “It’s hard to believe the needles are big enough to give the vaccine, I 
mean, they’re tiny” 
P31 “By creating loads of holes in your skin are you not increasing the risk 
of picking up an infection?” 
3.5.2 Suitability for paediatric use 
Focus groups participants acknowledged the advantages of microneedle-patch 
vaccines for paediatric use. These included a reduction in pain and bleeding and an 
attractive visual appearance. However, the practicality and feasibility of using a 
patch delivery system in a paediatric population was explored: 
 P4 “If the child finds something on their arm, they will take it off” 
P9 “You would have to monitor a child a lot more to make sure they 
keep it on and everything” 
P7 “I’m just thinking of the practicality though you know…if you’re using 
the thigh and what if they have an explosive nappy?”  
In addition, the current design of the patch was challenged and suggestions were 
offered to make the delivery system more ‘child-friendly’: 
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P4 “If they are designing those and especially for children, they would 
want to make them child friendly, in other words put some type of 
funny face or something on the patch so that the child would keep 
them on…make it completely invisible so the child doesn’t notice it” 
P13 “What about making them more child-friendly, like with Disney 
princesses or superheroes or something?” 
Focus groups discussed that acceptability for use in a paediatric population would 
be increased by an initial period of use in an adult population, permitting 
familiarisation with the microneedle technology: 
P1 “But if it becomes an accepted norm for adults, then they’ll more 
easily put it on their kids” 
P7 “If it was in widespread use as a technology for adults that we were 
more comfortable with it, familiar with it, you know that you’d be a 
bit more open to extending what’s normal for an adult to a child” 
3.5.3 Potential for parental administration 
Participants acknowledged the potential benefits of parental administration, 
including convenience and a reduction in fear for the child: 
 P1 “Avoids the hassle of having to go” 
P11 “It would be a lot easier, as parents to put them on ourselves because 
bringing any child to a doctor is going to put fear in them anyway so 
doing it ourselves, it takes the fear factor completely out of it” 
P29 “This is more casual and relaxed. Just like putting on a band aid” 
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However, a large number of parents indicated a level of discomfort with 
administration to their own children. Many participants believed that HCPs ought to 
administer the vaccine, regardless of the delivery system; while others recognised 
the benefits of parental administration but would prefer medical supervision and 
reassurance should they be administering the vaccine to their own child. 
Participants discussed the need for reassurance that the patches would be easy to 
use, with minimal guidance or training.  
P2 “You’d need to be told or shown first…before you did it yourself” 
P7 “How hard would you need to push, would you be literally ramming it 
against the skin?...my child I guarantee would end up with a bruised 
arm I’d be pushing so hard…like I presume there’s no danger with us 
putting them on ourselves, you know, there’s no special way to put 
them on or anything like that” 
In addition, participants raised concerns regarding the potential elimination of 
current vaccine surveillance and monitoring systems and reduced traceability that 
may be associated with wide-spread parental administration, suggesting that 
convenience may result in a level of complacency and/or non-compliance: 
P4 “The HSE will send you out a letter to tell you your vaccination is due. 
If you don’t go, they will keep contacting you with letters…I know I 
would be quite lackadaisical, knowing it’s there and I can do it any 
time, I won’t do it” 
P14 “People could genuinely forget, leave it in the cupboard and say I’ll 
do it later” 
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P1 “We’d have to put something in place or else we would have no idea 
who was vaccinated” 
Many groups discussed how the inclusion of a delivery indicator would be 
necessary to provide reassurance that the appropriate dose had been administered, 
with participants offering suggested alterations to the current patch system.  
P5 “But even something that when you put it on and then when it 
changed colour or did something, 100%, you know it’s done” 
P16 “Is there any way you could tell they got the full amount? Like if it 
just fell off or something when it was done dissolving” 
P27 “It would be great if it changed colour or something, like change to 
green when it’s time to take it off and stay red when it’s dissolving or 
whatever. That could almost turn into a game and encourage the 
child to leave it on” 
3.5.4 The role of the HCP 
The pivotal role played by HCPs, such as doctors, nurses and pharmacists, in guiding 
healthcare decisions and supervising and providing medical care was revealed.  
 P20 “When the doctor told me to come in for the jabs, I just did” 
P26 “I think if my doctor recommended this patch and trusted it, I would 
be happy with it. I have to rely on them for information because if 
you gave me all the clinical study information or whatever in the 
world, I would not understand it” 
P3 “Even if the pharmacist would administer it. At least there’s some 
kind of monitoring then” 
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3.5.5 Special populations 
Participants identified the potential for allergy associated with microneedle-patch 
vaccines, suggesting that this technology may be unsuitable for hypersensitive 
individuals. 
P8 “Would you not expect reactions to occur, if dissolving in the skin, like 
allergy?” 
P18 “Could kids be allergic to it? To the plaster part? People are allergic 
to plasters aren’t they?” 
P23 “Or what if a child has very sensitive skin, would the patch irritate 
it?” 
Focus group participants discussed alternative uses for the microneedle-patch, 
without prompt. It was highlighted that because a microneedle-patch would cause 
less pain on administration, the technology could provide an attractive alternative 
in the treatment of a variety of conditions, where a needle and syringe are 
conventionally required. This was deemed particularly useful in situations where 
multiple, repeated injections are required.  
P13 “You know people are on monthly injections of immune suppressants 
and stuff, maybe it could replace those…and diabetics as well, poor 
things have to inject loads of times per day” 
P17 “My nephew is diabetic and has to give himself insulin all the time. 
He’s 15 you know and poor fella hates being different and kind of, 
standing out. Wouldn’t it be great if he could just stick on the patch 
instead? No one would even see it” 
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P21 “Wouldn’t they be great for babies in neonatal? The ‘preemies’ or 
even the sick babies and children that need to get lots of daily 
injections?” 
P27 “Like insulin for diabetics. I think a patch like this would be great and 
they’d be checking their sugars anyway so they’d be sure it was 
working” 
3.6 Discussion 
The aim of this qualitative study was to determine the acceptability of microneedle 
technology for paediatric vaccination in a population of Cork city parents. According 
to the HSE in Ireland, the target vaccine uptake rate for childhood immunisations is 
≥95%. In their most recently available data, the Health Protection and Surveillance 
Centre (HPSC) reports that only the 6-in-1 vaccine (D3, T3, P3, Hib3, Polio3 and 
HepB3) administered to children at 24 months of age in 2015 had reached the 
target uptake rate of 95% (Figure 2). Therefore, there is scope for improving vaccine 
uptake, potentially through the introduction of novel immunisation methods, such 
as microneedle technology, as explored in this study. Whilst many sub-themes 
emerged, the five dominant themes that were revealed by thematic analysis were: 
concern, suitability for paediatric use, potential for parental administration, the role 
of the HCP and special populations. Capturing the opinions of parents, the ultimate 
decision-makers in paediatric vaccination, is crucial in the understanding of the 




Six focus groups compiled the opinions of 32 participants (29 female). Such a 
gender imbalance is not unusual: mothers are found to be more likely to participate 
in clinical research [84]. Parental concern emerged as an overarching theme in this 
qualitative study. Participants alluded to established issues associated with 
conventional hypodermic needles, including phobias, pain, side effects and 
paediatric and parental anxiety [75, 78, 289]. In addition, some parents expressed 
concern regarding school vaccination programmes and their potential to cause 
hysteria, particularly in association with the administration of adolescent vaccines 
[290, 291]. These concerns may act as drivers for the acceptance of an alternative 
vaccine delivery system, such as microneedle technology. However, before a novel 
vaccine delivery system can be considered for acceptance, an effort must be made 
to address current vaccine concerns. Despite declaring that their children were fully 
vaccinated, one participant in this study expressed opinions which questioned the 
safety and efficacy of vaccines. Benin et al would categorise this participant as 
“vaccine-hesitant”, accepting vaccination in spite of significant concerns [265, 292]. 
Vaccine hesitancy presents a significant challenge, requiring a multidisciplinary 
approach [293]. Many studies have shown that increasing knowledge alone will not 
change behaviour and reduce vaccine hesitancy [294]. Efforts focussed on 
determining how parents make decisions regarding vaccination, how their attitudes 
and beliefs develop, and where they obtain information, should contribute to 
better understanding of vaccine hesitancy [293, 295]. This study revealed that even 
“vaccine-acceptors”, those who agree with or do not question vaccination [292], 
will question the safety and efficacy of novel immunisation methods [296]. In 
agreement with published literature, our results suggest that lack of familiarity may 
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act as a barrier to acceptance [84, 86, 261]. However this barrier may be diminished 
by highlighting the advantages of microneedle-patch vaccines over conventional 
vaccination, by administering adult vaccines, such as influenza, using microneedle 
technology before progressing to paediatric use [89, 101, 265] and by securing HCP 
endorsement [296]. In addition, it is likely that parents would benefit from 
educational programmes that highlight the manner in which safety and efficacy 
assessments are conducted prior to licensure [296].  
Microneedle technology has been identified as ideal for paediatric use [84, 86, 261]. 
However, this is the first study which asked participants to specifically consider a 
patch delivery system and this resulted in both the suitability and feasibility being 
challenged. Whilst participants recognised and acknowledged the benefits of the 
technology, concern was expressed regarding the wear-time required. Vaccinees 
must wait for the required periods of time for the microneedle to detach from the 
backing layer or dissolve into the skin before the patch can be removed. 
Participants expressed concern that paediatric tolerance of such a requirement 
would be low. In agreement with previous research, it was suggested that by 
creating a child-friendly version of the delivery system, children may be encouraged 
to leave the patch in place for the required amount of time [261]. Various 
approaches have been developed to overcome the issue of prolonged wear-time 
[99]. Two layered dissolving microneedle and arrowhead microneedle, consisting of 
a therapeutic polymer layer and a shaft, respectively, have been designed to deliver 
with greater efficiency [297, 298]. Alternatively, a soft lithography approach based 
on a water soluble patch system has been introduced to increase delivery efficiency 
by dissolving the patch after microneedle application [299]. Given the parental 
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concerns expressed, these approaches may warrant further investigation for the 
delivery of paediatric vaccines.  
A well-documented advantage of microneedle-patch vaccines is the potential for 
self-administration [86, 101, 110-112, 261]. One US study which examined the 
usability and acceptability of microneedle patches for self-vaccination against 
influenza reported that when given self-administration options, intention to be 
immunised increased significantly, suggesting that microneedle technology could 
increase vaccine coverage [101]. Of those participants who expressed a preference 
for microneedle-mediated immunisation, 72% preferred self-administration at 
home, 12% preferred self-administration in the presence of a HCP and 16% 
preferred administration by a HCP [101]. While self-administration of paediatric 
vaccines is not feasible, participants were asked to consider the acceptability of 
parental administration. The majority of participants in our study preferred vaccine 
administration by a HCP, contradicting research by Birchall et al, who reported that 
80% of participants disagreed with the statement “I don’t think I would want to 
administer microneedles to a child in my care” [86]. In agreement with previous 
research, participants suggested that the inclusion of a delivery indicator would be 
a desirable augmentation of the current design [86, 261]. A colour change was also 
suggested, combining dual benefits of increasing paediatric appeal and confirming 
delivery. Participants expressed concern that widespread parental administration 
could result in an intentional or unintentional reduction in immunisation rates and 
a decrease in population vaccine coverage overall. The national childhood 
immunisation programme, which recommends the administration of 15 vaccines 
from birth to approximately five years of age, is currently co-ordinated by General 
108 
 
Practitioners (GPs) and a series of Local Health Offices. The introduction of parental 
administration of vaccines would warrant the development of a National 
Immunisation Database, which would facilitate self-reporting of immunisation 
status and ensure vaccine traceability.   
The purpose of this study was to determine the acceptability of vaccine delivery by 
microneedle technology. However, similar to previous research, participants 
discussed alternative uses of this technology, particularly in the management of 
conditions where repeated injections are warranted, such as insulin in the 
management of diabetes, analgesics in the management of chronic pain, anti-
rheumatic agents in the management of arthritis and chemotherapeutic agents in 
the treatment of cancer  [86]. The clinical assessment of microneedle-mediated 
delivery of many drugs and macromolecules is already established [74, 245, 246, 
248-250]. Parental enthusiasm for microneedle-patch technology was increased by 
the exploration of alternative uses other than vaccination. It may be suggested that 
on-going monitoring in conditions such as diabetes is routine, thus providing 
continuous confirmation of efficacy, unlike vaccination, where confirmation of 
immunity is not routinely performed. By introducing microneedle technology for 
the management and treatment of these identified conditions, familiarity would be 
increased; there would be a tangible demonstration of safety and efficacy; and 
parental acceptance of microneedle-patch vaccines could be increased. In 
agreement with previous research, parents compared the delivery system to a 
sticking plaster and therefore expressed concern regarding the allergenic potential 
of microneedle-patch vaccines [84, 86, 261]. Similar to transdermal patch products, 
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the use of a hypoallergenic system to ensure more widespread suitability and to 
reduce allergy potential would be necessary. 
HCPs including doctors, nurses and pharmacists will play a crucial role in the clinical 
success of microneedle-patch vaccines. Parent interactions with HCPs are a key 
factor shaping parental attitudes to vaccination [300]. An effective interaction can 
alleviate concerns of vaccine supportive parents and motivate a hesitant parent 
towards acceptance [33, 38]. These parental concerns are likely to escalate with 
increased complexity of vaccination schedules, increased access to information 
sources of variable reliability [134] and the emergence of novel immunisation 
methods, such as microneedle technology. HCP endorsement of a novel technology 
is critical to its success. Previous research has reported a positive response to 
microneedle technology by HCPs [86, 101]. Continuing professional development 
(CPD) could facilitate training in this technology and in parent engagement, 
according to proposed recommendations [301-303]. Guided by parental concerns 
expressed in relation to parental and self-administration, it is likely HCPs will retain 
the responsibility of vaccination, ensuring traceability and appropriate clinical 
management. Limitations of this study include small sample size (n=32), participant 
self-selection and the necessary provision of factual information by the moderator. 
3.7 Conclusion  
This is the first study to explore parental acceptance of microneedle-patch vaccines. 
While participants in this study remained tentative regarding microneedle 
technology, it was revealed that this tentativeness could be reduced by HCP 
endorsement. Therefore, this study has identified the role of HCPs in disseminating 
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information and providing support to parents. An increased awareness of 
developments in microneedle technology is needed to permit informed decision-
making by parents.  
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3.9 Chapter conclusion and context within thesis 
This chapter presented the findings of a qualitative focus group study which 
explored the parental perception of microneedle-patch mediated paediatric 
immunisation, therefore addressing the second objective of this doctoral thesis i.e. 
to ascertain the knowledge, attitudes, and beliefs of key stakeholders to elucidate 
vaccine decision-making and to identify barriers to vaccine uptake in Ireland. It had 
been suggested in Chapter 2 that needle fear may be a barrier to vaccine uptake 
and that microneedle technology may offer a solution. Focus group participants 
recognised the positive attributes of microneedle-patch mediated vaccination i.e. 
reduced pain and bleeding and attractive visual experience, but expressed concern 
in their lack of familiarity with the technology. While needle fear was 
acknowledged, the participants did not feel this was a significant deterrent to 
vaccination. This research has been published in a peer-reviewed journal and has 
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SM was involved in the overall design of the research, registered the project on the 
International Prospective Register of Systematic Reviews (PROSPERO), developed a 
search strategy (in consultation with a health sciences librarian), performed the 
literature searches, assessed titles and abstracts of all retrieved citations, retrieved 
full articles for all potentially relevant studies, recorded individual study 
characteristics, wrote the draft manuscript and was involved in manuscript editing. 
SM, AF and LS assessed full articles for inclusion, assessed study quality using the 
Critical Appraisal Skills Programme (CASP) for qualitative research, read and 
independently identified key concepts, and performed the meta-ethnographic 
synthesis. SM, AF, AM and LS defined the inclusion and exclusion criteria. AF, AM 





Human papillomavirus (HPV) is the most common viral infection of the reproductive 
tract. Three prophylactic HPV vaccines are available for the prevention of HPV-
related disease. Despite clinical success, immunisation rates remain sub-optimal.  
Aim 
The aim of this systematic review is to synthesise qualitative literature to achieve 
an understanding of the drivers and barriers to HPV vaccine acceptability and to 
determine targets for an intervention to improve vaccine uptake.  
Methods 
The seven-step model of meta-ethnography described by Noblit and Hare was used. 
The quality of the studies was assessed using the CASP (Critical Appraisal Skills 
Programme) for qualitative research. The ENTREQ (Enhancing transparency in 
reporting the synthesis of qualitative research) statement was used to guide 
reporting of results. 
Results 
Thirty-three studies were included in the final analysis, compiling the opinions of 
1280 parents from 14 countries. Five key concepts that reflected the principal 
findings of studies were determined: is prevention better than cure; the fear of the 
unknown; limited knowledge and understanding; complex vaccination decisions 
and; parental responsibility. Third-order interpretations were developed and linked 




The majority of parents are motivated to protect their children and prevent disease. 
The link to sexual intercourse associated with the HPV vaccine often complicates 
the vaccination decision. Vaccine manufacturers, national healthcare systems and 
HCPs can reinforce the importance of HPV immunisation and reiterate the rationale 
behind vaccination recommendations, by providing unambiguous information in a 
timely manner, transparently addressing parental concerns regarding vaccine safety 
and efficacy, whilst taking account of cultural and religious sensitivities and varying 
health literacy levels. In recent years, there has been a reduction in HPV vaccine 
uptake worldwide. Currently, there is a paucity of published qualitative studies 
addressing these new vaccine concerns. Therefore, such research is required to 
guide intervention development, to improve HPV vaccine uptake. 
Graphical Abstract 
 
What is already known on this 
subject? 
Qualitative studies from a range of 
countries have elicited parents views 
regarding HPV vaccination 
What does this study add? 
The synthesis of these studies has provided a greater understanding of the drivers and 
barriers to HPV vaccine acceptability. While a level of vaccine hesitancy is evident in all 
populations, the majority of parents are motivated to protect their children and prevent 
disease by accepting vaccines. In contrast to other vaccines, the link to sex associated with 
this vaccine complicates the decision. Vaccine manufacturers, national healthcare systems 
and HCP can reinforce the importance of HPV immunisation and reiterate the rationale 
behind vaccine recommendations by providing unambiguous information in a timely 
manner, transparently addressing parental concerns regarding vaccine safety and efficacy, 




Human papillomavirus (HPV) is the most common viral infection of the reproductive 
tract in both men and women [304]. The virus is spread through contact with 
infected genital skin, mucous membranes or bodily fluids, and is transmitted 
through sexual intercourse [304]. Although the majority of HPV infections are 
asymptomatic, and resolve spontaneously within six to 18 months [305], persistent 
infection with HPV may result in disease, including cancers [304, 306-308]. It was 
estimated that 630 000 new HPV-related cancers occurred internationally in 
women in 2012, of which 530 000 were cervical cancer [304]. This resulted in an 
estimated 266 000 deaths worldwide, accounting for 8% of all female cancer deaths 
in that year [309]. Three prophylactic HPV vaccines are currently available and 
marketed in many countries worldwide for the prevention of HPV-related disease 
[144-146]. For the prevention of cervical cancer, the WHO recommends vaccination 
of girls aged 9-14 years, prior to onset of sexual activity [304]. While the maximum 
public health potential of HPV vaccination is not yet realised, ten years of vaccine 
usage has resulted in: a 90% reduction in HPV 6, 11, 16 and 18 infections and 
genital warts; a 45% reduction for low-grade cytological cervical abnormalities; and 
a 85% reduction for high-grade histologically proven cervical abnormalities [310]. 
Despite this clinical success, immunisation rates worldwide remain sub-optimal 
[147, 223], thus there is a need for interventions to increase vaccine uptake. 
Parents have the responsibility and authority to make healthcare decisions on 
behalf of their adolescent children. To develop a successful intervention, it is 
essential to understand the factors underlying parental apprehension. Qualitative 
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studies, from a range of countries have elicited parents’ views regarding HPV 
vaccination and a synthesis of these studies has the potential to achieve a greater 
understanding of the drivers and barriers to HPV vaccine acceptability. 
4.3 Aim 
The aim of this review is to synthesise this qualitative literature and to determine 
targets for a theoretically informed, evidence-based intervention to improve 
vaccine uptake.  
4.4 Methods 
The seven-step model of meta-ethnography described by Noblit and Hare was used 
[311]. Meta-ethnography uses a process of comparison and cross-interpretation 
between studies while preserving the context of the primary data [311]. This 
synthesis method has the potential to provide a higher level of analysis, generate 
new research questions and reduce research duplication [312].  
1. The first step involved a clear statement of the research question and the 
development of inclusion and exclusion criteria (Appendix 4.1). The review 
protocol was registered on the International Prospective Register of Systematic 
Reviews (PROSPERO) and may be accessed at:  
http://www.crd.york.ac.uk/prospero/DisplayPDF.php?ID=CRD42017048714. 
2. A search strategy was developed to retrieve articles related to the research 
question in consultation with a health sciences librarian at Mercy University 
Hospital, Cork (Appendix 4.2). The search was focused to locate primary studies 
that explored parent opinions on HPV vaccination. Three databases were 
searched using database-specific search terms: MEDLINE (Ovid), CINAHL and 
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EMBASE (Elsevier), from inception to December 2016. This was supplemented 
by searching databases of grey literature (Google Scholar) and reference lists of 
included citations. The search was not limited by language. Following removal 
of duplicates, the titles and abstracts of retrieved citations were assessed by 
one reviewer (SM). Full articles were retrieved for all potentially relevant 
articles. These articles were reviewed by three reviewers (SM, LS and AF) and 
were included if they fulfilled the inclusion criteria. Any disagreement regarding 
the eligibility of particular studies was resolved through discussion with a fourth 
reviewer (AM). The quality of included studies was assessed by SM, LS and AF, 
using the Critical Appraisal Skills Programme (CASP) for qualitative research 
[313]. However, studies that otherwise met the inclusion criteria, were not 
excluded based on the quality assessment, as lower quality studies may still 
provide evidence to address the research question [314].  
3. Three reviewers (SM, LS and AF) carefully read the included studies and 
independently identified the key concepts from information detailed in the 
results and discussion sections of the studies. These included both first-order 
(views of participants) and second-order (views of authors) interpretations [315, 
316]. In studies in which parents were included in focus groups with other 
individuals not meeting the defined inclusion criteria e.g. HCPs, the analysis was 
restricted to the views of the parents. In tandem with this process, SM recorded 
individual study characteristics, to provide the context for the interpretations 
and explanations of each study [316]. 
4. It was determined how the studies were related to each other by comparing 
individual findings. Key concepts were chosen which reflected the main findings 
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of all included studies. Data were entered into QSR International’s NVivo V.11 
software to assist our qualitative analysis and synthesis.  
5. The studies were translated into each other, by examining the contribution of 
each study to a key concept. Similarities and differences in study findings were 
recorded.  
6. Translations in each key concept were synthesised to develop third-order 
interpretations, linked using a ‘line of argument’ to develop a conceptual model 
which represents parental views regarding adolescent HPV vaccination.  
7. Finally, the ‘Enhancing transparency in reporting the synthesis of qualitative 
research (ENTREQ)’ statement was used to guide reporting of results [317] 
(Appendix 4.3). 
4.5 Results 




Figure 13 PRISMA flow diagram of search strategy 
 
The included studies were conducted in 14 countries: Australia (n=1), France (n=1), 
Hong Kong (n=1), India (n=1), Kenya (n=1), Malaysia (n=1), Peru (n=1), Romania 
(n=1), South Africa (n=1), Sweden (n=1), Tanzania (n=1), United Kingdom (n=4), USA 
(n=17) and Vietnam (n=1). A total of 1280 parents were included. Twenty-two 
studies used interviews, seven studies used focus groups and four studies used a 
combination of interview and focus group methods. The HPV vaccine was available 
in the jurisdictions in which 26 of the studies were conducted, while seven studies 
were conducted prior to vaccine implementation [318, 326, 332, 339, 340, 343, 
348] (Appendix 4.4). The overall quality of included studies was assessed to be 
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moderate to high (Appendix 4.5). A common weakness, found in 27 studies [318-
333, 335, 338-342, 345-349] was inadequate researcher reflexivity, where the 
relationship between researcher and participants had not been adequately 
considered.  
Five key concepts that reflected the principal findings of all studies were 
determined. Within each key concept, subthemes arose and are highlighted in bold. 
A summary of the occurrence of these key concepts and subthemes is provided in 
Appendix 4.6. 
4.5.1 Is prevention better than cure? 
The majority of parents expressed a desire to prevent HPV infection and its 
sequelae [174, 318, 319, 321, 324-327, 329-332, 334, 335, 337, 338, 340-343, 348, 
349]. There was a high level of vaccine acceptance in general [174, 319-321, 326, 
328, 329, 334, 339, 340, 342, 343, 348, 349], with parents recognising the financial 
savings associated with immunisations [319, 321, 325], especially in jurisdictions 
where there is a lack of access to treatments [319, 326]. Conversely, in several 
studies, a level of vaccine hesitancy was evident [174, 326, 334, 336, 337, 346, 
348]: a behaviour influenced by a number of factors including issues of confidence,  
complacency and convenience [48]. Regarding the HPV vaccine specifically, some 
parents expressed trust in the vaccine [328, 329] and were reassured by the use of 
the vaccine elsewhere [321, 328, 334]. In addition, some parents felt it would be 
important to participate in immunisation programmes, if access was provided [174, 
326, 328, 332, 349]. 
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4.5.2 The fear of the unknown 
Parents expressed their concerns and their lack of familiarity associated with this 
new vaccine [174, 321, 324, 328-330, 333, 334, 336, 343, 349]. The safety and 
efficacy of the vaccine was discussed in detail [174, 318, 320-322, 324-326, 328, 
332-335, 338, 340, 341, 344-349], in particular the potential for side effects, 
ranging from mild discomfort to paralysis, infertility, impaired development, 
increased risk of HPV infection and cancer, allergy, autism and death [174, 319, 321, 
322, 325, 326, 328, 330, 332, 334, 336, 339, 340, 342-345, 348, 349]. Some parents 
viewed the vaccine as experimental [319, 321, 322, 332, 335, 347], fearing their 
children could be ‘guinea pigs’ in a clinical trial. Others suspected a conspiracy 
theory, whereby the vaccine was a tool to impair fertility and therefore reduce the 
world population [322, 336, 343]. These factors encouraged watchful waiting; 
whereby parents delayed vaccination until their concerns were alleviated [174, 318, 
321, 323, 324, 333, 334, 336-338, 341, 342, 349]. Some parents were concerned 
that vaccination would give their daughter a false sense of security and invincibility, 
leading her to engage in risky behaviour [334, 336, 341, 343, 347-349], impacting 
their sexual and general health. Conversely, parents discussed their fears of HPV 
infection and cancer [321, 330, 331, 335, 345]. The potential for anticipated regret, 
should they withhold vaccination was explored [328-330, 334]: the potential that 
their child could suffer unnecessarily from a vaccine-preventable illness. Parents 
also discussed how HPV vaccination could offer a level of protection and security if 





4.5.3 Limited knowledge and understanding 
The majority of parents exhibited limited knowledge of the HPV vaccine [174, 318, 
320, 325-328, 330-332, 334-345, 347-349] and recognised that this limited 
knowledge prevents them from making an informed decision regarding 
vaccination [318-320, 322, 324, 330, 333, 335, 338, 341, 345, 347-349]. A lack of 
understanding was evident from the majority of studies [174, 318, 319, 321, 322, 
325, 326, 329-338, 340, 341, 345-349], in particular regarding the recommendation 
for vaccination at such a young age [174, 318, 321, 322, 324, 328, 330, 333-336, 
338, 341, 344, 346-349], prior to sexual debut. In some studies, the low levels of 
knowledge and understanding was reportedly associated with limited health 
literacy [327, 331, 340, 347], the reduced capacity to obtain, process, and 
understand basic health information and services needed to make appropriate 
health decisions [67]. 
4.5.4 Complex vaccination decisions 
These studies highlighted the multifactorial process involved in making healthcare 
decisions. Parents believed that provision of information [174, 319, 321, 326, 328, 
329, 332, 333, 337, 341, 343, 345, 347] would encourage vaccination, while poor 
provision of information [174, 318, 321, 322, 328, 331, 341, 344, 347-349] was 
identified as a barrier to acceptance. The desire to vaccinate was often associated 
with parental perception of risk [174, 318, 321, 323, 324, 327, 329, 331, 332, 334-
339, 341, 342, 344, 348, 349]: those parents who accepted that their daughter was 
already or would become sexually active. Conversely, many parents declared a low 
perception of risk [174, 318, 321, 323, 324, 326, 327, 333, 334, 336-339, 341, 344, 
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346-349], and questioned the necessity of HPV vaccine. These believed their 
daughters’ young age and/or their sexual education and cultural or religious 
upbringing would preclude sexual activity and thus protect against infection. The 
role of the HCP, namely the family physician, was discussed across the studies. 
Many parents discussed how HCP endorsement of the vaccine [235, 321-324, 326, 
327, 329-331, 333-335, 339-341, 344, 345, 347-349], trust in the healthcare system 
[174, 322, 327-331, 340, 344, 347-349] and a governmental immunisation 
programme [321, 326, 328, 340, 343] would persuade them to vaccinate their 
daughters. In contrast some parents expressed a lack of trust in the healthcare 
system [174, 322, 324, 326, 349], believing that the physicians were endorsing the 
vaccine, in accordance with the pharmaceutical industries [328], for personal 
financial gain. Parents also discussed how they can be influenced by media 
coverage of the HPV vaccine and vaccines in general, both positively [321, 329] and 
negatively [174, 321, 328, 329, 334]. In addition, parents discussed how vaccine 
support from peers [174, 322, 327, 329, 334, 336] and family members [174, 329, 
334, 336, 344] can encourage immunisation while indifference or a lack of vaccine 
support can act as a deterrent [174, 322, 327, 329, 334, 336, 344]. A minority of 
parents stated they would take their daughter’s opinion into consideration [327, 
329, 348]. Vaccine cost was a major consideration [325, 332, 335, 340, 344, 348, 
349], with many parents discussing how pricing might prevent access. Those 
parents with personal experience of HPV and HPV-related illnesses were 
motivated to accept vaccination for their daughters, to prevent the suffering they 
had experienced [174, 319, 321, 324, 327-329, 331, 334, 335, 337, 348]. In addition, 
some parents felt that by marketing as a cancer vaccine, the sexual stigma could be 
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reduced [332, 337]. Optional vaccination appeared to reduce desire to vaccinate 
[333, 341, 346] while mandatory vaccination and inclusion in national 
immunisation programmes reinforced the importance of the HPV vaccine [349]. 
4.5.6 Parental responsibility 
The majority of parents felt it was their responsibility to protect their daughters 
from HPV infection and its sequelae, by accepting vaccination [174, 235, 318, 319, 
321, 324, 326-331, 334-337, 342, 344, 346-349]. In addition, some parents 
understood the concept of herd immunity and perceived the societal responsibility 
to vaccinate [328]. Conversely, some parents felt that it was their duty to protect 
their daughters from perceived harmful side effects associated with this novel 
vaccine and refuse immunisation [322]. When considering a vaccination decision, 
many parents chose to defer responsibility [318-320, 322, 324, 327, 334, 336, 339] 
to a family member, such as a spouse, parent or daughter, while others preferred 
to follow guidance provided by their HCP, as already presented. Parents were 
happy to exert control over their daughters healthcare decisions [174, 323, 328, 
329, 331, 333, 344, 349]. Many parents feared that vaccinating against a sexually 
transmission infection might encourage sexual activity [318, 319, 330, 334-336, 
339, 341, 342, 346-349]. Parents felt this link to sexual activity warrants a difficult 
conversation [174, 325, 326, 330, 334-336, 339, 347] with their daughters, a 
conversation that many would be uncomfortable with conducting. Another factor 
that some parents were uncomfortable with was the requirement for parental 
consent [319, 322], believing that this would equate to an acceptance of 
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responsibility for any harm caused by the vaccine. This last finding was only evident 
in jurisdictions where parental consent was not usually required for vaccination. 
 












Vaccination decisions were commonly the responsibility of 
the female primary caregiver. 
Parental vaccination decisions were complex and 
multifactorial. An understanding of the true perception of 
infection risk and a trusting relationship with vaccine 
supportive peers, family members and HCPs, who can 
provide an unambiguous endorsement, drove 
acceptability. Parents independently assessed these 
interconnected factors to make their final decision. 
Parents felt a responsibility to protect their daughters 
either as a consequence of HPV infection or as a 
consequence of the perceived risks associated with HPV 
vaccination. Accepting responsibility was difficult due to 
the mode of transmission of HPV and the inherent link to 
sexuality. 
There was limited parental knowledge of HPV, even in 
those who had already made vaccination decisions for 
their daughters and in regions where immunisation had 
been initiated. Even those parents that were informed 
demonstrated a limited understanding of the vaccination 
recommendations. 
While parents had a fear of HPV infection and its sequelae, 
namely cancer, a lack of familiarity and experience with 
this 'novel' therapy resulted in apprehension and 
scepticism. 
Vaccination programmes were seen as well-recognised 
and trusted preventive health measures.  
Line of argument 
While a level of vaccine hesitancy is 
evident in all populations, the majority 
of parents are motivated to protect 
their children and prevent disease by 
accepting vaccines. In contrast to other 
paediatric and adolescent vaccines, the 
link to sexual intercourse associated 
with the HPV vaccine often complicates 
the vaccination decision. Vaccine 
manufacturers, national healthcare 
systems and HCPs can reinforce the 
importance of HPV immunisation and 
reiterate the rationale behind 
vaccination recommendations, by 
providing unambiguous information in 
a timely manner, transparently 
addressing parental concerns regarding 
vaccine safety and efficacy, whilst 
taking account of cultural and religious 





Figure 15 Conceptual Model 
 
4.6 Discussion 
This article is the first, to our knowledge, to systematically review and analyse the 
qualitative literature on the parental views regarding adolescent HPV vaccination. 
The five key concepts, combined to produce a novel conceptual model (Figure 15), 
highlight the separate, yet interacting factors that require intervention to improve 
vaccine uptake. Interestingly, there is no difference in the occurrence of concepts 
and sub-themes in regions where vaccination has been initiated compared to those 
where it has not. Nor is there a difference in their occurrence in high-income 
countries compared with low- to middle-income countries. However, it is important 
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to note that these concepts are not necessarily representative of all participants 
within each study, due to the qualitative nature of the research.   
In agreement with published literature, this synthesis has demonstrated how 
healthcare decisions, such as vaccinations, are commonly the responsibility of the 
female primary caregiver [350-352]. However, in some studies, it was evident that 
the decision-making appeared to be centred on the father [319, 336]. These studies 
conform to certain gender culture guidelines which stipulate that males should 
demonstrate masculinity and strength by exerting control over their families [353], 
an important consideration if designing an intervention for such populations. It is 
clear that vaccination decisions are complex and multifactorial. The success of a 
vaccination programme is often dependent on parental understanding of the true 
perception of infection risk. Perceptions of risk are subjective and depend 
fundamentally on circumstances [354]. In this synthesis, a low perception of risk 
was primarily associated with the young vaccination age [174, 318, 321, 322, 324, 
328, 330, 333-336, 338, 341, 344, 346-349]. At this age, parents do not believe their 
children to be sexually active, thus the urgency of vaccination is reduced. This was 
particularly evident in populations where religious beliefs vehemently oppose pre-
marital sexual activity [174, 334, 336, 346, 347, 349]. In addition, parents were 
often concerned about the potential encouragement of sexual activity associated 
with vaccination [318, 319, 330, 334-336, 339, 341, 342, 346-349] and the difficult 
conversation associated with vaccination decisions due to the inherent link to 
sexuality [174, 325, 326, 330, 334-336, 339, 347]. The rationale for 
recommendation of vaccination at 9-14 years is two-fold: the immune response to 
the vaccine is superior in this age group and it maximises the potential for 
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immunisation prior to HPV virus exposure. It is important that parents understand 
this rationale and the importance of vaccination, regardless of their personal 
perception of risk.  
This synthesis highlights the crucial role played by HCPs, namely physicians, in the 
continuing success of HPV vaccination. It was repeatedly reported that an 
unambiguous endorsement of vaccination will drive acceptability [183, 321-327, 
329-331, 333-335, 339, 341, 344, 345, 347-349]. Effective interactions with HCPs 
have the potential to alleviate concerns of vaccine supportive parents and motivate 
a vaccine-hesitant parent towards acceptance [33, 38]. A recent study reports that 
HCPs endorse the HPV vaccine less enthusiastically than other vaccines [355], 
perceiving HPV discussions as laborious and garnering less support. These 
interactions are likely to discourage timely HPV vaccination and encourage watchful 
waiting, as evident from this synthesis [174, 318, 321, 323, 324, 333, 334, 336-338, 
341, 342, 349]. This highlights the requirement for the development of 
communication strategies to support HCPs in recommending the HPV vaccine with 
confidence. This review has shown the diverse and sometimes conflicting views in 
parent groups within the same study, from similar social, cultural, educational and 
religious backgrounds. Therefore it is essential that HCPs are cognisant of these 
differences. Continuing professional development could facilitate training in 
adaptable parent engagement, according to proposed recommendations [301-303]. 
This review also describes the limited parental knowledge of HPV, even in those 
who have already made vaccination decisions for their daughter, in regions where 
immunisation has been initiated. Even those parents that appear knowledgeable 
demonstrate a limited understanding of the vaccination recommendations. An 
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effort should be made to evaluate the standardised information provided to 
parents regarding the HPV vaccine for accuracy, readability and understandability, 
with a special consideration for those of lower health literacy levels [356].  
It is clear that parents are motivated to protect their children [174, 318, 319, 321, 
322, 324-331, 334-337, 342, 344, 346-349] and are fearful of HPV infections and 
their sequelae, namely cancer [321, 330, 331, 335, 345]. However, a lack of 
familiarity with the novel HPV vaccine results in apprehension [174, 321, 324, 325, 
328-330, 333, 334, 336, 343, 349] and safety and efficacy concerns [174, 318, 320-
322, 324-326, 328, 332-335, 338, 340, 341, 344-349]. The most commonly 
suggested unknown side effect was the potential for impaired fertility following 
immunisation [319, 321, 322, 326, 332, 336, 343, 344, 349]. To reassure parents of 
the safety of HPV vaccination, information pertaining to the known side effects: 
pain, redness, swelling of the injection site; headache; dizziness; nausea; and/or 
mild pyrexia, should be transparently provided.  
Research has shown how parental concerns can be escalated by increased access to 
information sources of variable reliability [134], namely the internet [357]. 
Widespread use of online information-seeking predated the rise of interactive 
content, targeted advertising and social networking, which prevents the regulation 
of information that reaches parents [357]. Much of this online information contains 
anti-vaccine content [130, 358-361], often presented in scientific language to lend 
an air of legitimacy [130]. This makes it difficult for parents to determine the 
accuracy and validity of retrieved information. Acknowledging this issue, the WHO 
initiated the Vaccine Safety Net Project, in 2003 [362]. The ongoing, ever-expanding 
project is a global network of websites that provide reliable, scientifically based 
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information on vaccines. The network is currently reviewing Facebook pages to 
deliver trustworthy vaccine safety messages to more diverse audiences. This 
expansion could permit personalisation of healthcare information: the dynamic 
customisation of generic vaccine information, to specifically address the needs of 
the individual [363].  
4.6.1 Implications and contribution: HPV vaccine crisis 
Due to the significant overlap and recurrent data reported by the primary studies, it 
would appear unlikely that further research in this area would generate new 
themes. However, in recent years, there has been a reduction in vaccine uptake in 
several countries worldwide including Denmark, France, Japan and Ireland [223, 
364-366]. This observed reduction is primarily due to a series of case reports which 
identify a range of new onset chronic conditions, occurring post immunisation. 
Comprehensive reviews of both pre- and post-licensure data provide no causal link 
and the reported incidence of these conditions is within the expected range of the 
general population [367, 368]. However, countries remain unconvinced: in 
Denmark, the Ministry of Health announced and conducted an independent 
investigation into the safety of the vaccine; in Spain, the Association of People 
Affected by HPV vaccine (AAVP) was created and a prominent public health 
professor spear-headed a petition that calls for a moratorium on vaccination; in the 
UK, the Association of HPV Vaccine Injured Daughters (AHVID) was created; in 
France, a petition signed by more than 700 doctors and 300 midwives was sent to 
policymakers demanding further investigation; and in Japan, the Ministry of Health, 
Labour, and Welfare suspended proactive vaccine recommendations [171]. Since its 
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introduction in Ireland in 2010, maximal vaccination rates of 86.9% were reported 
in 2014/2015 [168]. These rates decreased to 72.3% in 2015/2016, and to 50% in 
2016/2017 [26]. Interventions are urgently required to restore confidence in the 
HPV vaccine. It is likely that effective interventions will be multi-component, using a 
combination of strategies including: engagement of religious or other influential 
leaders to promote vaccination; mass media; improving convenience and access to 
vaccination; mandating vaccinations or imposing sanctions for non-vaccination; 
employing reminder and follow-up; communication training for HCPs and; offering 
non-financial incentives [189]. Currently, there is a paucity of published qualitative 
studies addressing these new vaccine concerns. Therefore, such research is 
required to guide intervention development, to improve HPV vaccine uptake. 
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4.9 Chapter conclusion and context within thesis 
This chapter presented the findings of an extensive systematic review and meta-
ethnographic synthesis of the qualitative literature on the views of parents 
regarding HPV vaccination, thereby addressing the first objective of the doctoral 
research i.e. to generate an evidence-base. Systematic reviews are the gold 
standard to search for, collate, critique and summarise the best available evidence 
and the meta-ethnographic synthesis method has the potential to provide a higher 
level of analysis, and generate new research questions. Similar to Chapter 2, the 
research conducted in this chapter informed the design of qualitative studies, 
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presented in Chapters 4 and 5. These chapters seek to address the research 
question: ‘what are the views of key stakeholders (adolescents and parents), in light 
of recent HPV vaccine instability?’ This research has been published in a peer-
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Unsubstantiated safety concerns with Human Papillomavirus (HPV) vaccines 
continue to linger.  
Aim 
This study sought to identify factors which influence the adolescent HPV vaccine 
decision and systematically identify intervention functions and strategies likely to 
be effective in reducing vaccine hesitancy. 
Methods 
Focus groups were conducted with female adolescents (14-16 years) in Cork and 
Kerry. During focus groups, the trained facilitator used a semi-structured, 
Theoretical Domains Framework (TDF)-based topic guide to prompt discussion. 
Transcripts were thematically analysed using the TDF and Behaviour Change Wheel 
(BCW). The Behaviour Change Technique Taxonomy version 1 (BCTTv1) was applied 
to suggest intervention functions and strategies for addressing HPV vaccine 
hesitancy. 
Results 
A total of 50 adolescents (96% vaccinated), participated in 10 focus groups. The key 
themes were presented by means of the relevant TDF domains. Seven domains 
were selected as most relevant: knowledge, social influences, beliefs about 
capabilities, optimism, beliefs about consequences, emotion, and environmental 
context and resources. Five intervention functions were identified: education, 
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persuasion, enablement, modelling, and environmental restructuring and linked to 
11 relevant BCTs. Potential intervention strategies were developed. 
Conclusion 
This study provided a detailed insight into behavioural factors influencing the 
vaccine decision-making process. It was identified that awareness and knowledge 
about HPV and its health sequelae was low. Lack of information is a well-recognised 
determinant of vaccine hesitancy. Therefore education was recommended as a key 
area to address in future intervention studies.  
5.2 Introduction 
Human papillomavirus (HPV) is the most common sexually transmitted infection 
worldwide [140]. Although the majority of infections are transient, persistent 
infection is a pre-requisite for pre-cancerous lesions and malignancies, including 
cervical and oropharyngeal cancers [142]. Three prophylactic HPV vaccines are 
marketed for the prevention of HPV-related disease, intended to be administered 
before the onset of sexual activity. By the end of 2017, 80 countries had included 
the HPV vaccine in their immunisation programmes. In Ireland, the Health Service 
Executive (HSE) has offered the quadrivalent vaccine to all girls in the first year of 
second level schools, vaccinating more than 240,000 girls since 2010 [148]. There is 
high grade evidence that HPV vaccines protect against cervical pre-cancer in 
adolescent females [369], with significant decreases in vaccine-type HPV in 
vaccinated women [150]. In addition, HPV vaccines have been shown to reduce 
abnormal screening tests, colposcopies and excisions [151]. This reduction in 
diagnostic and therapeutic procedures not only lowers healthcare expenditure 
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[151, 152] but also reduces their negative psychological effects for the women 
involved [153]. The safety of these vaccines is well established [155, 156]. However, 
recently there has been a focus on a number of safety signals for the vaccines [154]. 
While none have been substantiated [155], they remain a public concern. In Ireland, 
maximal vaccination rates of 86.9% were reported in 2014/2015 [168] but these 
plummeted to 50% in 2016/2017 [26]. While significant research has been 
conducted into determining vaccine acceptability in parent populations [4], minimal 
research has included the views of adolescents; the intended vaccinees. Research, 
guidelines and policies stress the importance of including adolescents in healthcare 
decisions [370, 371]. Therefore stakeholder engagement, including both 
adolescents and parents is integral to the successful development of interventions, 
urgently required to restore confidence in the HPV vaccine [372].  
Changing behaviour is complex and a systematic approach is required to 
understand the factors that influence vaccine hesitancy, so as to inform the design 
of future interventions. In general, providing information alone does not change 
behaviour [179, 180]. Instead, one must gain an insight into the knowledge, beliefs, 
attitudes and current behaviours of the target audience, and the environmental 
context in which they occur [373]. The Theoretical Domains Framework (TDF) is a 
framework which has synthesised 33 theories of behaviour and behaviour change, 
clustered into 14 domains [206]. The TDF is useful for understanding the factors 
influencing specific behaviours [206, 374]. The associated Behaviour Change Wheel 
(BCW) is a synthesis of 19 behaviour change frameworks that draw on a wide range 
of disciplines and approaches and connects this understanding to intervention 
design [210, 375]. The BCW links behaviour components with capability, 
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opportunity and motivation (COM-B model) [375]. The Behaviour Change 
Technique Taxonomy version 1 (BCTTv1) is a set of active components developed to 
standardise the content and reporting of intervention studies [215].  
5.3 Aim 
This study sought to identify factors which influence the adolescent HPV vaccine 
decision and systematically identify intervention functions and strategies likely to 
be effective in reducing vaccine hesitancy. 
5.4 Methods 
5.4.1 Ethical approval 
Ethical approval was obtained from the Social Research and Ethics Committee, 
University College Cork (Log 2016-122). 
5.4.2 Data collection 
A list of second level schools (n=67) and education centres (n=12) was compiled and 
classified according to the Irish Pobal HP Deprivation Indices [376]. The (i) 
recruitment poster, (ii) informed consent form and (iii) cover letter detailing the 
project overview, (Appendix 5.1-5.3) were sent to each school principal. Focus 
group participants were recruited using purposive sampling: the principal invited 
eligible students to participate. Inclusion criteria included self-declared satisfactory 
English language, female gender and aged 14-16 years. A TDF-based topic guide, 
with a semi-structured design was developed based on a review of previous 
literature and discussion among the authors (Appendix 5.4). All focus groups were 
conducted by SM, a female pharmacist/clinical pharmacy researcher, with 
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experience in conducting qualitative research. Focus group methods were chosen 
as they are recognised as a valuable means of eliciting adolescent’s views on health-
related matters [377, 378]. The facilitator prompted and explored issues in more 
detail as appropriate [379]. Written informed consent to participate was obtained, 
via the school Principal, from the parent of each participant. Focus groups were 
conducted until no new themes emerged. Field notes were recorded after each 
session. 
5.4.3 Data analysis 
Audio-recorded sessions (OLYMPUS Digital Voice Recorder VN-731PC) were 
transcribed verbatim by SM and preliminary familiarisation was begun during the 
transcription process. Computer software (QSR International’s NVivo V.11) was 
used to organise the data and analysis. Each participant was assigned an 
anonymised identifier. Transcripts were verified against audio-recordings with a 
random sample verified by an independent researcher and analysed using an 
inductive thematic analysis. Codes were compared within and between focus 
groups for constant comparison. Transcripts were independently coded by one 
other member of the research team (LS and AF) and any disagreements were 
resolved through discussion. The codes were then attributed to the domains of the 
TDF. The TDF domains were then linked to the core COM-B components of the BCW 
[204]. The COM-B model recognises that behaviour is part of an interacting system 
involving capability, opportunity and motivation [204]. Finally, the BCTTv1 was 
applied to suggest intervention functions and strategies for addressing HPV vaccine 
hesitancy [204, 210, 215]. The APEASE (Affordability, Practicability, Effectiveness 
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and cost-effectiveness, Acceptability, Side-effects/safety and Equity) criteria were 
applied to select the most appropriate intervention functions and BCTs [210]. 
Reporting was guided by the Consolidated Criteria for Reporting Qualitative Studies 
(COREQ) checklist [380] (Appendix 5.5). 
5.5 Results 
Ten focus groups were completed between the 10th November 2017 and 5th 
February 2018 (12.66% recruitment rate). Focus groups were completed on school 
grounds and had a mean duration of 36 minutes (range: 21 to 55 minutes). The 
opinions of 50 adolescents were compiled: two unvaccinated, 48 vaccinated 
(Appendix 5.6). The key themes are presented by means of the relevant domain 
from the TDF. Participant quotes are represented in italics. 
Theoretical Domains Framework 
Based on a familiarisation with the theoretical constructs under each domain [206] 
and a comprehensive review of the themes, seven key TDF domains were selected 
as the most relevant [381]. 
Knowledge 
Knowledge of HPV, HPV-related disease and HPV vaccination was poor among all 
adolescents. Some were aware that the HPV vaccine was a “cancer vaccine”, but 
were unable to elaborate. Understanding of the topic was also limited, with 
participants being unfamiliar with the association between sexual activity, HPV and 
cervical cancer. In addition, some adolescents expressed doubt in their parents’ 
understanding of the topic. The participants expressed the requirement for basic 
information, questioning the efficacy, safety and mechanism of action of the 
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vaccine, requested international data on Gardasil® and discussed how expected 
adverse drug reactions (ADRs), including potential pain should be divulged in full. 
However, pain was primarily discussed by those needle-phobic participants, and 
acknowledged as an acceptable vaccine side effect by the majority. 
“…just a pinch and you’re done I mean there are other things that definitely 
hurt way more…” (P28, vaccinated, 16 years). 
In spite of their poor knowledge and understanding, the participants were intrigued 
by the topic, constantly questioning and seeking information. 
Social influences 
The responsibility for vaccine decision-making was clearly assigned to the parent. 
Participants discussed how they were influenced by their parents and often 
accepted the parental recommendation, with minimal or no discussion. The 
requirement for parental consent further consolidated the role of the parent as 
decision-maker. 
“I’d probably listen to my mam too, she’s not going to let me get something 
that’s not good for me” (P3, vaccinated, 15 years), 
 “You kind of just have to do whatever your parent…or whoever is signing the 
form, says” (P21, vaccinated, 15 years).  
Participants acknowledged the influence of HCPs, who they believed were equipped 
to guide the vaccine decision, either positively or negatively. However, adolescents 
discussed how they felt obliged to follow recommendations without discussion and 
without active participation, highlighting their lack of influence in the decision.  
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“Because they’re not going to tell you to get something if you shouldn’t, they 
know your background and stuff so they’ll know what you need, and what 
you don’t” (P38, vaccinated, 15 years), 
“…like if my doctor said not to get it, then it would be hard for me to get it 
then because you should probably do what your doctor says” (P42, 
vaccinated, 16 years). 
Participants also viewed vaccinated peers as role models, as a source of information 
and feedback, on their experience with the vaccine. They acknowledged their own 
potential to become role models to unvaccinated girls, once vaccinated. 
“I’d listen to people who had gotten it already ‘cos they’ve been through it 
and they know the story” (P26, vaccinated, 16 years).  
 “If they were nervous about getting the vaccine because of the side effects, 
I’d say I got it and look at me, I’m grand, you should just get it” (P22, 
vaccinated, 15 years). 
Group conformity and the power of the social norm was a major theme, with many 
adolescents admitting to conforming to the behaviour of their peers. 
 “I’d probably be more worried if a load of people weren’t getting it, you’d be 
wondering why not…I think it might make me not want to get it” (P21, 
vaccinated, 15 years). 
Beliefs about capabilities 
Some participants felt, on reflection, that they would have been capable of making 
the vaccine decision and would have appreciated this empowerment and were 
disappointed with the lack of autonomy and choice afforded.  
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“If you were given, told what it was about then you might have (been able to 
make the decision), it’s not that hard, I know parents just make the decision 
for you but it would be nice to know a bit about it before they just jab you in 
the arm…” (P31, vaccinated, 16 years), 
However, many preferred to defer responsibility to the aforementioned individuals, 
justifying their lack of involvement in the decision with poor knowledge and young 
vaccination age, associated with a lack of sexual experience and an inability to 
comprehend the complexities of the HPV vaccine. 
“…it’s probably better to let the parents or whoever decide, I mean, what do 
you know about vaccines or even cancer, when you’re 13?…” (P35, 
vaccinated, 15 years).  
Optimism 
While many participants believed that freedom of medical choice regarding 
immunisation should remain, they were optimistic that teenage girls and their 
parents would accept HPV vaccination, should they receive appropriate 
information. 
“…if people get all the information and they understand what the vaccine is 
for and what will happen if they don’t get it…I think people would risk a lot 
to stop them getting cancer” (P34, vaccinated, 16 years). 
Beliefs about consequences 
Vaccination was viewed as an accepted norm and participants recognised the 
importance and benefits of immunisation. 
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“Some diseases aren’t even around anymore, if enough people get them… If 
there’s a vaccine there, I’ll want to get it” (P32, vaccinated, 15 years).  
The participants discussed the consequences of vaccination, confident in its effect 
yet pragmatic in its ability to prevent cancer and acknowledged the potential for 
anticipated regret should vaccination be refused. 
 “Even if it’s not guaranteed to stop you getting cancer, it’s better than 
nothing, it means it’s something less to worry about” (P31, vaccinated, 16 
years).  
“Imagine how they’d feel in a few years or whatever if they got cervical 
cancer” (P22, vaccinated, 15 years). 
Emotion 
Vaccination was an emotive topic. Adolescents discussed their fear of needles, fear 
of cancer, fear of vaccine side effects and fear of the unknown. 
 “…even if you’re scared of needles, you should be way more scared of 
cancer” (P38, vaccinated, 15 years), 
“…it’s a way bigger deal getting cancer than it is getting another disease like 
a cold or whatever, cancer can kill you” (P46, vaccinated, 15 years), 
“As long as they’re safe...and parents are worried about the side effects…” 
(P7, vaccinated, 16 years),  
“…it doesn’t mean you will get cancer but you don’t know what’s going to 




However, even those who exhibited needle-phobic tendencies revealed that these 
fears did not discourage vaccination. 
“…even though I hate needles, if it stops cancer, then I’d get a million 
needles” (P15, vaccinated, 16 years). 
Two of the adolescents realised that they had not received the HPV vaccine. This 
was not an intentional avoidance of immunisation: these girls were not enrolled in 
formal education when the vaccine was offered and expressed fear and anxiety 
over this missed opportunity.  
Environmental context and resources 
Adolescents acknowledged the influence of the government immunisation 
programmes, expressing the view that the vaccine would not be offered free of 
charge if it was unsafe or ineffective:  
“The government isn’t going to pay for the vaccine for children unless they 
need it and it’s good for them so if the government says to get it, I would” 
(P32, vaccinated, 15 years). 
Some participants acknowledged their awareness of alleged Adverse Drug 
Reactions (ADRs) associated with the vaccine and expressed safety concerns due to 
media exposure: the primary information source that was mentioned was radio. 
None of these girls were able to recall any details of the vaccine reactions and were 
non-specific in their knowledge. 
“Wasn’t there girls who said they had problems after getting the vaccine? I 
think it was seizures? I heard about it on the radio and there was a girl who 
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had to leave school because of it, she couldn’t walk after it” (P7, vaccinated, 
16 years). 
However, some participants discussed how this negative media attention had 
resulted in a variation in vaccine uptake among family members and how the 
participants themselves would potentially change their mind about the vaccine in 
light of recent information:  
“Mum was like, I know you’re fine but I wouldn’t let you get the vaccine, if 
you were back in first year, I don’t know if my sister got it after me either” 
(P7, vaccinated, 16 years). 
Conversely, many participants expressed a lack of belief in the girls allegedly 
affected by the vaccine, believing them to be over-reactive and attention-seeking. 
Participants were asked about resources accessed when making a healthcare 
decision. Once again HCPs were identified as excellent sources of information, 
highlighting the importance of the patient-HCP relationship. However, it was 
discussed how access to general practitioners (GPs) can be difficult and many 
participants felt that they would not make an appointment with their GP to speak 
exclusively about vaccination, perceiving this to be a waste of time. 
“…I wouldn’t go to the doctor just to find out about it…like I only go to the 
doctor when I’m properly sick” (P28, vaccinated, 16 years). 
The participants were asked to discuss the internet as a source of vaccine 
information: while some adolescents acknowledged the internet as a useful source, 
being readily accessible, many participants were cynical about its use. They felt that 
it was often difficult to determine the reliability of content on the internet, with 
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websites often offering the impression of credibility while presenting excessive, 
inaccurate information. 
“Because even if it’s completely fake and bad, it might look 
really…professional or something and sound like it’s been written by 
someone who actually knows what they’re talking about, when really they 
don’t know anything and they could be just making stuff up. You know in 
Wikipedia you can just write whatever you want and it goes up online” (P32, 
vaccinated, 15 years).  
In addition, adolescents felt that internet searches of health topics generate 
extreme, dramatized and sensationalised results, often terrifying the searcher. 
“…you look up something online and it will tell you you’re dying, imagine if 
you looked up cancer vaccine what you get back” (P47, vaccinated, 15 
years).  
When questioned on the existence of reliable resources, the adolescents were 
mostly unaware. A minority mentioned the Health Service Executive (Ireland) and 
National Health Service (UK) websites. However, while these participants knew of 
the existence of these websites, they had not personally accessed them. When 
asked if they had read the information supplied prior to HPV vaccination; none had, 
with many believing the information was intended only for their parents:  
“…that was for whoever was signing the forms” (P47, vaccinated, 15 years). 
Even though they had not read the information, the adolescents were quick to offer 
their opinion.  Some participants assumed the information would have been too 
complex while others felt that it would have been easy to understand but boring. 
Participants believed information should be delivered to both vaccinees and their 
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parents and several methods of dissemination were suggested: a leaflet providing 
concise, interesting, user-friendly and accessible information, an audience with an 
expert, providing information and affording the opportunity to ask questions 
and/or an advertisement on digital or social media. 
Application of the BCT Taxonomy and identification of potential intervention 
functions 
Guided by links between COM-B and TDF domains [204], five intervention functions 
were identified and linked to 11 relevant BCTs, as outlined in Table 10 [210, 215]. 
Potential intervention strategies were developed and listed in Table 11. Some of 
these strategies were points raised by participants in the focus groups. 
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Table 10 Intervention functions identified by applying the TDF and BCTT(v1) to the study findings [204] 
COM-B  TDF domain BCT Taxonomy BCT Label Intervention functions 
Psychological Capability Knowledge 5. Natural consequences 5.1. Information about health consequences  
5.3. Information about social and environmental consequences  
5.6. Information about emotional consequences  
Education 
Social Opportunity Social 
influences 
5. Natural consequences 
 
6. Comparison of behaviour  
9. Comparison of outcomes  
13. Identity 
15. Self-Belief  
5.2. Salience of consequences 
5.5. Anticipated regret 
6.1. Demonstration of the behaviour 
9.2. Pros and cons  
13.1. Identification of self as role model 
15.3. Focus on past success  
Modelling 
Enablement 
Physical Opportunity Environmental 
context and 
resources 
5. Natural consequences 
 
9. Comparison of outcomes  
12. Antecedents 
13. Identity 
15. Self-Belief  
5.2. Salience of consequences 
5.5. Anticipated regret 
9.2. Pros and cons  
12.1. Restructuring the physical environment 
13.1. Identification of self as role model 
15.3. Focus on past success  
Enablement 
Environmental restructuring 









6. Comparison of behaviour  
9. Comparison of outcomes 
13. Identity 
15. Self-belief 
5.1. Information about health consequences  
5.2. Salience of consequences 
5.3. Information about social and environmental consequences  
5.6. Information about emotional consequences  
6.1. Demonstration of the behaviour 
9.1. Credible source 
13.1. Identification of self as role model 





Automatic Motivation Emotion 5. Natural consequences 
6. Comparison of behaviour  
9. Comparison of outcomes 
13. Identity 
15. Self-belief 
5.1. Information about health consequences  
5.2. Salience of consequences 
5.3. Information about social and environmental consequences  
5.6. Information about emotional consequences  
6.1. Demonstration of the behaviour 






13.1. Identification of self as role model 
15.3. Focus on past success 
  




Potential Intervention Strategies 
Intervention target 
population 




Explain that not accepting the HPV vaccine can increase susceptibility to HPV-related diseases 
Explain the lifetime susceptibility to HPV 
Adolescents & Parents  
5.2. Salience of consequences 
Persuasion and 
Enablement 
Highlight the prevalence of HPV-related diseases Adolescents & Parents 
5.3. Information about social and 
environmental consequences  
Education and 
Persuasion 
Explain the concept of herd immunity and its importance in disease prevention Adolescents & Parents 
5.5. Anticipated regret Enablement 
Ask the person to assess the degree of regret they will feel if they do not get the vaccine and 
subsequently develop a HPV-related disease 
Adolescents & Parents 




Explain that accepting the HPV vaccine will allow the person to feel protected from HPV-related 
diseases 
Adolescents & Parents 
6.1. Demonstration of the behaviour Modelling Present a vaccinated adolescent female discussing their experience with vaccine Adolescents 
9.1. Credible source Persuasion 
Present a speech given by an identified ‘vaccine expert’ to emphasise the importance of 
accepting the HPV vaccine e.g. Consultant in Public Health/Gynaecologist 
Highlight the availability of reliable sources of information  
Adolescents & Parents 
 
Adolescents & Parents 
9.2. Pros and cons  Enablement Present the advantages and disadvantages (adverse effects) of HPV vaccination Adolescents & Parents  




Increase the vaccinator population by including public health nurses and pharmacists  HCPs  
13.1. Identification of self as role model Enablement 
Inform the person that if they accept the vaccine, they may be a good example for unvaccinated 
girls 
Adolescents 
15.3. Focus on past success 
Persuasion and 
Enablement 






This is one of the first studies to investigate the views of female adolescents, living 
in Ireland, on the HPV vaccine and to use a behavioural change theory to analyse 
the findings and systematically suggest intervention functions and strategies to 
address vaccine hesitancy. Recommendations are based on the identified factors 
that influence the HPV vaccine decision and a systematic approach. All 
recommendations need to be considered for future public health vaccination 
campaigns and intervention studies, as no single recommended BCT or intervention 
strategy will address all identified factors. 
Adolescents demonstrated poor knowledge and understanding of HPV, HPV-related 
diseases and/or the HPV vaccine and relied on their parent to provide information 
and make healthcare decisions on their behalf. Our finding is comparable with 
published literature [84], where parents remained the leading source of health 
information for 55% of the adolescents surveyed. However, a large systematic 
review has described the limited parental knowledge of HPV, even in those who 
had already made vaccination decisions for their daughter(s), in regions where 
immunisation had been initiated [4]. Even those parents who appeared 
knowledgeable demonstrated a limited understanding of recommendations [4]. 
Therefore, providing knowledge about HPV and HPV-related diseases (‘information 
about health consequences’ and ‘salience of consequences’), explaining the societal 
benefits of herd immunity (‘information about social and environmental 





(‘information about emotional consequences’ and ‘focus on past success’) should 
be key components in future interventions.  
Our study highlights the importance of considering ‘credible source’, 
‘demonstration of the behaviour’ and ‘identification of self as role model’ as 
possible components of an intervention. Several ‘vaccine experts’ were suggested 
by participants including HCPs, vaccine researchers and previously vaccinated girls. 
In addition, vaccinated participants self-identified as vaccine advocates; credible 
and trusted champions for immunisation to build support and trust in vaccine 
efficacy and safety, and raise awareness of benefits. Participants were unaware of 
reliable resources, had not read the HPV vaccine information leaflet provided by 
the HSE and were sceptical about online health information. Intervention 
components should highlight the availability of reliable online resources (‘credible 
source’) e.g. Health Service Executive (HSE) Immunisations, Centres for Disease 
Control and Prevention (CDC) Teen Website, adolescentvaccination.org., that 
present balanced communication about effectiveness and side effects (‘pros and 
cons’). 
A major concern highlighted by this study was the exclusion of adolescents not 
enrolled in the State school system from the national immunisation programme. 
‘Restructuring the physical environment’ by expanding the range of HPV vaccinators 
to include those in the community setting e.g. public health nurses and 
pharmacists, who may be able to improve vaccine accessibility to this specific 
adolescent cohort. 
The challenge of designing interventions that combat vaccine hesitancy may be 





representation of vaccine ‘harm’ [382]. Even though adolescents in this study were 
offered the vaccine prior to the national decline in uptake, they were familiar with 
media coverage of suspected ‘adverse events’. Therefore, as well as providing 
evidence based assurances of vaccine safety, efficacy and durability, future 
interventions should include an ‘anticipated regret’ component, where adolescents 
are asked to consider how they would feel should they refuse vaccination and later 
develop a HPV-related disease. 
Limitations of this study included the fact that participants were asked to 
retrospectively reflect on their vaccine decision. In addition, two of the 50 
participants were unvaccinated but this was not necessarily by choice. Therefore it 
was not possible to collect the views of true vaccine-hesitant adolescents. Finally, 
while the focus group facilitator was not known to the participants, the adolescents 
were aware that SM was a pharmacist and assumptions may have been made 
regarding her attitudes towards vaccination. 
A key strength of this study is the systematic approach (TDF and BCW) that was 
applied to map the adolescent HPV vaccine decision and to recommend a range of 
potential intervention strategies. It has been shown that using theory to 
understand the mechanisms of action of intervention strategies improves the 
effectiveness of interventions [383]. In addition, the WHO has declared vaccine 
hesitancy as one of the ten global threats to health in 2019 and intervention 







In summary, this study provided a detailed insight into behavioural factors 
influencing the vaccine decision-making process. It was identified that awareness 
and knowledge about HPV and its health sequelae was low. Lack of information is a 
well-recognised determinant of vaccine hesitancy [49, 384]. Therefore education 
was recommended as a key area to address in future intervention studies. 
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5.9 Chapter conclusion and context within thesis 
This chapter described the qualitative, focus group study, undertaken with female 
adolescents, guided by the research questions generated in Chapter 4, to explore 
the knowledge, attitudes, and beliefs about HPV vaccination, thereby addressing 
the second objective of this doctoral thesis i.e. to elucidate vaccine decision-making 
and to identify barriers to vaccine uptake. It was evident that the majority of 
adolescents included in this study preferred to defer the responsibility of the 
vaccine decision to their parent(s). This finding guided the development of further 
qualitative research, presented in Chapter 6. This research has been published in a 
peer-reviewed journal and has been presented at conferences internationally.  







Chapter 6 Identifying intervention 
strategies to improve HPV vaccine 
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Although the HPV vaccine is highly safe and effective, its uptake is sub-optimal in 
many countries, including Ireland. There is therefore a need to identify appropriate 
interventions that will increase HPV vaccine acceptance by parents.   
Aim 
In this study, we took a systematic approach to understand the factors that 
influence HPV vaccine uptake by parents of adolescent girls in Ireland in order to 
define suitable behaviour change interventions that would support positive vaccine 
decision-making in the future. 
Methods 
We conducted semi-structured interviews, used a Theoretical Domains Framework 
(TDF)-based topic guide, to gain insight into the knowledge, beliefs, attitudes and 
current behaviours of parents with respect to their HPV vaccine decision. 
Transcripts were analysed using the TDF. The Behaviour Change Wheel (BCW) was 
used to identify relevant intervention functions and the Behaviour Change 
Technique Taxonomy version 1 (BCTTv1), to identify relevant intervention 
techniques. 
Results 
All parents discussed the essential role of healthcare providers in vaccine decision-
making. Complacency and confidence were important factors in decision-making by 





appropriate, namely; education; persuasion; environmental restructuring; 
modelling and enablement. 
Conclusion 
To our knowledge, this is the first study to systematically evaluate HPV vaccine 
decision-making using behaviour change theory and identify suitable intervention 






Human papillomavirus (HPV) is the most common sexually transmitted viral 
infection worldwide [140]. Although the majority of infections are transient, 
persistent infection is a pre-requisite for pre-cancerous lesions and malignancies, 
including cervical and oropharyngeal cancers [142]. Three prophylactic HPV 
vaccines are licensed, and marketed for use for the prevention of HPV-related 
disease. These are intended to be administered before the onset of sexual activity. 
By the end of 2017, 80 countries had included the HPV vaccine in their 
immunisation programmes. In Ireland, the quadrivalent vaccine has been offered to 
all girls in the first year of second-level schools (aged 12-13 years) by the national 
healthcare service, the Health Service Executive (HSE), and more than 230,000 girls 
have been vaccinated since 2010. The vaccine is available to boys in Ireland from 
September 2019. However, at the time of our research, only girls were included in 
the vaccination programme, hence the focus of the study. There is high grade 
evidence that HPV vaccines protect against cervical pre-cancer, with significant 
decreases in vaccine-type HPV in vaccinated women [150]. The safety of these 
vaccines is well established [155]. However, recently there has been a focus on a 
number of safety signals for the vaccines [154]. While none have been 
substantiated [155], they remain a public concern. In Ireland, maximal vaccination 
rates of 87% were reported in 2014/2015 but these plummeted to 51% in 
2016/2017 [26]. According to the WHO SAGE Vaccine Hesitancy Working Group, 
vaccine hesitancy refers to “delay in acceptance or refusal of vaccines despite 





varying across time, place and vaccines. It includes factors such as complacency, 
convenience and confidence” [48]. Currently, there is a paucity of published 
qualitative research addressing these new concerns [4]. Therefore, understanding 
the reasons why parents may accept or decline the HPV vaccine for their adolescent 
daughter is important, in order to inform future strategies to restore confidence 
and increase HPV vaccine uptake. In this study, we examined the decision-making 
process of parents of adolescent females in Ireland with respect to the HPV vaccine 
through semi-structured interviews with parents.  
It is well established that changing behaviour is complex, and a systematic approach 
is required to understand the factors that influence vaccine uptake. In general, 
providing information alone does not change behaviour [179]. Instead, one must 
gain an insight into the knowledge, beliefs, attitudes and current behaviours of the 
target audience, and the environmental context in which they occur. Behavioural 
change has been shown to be more effective if interventions are based on 
principles drawn from evidence and theories of behaviour and behavioural change 
[184]. The Theoretical Domains Framework (TDF) provides a systematic and 
theoretical basis for understanding and changing behaviour [204]. It has been used 
in qualitative studies to guide the development of interview topic guides, and as a 
coding framework in the analysis of qualitative material [385]. The framework 
simplifies 33 theories and 128 constructs into 14 validated domains, underpinned 
by psychological theory [206]. The capability, opportunity, motivation model of 
behaviour (COM-B) distils the TDF into three domains, that interact to predict 
behaviour and include the individual’s capability, motivation and opportunities for 





capability may be physical or psychological; opportunity may be physical or social; 
and motivation may be reflective or automatic [204]. The COM-B model guides the 
choice of intervention functions or strategies most likely to achieve behavioural 
change and forms the central component of the Behaviour Change Wheel (BCW) 
[210]. Within 19 frameworks for classifying behaviour change interventions, over a 
wide range of were discerned to construct the BCW [210]. Additionally, the nine 
intervention functions have been linked to a taxonomy of 93 Behaviour Change 
Techniques (BCTs), organised into 16 groups [215]. The BCW is divided into three 
broad stages: understanding the behaviour; identify intervention options; and 
identifying content and implementation options [204]. Following this structured 
approach lends transparency to the intervention design process and facilitates its 
subsequent evaluation [204].  
6.3 Aim 
The aim of this study was to apply the TDF, the COM-B system of behavioural 
change and the associated BCW, as tools for describing the factors that influence 
the parental HPV vaccine decision, identified using semi-structured interviews, to 
inform the choice of intervention components and strategies. 
6.4 Methods 
6.4.1 Stage 1: Understanding the behaviour [210] 





6.4.1.1 Select and specify the target behaviour 
The target behaviour was parental acceptance of the HPV vaccine. This behaviour 
was explored in a cohort of parents of female adolescents (aged 14-16 years) who 
had been offered the HPV vaccine within the previous three years, when their 
daughters were aged 11-12 years, in accordance with national recommendations. 
Therefore, these parents would have been offered the vaccine prior to vaccine 
instability observed in 2016/2017.  
6.4.1.2 Select the study design 
Qualitative, semi-structured interviews were conducted.  
6.4.1.3 Develop study materials  
A TDF-based interview topic guide was developed by the authors, based on a 
review of the literature [4] and previous qualitative research [5]. The topic guide 
was modified following piloting and underwent iterative revision throughout the 
study to ensure that emerging themes were captured in subsequent interviews 
(Appendix 6.1). 
6.4.1.4 Decide the sampling strategy 
A purposive sampling strategy was used to recruit participants [386]. This strategy is 
outlined in Appendix 6.2. An initial analysis sample of ten and a stopping criterion 
of three were specified a priori, as outlined in the Francis method of determining 





6.4.1.5 Collect the data 
All semi-structured interviews were conducted by SM, a research pharmacist with 
training in qualitative research methods and qualitative interviewing techniques. 
No relationship was established between the interviewer and the participants prior 
to study commencement. However, participants were aware that SM was a 
pharmacist. The interviews were conducted, in a location convenient for the 
participant, between 20th August 2018 and 21st January 2019. Only the interviewer 
and participant were present during the interview. All participants provided written 
informed consent. Prior to interview commencement, participants completed a 
demographic data collection form which recorded details including: gender; 
parental age; daughter age; highest education level achieved; number of children; 
and HPV vaccine status of daughter. The interviews were audio-recorded and 
transcribed verbatim by SM. Transcripts were not returned to participants and 
repeat interviews were not conducted. SM recorded relevant field notes after 
interview completion.  
6.4.1.6 Analyse the data 
Audio-recorded sessions (OLYMPUS Digital Voice Recorder VN-731PC) were 
transcribed verbatim by SM and preliminary familiarisation was begun during the 
transcription process. Computer software (QSR International’s NVivo V.11) was 
used to organise the data and analysis. Each participant was assigned an 
anonymised identifier. Transcripts were verified against audio-recordings with a 
random sample verified by an independent researcher and analysed using an 





between, interviews for constant comparison. Transcripts were independently 
coded by one other member of the research team (LS, AF). Any disagreements were 
resolved through discussion. The codes were then attributed to the domains of the 
TDF. 
6.4.1.7 Report findings 
The key findings were reported in the Results section of this manuscript. Reporting 
was guided by the Consolidated Criteria for Reporting Qualitative Studies (COREQ) 
checklist [389].  
6.4.2 Stage 2: Identifying intervention options  [210] 
The TDF domains were then linked to the core COM-B components of the BCW 
[204]. Relevant intervention functions were identified using the APEASE criteria, a 
set of criteria used to make context-based decisions on intervention content and 
delivery consisting of affordability, practicability, effectiveness and cost-
effectiveness, acceptability, side-effects/safety and equity considerations [204].  
6.4.3 Stage 3: Identifying intervention content and implementation options  
The identified intervention functions were then linked through consensus 
discussion to relevant BCTs in the BCT taxonomy (v1) [215]. 
6.4.4 Ethical approval 
Ethical approval was obtained from the Social Research Ethics Committee, 






6.3.1 Stage 1: Understanding the behaviour [210] 
Characteristics of interview participants 
Thirteen interviews were conducted (Appendix 6.4). Of the parents who 
participated in the study, 23% were male and 31% of all parents had declined the 
HPV vaccine for their daughter. In addition, 39% of participants were recruited from 
DEIS programme second level schools [390]. The interview duration ranged from 10 
to 43 minutes, with an average duration of 21 minutes. No demographic appeared 
to associate with the decision to accept or decline the HPV vaccine in this small 
group of 13 parents; all parents who had declined the HPV vaccine for their 
daughter were female, however this is likely to be due to a higher number of 
females in the study.  
Applying the TDF 
Based on a familiarisation with the theoretical constructs under each TDF domain 
[206] and a comprehensive review of the interview transcripts, ten of the 14 TDF 
domains were selected as the most relevant [381]. It emerged that the vaccine 
decision was complex, and often involved interactions between several of these 
domains, namely knowledge, memory, attention and decision processes, social role 
and identity, beliefs about capabilities, optimism, beliefs about consequences, 
goals, emotion, environmental context and resources and social influences. 
Participant quotes are represented in italics. Vaccine-acceptors (VA) are those who 
accepted the HPV vaccine for their daughter, while vaccine-decliners (VD) are those 





The parental vaccine decision process began when the HPV vaccine was offered in 
1st year of secondary school (adolescents are aged between 12-13 years). The 
parents recalled how they reflected on previous experience with vaccines, namely 
those included in the paediatric vaccination schedule (memory, attention and 
decision processes), with participants recognising the importance of immunisation 
(knowledge, goals): “I mean, they’re important because they stop lots of different 
diseases, especially in children” (P7, VA). Vaccination appeared to be the accepted 
norm (memory, attention and decision processes). Even those who chose to decline 
the HPV vaccine, discussed how they had accepted paediatric and other adolescent 
vaccines: “I mean my two have had all their baby vaccines and the ones in school 
like measles, mumps and all those and I never really worried that much about 
vaccines and didn’t really give them much thought” (P13, VD). Participants were 
asked to discuss what they could recall about HPV and the HPV vaccine 
(knowledge). Responses were variable, with some parents claiming they knew 
“nothing at all” (P3, VA), to others identifying the HPV vaccine as the “cervical 
cancer vaccine” (P12, VA). The participants readily identified and were transparent 
about their lack of knowledge: “To be honest, I don’t know much. I know it stops 
cervical cancer when she is older…and that is about it” (P12, VA). Those participants 
who were able to provide vaccine-specific information revealed occupational or 
academic public health experience in their own occupation (environmental context 
and resources). The participants discussed the vaccine information leaflet, produced 
by the HSE (environmental context and resources). For some parents, this resource 
was sufficient to guide their vaccine decision: “…I know that this vaccine can stop 





make my decision” (P2, VA), “I personally don’t think I needed to know any more 
than this vaccine will stop your daughter from getting cervical cancer…it becomes a 
no-brainer” (P8, VA), while others remained ambivalent and sought out 
supplementary information (beliefs about capabilities). This apprehension was 
reported to be primarily due to circulating claims of chronic side effects, e.g. 
fatigue, seizures, associated with the vaccine (environmental context and 
resources). Participants recalled radio interviews, television documentaries, 
newspaper articles and online information which discussed these allegations. 
Parents discussed the emotive nature of these reports (emotion): “I was listening to 
the radio and there was this mum and I, my heart just went out to her” (P1, VD), 
“The stories were so…powerful. It was hard to ignore them” (P5, VD). For some 
participants, these reports provided more weight than the vaccine information 
leaflet provided by the HSE, and dictated the vaccine decision (environmental 
context and resources, emotion, social identity): “I think listening to a mum affected 
me more than reading a leaflet” (P1, VD). All participants had been exposed in 
varying degrees to these reports (environmental context and resources). Many VA 
acknowledged their concerns regarding these alleged side effects (emotion), but 
were reassured by the continued, widespread use of the vaccine (beliefs about 
consequences, optimism): “My gut would tell me that obviously it’s safe if it’s on the 
market and given all over the world and yes there may be a risk of an after effect, 
but that’s true of everything” (P3, VA) and their trust in the scientific community 
(beliefs about capabilities, optimism, knowledge): “I trust vaccines, I trust the people 
in  charge of vaccines so no I don’t really have to think about it” (P6, VA), “I will 





and trust that they know what’s going on” (P2, VA). In addition, some participants 
appeared to discriminate between the sources of information (environmental 
context and resources): “it came across as like dramatic or something…I remember 
there was a big difference between, we’ll say, the tabloid style newspapers and the 
broadsheets, splashed all over the tabloids and not mentioned in the broadsheets” 
(P3, VA) and were cognisant of historical vaccine controversies (memory, attention 
and decision processes, knowledge): “It’s MMR and autism all over again, and we 
know what damage that has caused” (P6, VA).  
Participants consulted with other individuals, to varying degrees, while making their 
vaccine decision (social influences). Those individuals included their daughters, their 
partners, their peers and healthcare providers (HCP). While participants 
acknowledged that they had discussed the HPV vaccine with their adolescent 
daughter, it was evident that the vaccinee had had minimal control over the vaccine 
decision (social identity, social influences, beliefs about capabilities): “She doesn’t 
really have the luxury of making that type of decision, you know what I mean? I’m 
her parent and I’ll do what I think is best for her” (P3, VA). Some parents discussed 
the importance of exerting this control over healthcare decisions that would pro-
actively protect their daughters’ future (social identity, belief about capabilities): 
“Our daughters will be adults when they are invited for a smear, how can we control 
that?” (P2, VA). The female participants revealed that while they had discussed the 
HPV vaccine with their partner, the responsibility of healthcare decision-making 
often lay with them (social influences): “He kind of just said he was happy enough to 
go along with me and just support whatever decision I made” (P13, VD), “I would 





whatever I thought” (P11, VA). Similarly, the male participants reported how they 
had relied on their partner, or an alternative female, for guidance on the vaccine 
decision (social identity, social influences, beliefs about capabilities): “I just let my 
wife deal with that kind of stuff. If she needs my opinion, she’ll ask for it, the 
majority of time she doesn’t need it” (P9, VA), “I suppose the topic is very…female” 
(P3, VA). Some female participants acknowledged the influence of peers (social 
influences): “I have a good few friends who have daughters the same age…so it’s 
almost inevitable that it’ll come up” (P12, VA), while others believed the vaccine 
decision was a private matter (social influences): “I mean, it’s no one’s business but 
my own. We made our decision and we didn’t really need to hash it out” (P5, VD). 
However, even VA discussed how they would have questioned their decision had 
vaccine uptake dropped to an “unacceptably low level” (environmental context and 
resources, social influences): “I’d like to think I would opt in and get all the vaccines 
because I think that is what is for the best but if loads of people were not then 
maybe I’d struggle with it” (P11, VA). However this “unacceptably low level” was not 
defined. Many participants acknowledged how HCP such as nurses or GPs are 
perfectly positioned to guide and support vaccine decisions (social influences): 
“They’re (GPs) probably the ideal person to talk to really” (P2, VA) and responded 
positively to their GP sharing personal experiences (social influences): “I did 
mention it to my doctor alright about the vaccine…he said that if he was in my 
shoes, he would give his daughter the vaccine and that was enough for me” (P7, 
VA). However, many VA did not discuss their decision with the GP, reporting that 
they had not “felt the need”, while vaccine decliners avoided the discussion as they 





going to tell you to just get the vaccine…that would be the same as reading the HSE 
information” (P5, VD), “Of course they were going say ‘get it done, get it done, get it 
done’” (P1, VD).  
The ultimate vaccine decision appeared to lie in the participants “perception of 
risk”. VA acknowledged the risks associated with vaccination but prioritised disease 
and cancer prevention (beliefs about consequences, goals): “The only side effect I 
care about is that it will stop my little girl from getting cancer” (P6, VA), “A sore arm 
is a small price to pay for something that could save your life” (P3, VA). This was 
particularly evident in those participants who had personal experience with HPV-
related conditions or cancer in general (beliefs about consequences, goals, emotion 
and optimism): “I have had to get repeat smears done because of 
abnormalities…the worry and the fear when you get that letter, I never want her to 
go through that…I think she will walk into (cervical screening) appointments more 
confidently knowing that she has had the vaccine” (P2, VA), “Knowing what my wife 
went through, from the initial diagnosis to the treatment and right to the end, I 
wouldn’t wish it on my worst enemy. Getting the vaccine for my girls and knowing 
they have reduced chance of going through all that, it’s worth everything” (P8, VA). 
In contrast, vaccine decliners prioritised the alleged risk of chronic side effects in 
their decision (beliefs about consequences, emotion): “I just felt there was a higher 
chance of getting side effects from the vaccine than ever developing cervical cancer 
so it wasn’t worth the risk” (P5, vaccine decliner), “What it really boiled down to for 
me was that the side effects that I was hearing about were so severe, so life 
changing that I just couldn’t risk it” (P13, VD). Some inaccurately believed an 





cancer development (beliefs about consequences, knowledge): “I suppose, if I could 
get an injection tomorrow against dementia, I would because my mum’s father…but 
there’s no cervical cancer in my family” (P1, VD), “There isn’t any cervical cancer in 
the family so that helped it (the decision) too” (P5, VD). Others failed to understand 
the rationale for pre-pubescent immunisation (knowledge):  “She wasn’t at risk 
when she was that age so I didn’t feel the need to put her immune system through 
it…where I fell short was why she really needed it now” (P10, VD), “If you had a 
daughter that you’ve no control over or whatever maybe you’d have to look at 
something then to protect her...The decision may be very different depending on the 
child and the circumstances” (P1, VD). Those vaccine decliners interviewed 
acknowledged the potential for anticipated regret should their daughter develop 
HPV-related disease or malignancies (beliefs about consequences, emotion): “I 
know if, God forbid, if she gets cervical cancer in the next few years, I’ll blame 
myself” (P1, VD), “Like if she were to get cervical cancer, I would be completely 
devastated when the vaccine maybe could have stopped it” (P13, VD). However, 
some believed they could protect their daughters from these consequences 
through sex education and promoting cervical screening (beliefs about 
consequences, beliefs about capabilities, optimism): “How she can prevent HPV 
through her actions…practising safe sex when the time comes and making sure she 
goes for regular smears” (P10, VD), “Like sex education is just even more important 
for her to make sure she is safe” (P13, VD). All participants interviewed declared 
they were content with their respective vaccine decisions (optimism) and it was 
evident that the ultimate goal of these decisions was protection of their daughters’ 





6.3.2 Stage 2: Identifying intervention options [210] 
The ten TDF domains described in Stage 1 were then linked to several COM-B 
components: psychological capability; physical and social opportunity; and 
reflective and automatic motivation. The BCW was then used to identify 
intervention functions;  by consensus discussion of the data, five of the nine 
intervention functions were found to be relevant: education; persuasion; 
environmental restructuring; modelling; and enablement [210].   
6.3.2 Stage 3: Identifying content and implementation options [215] 
The five intervention functions from Stage 2 were linked to 13 BCTs, based on the 
relevance of the technique to the identified behaviours [204, 210, 215]. These are 
outlined in Table 12. Potential intervention strategies were developed and outlined 





Table 12 Intervention functions and BCTs identified using the TDF, the COM-B model and the BCW [11, 14-16] 















6. Comparison of behaviour 
7. Associations 




5.1 Information about health consequences 
5.2 Salience of consequences 
5.3 Information about social and environmental consequences 
5.5 Anticipated regret 
5.6 Information about emotional consequences 
6.3 Information about others’ approval 
7.1 Prompts/cues 
9.2 Pros and cons 
9.3 Comparative imagining of future outcomes 
12.1 Restructuring the physical environment 
15.3 Focus on past success 
Environmental context 
and resources 
Physical Opportunity Enablement 
Environmental restructuring 
5. Natural consequences 
 
7. Associations 




5.2 Salience of consequences 
5.3 Information about social and environmental consequences 
7.1 Prompts/cues 
9.2 Pros and cons 
9.3 Comparative imagining of future outcomes 
12.1 Restructuring the physical environment 




















9. Comparison of outcomes 
 
5.1 Information about health consequences 
5.2 Salience of consequences 
5.3 Information about social and environmental consequences 
5.5 Anticipated regret 
5.6 Information about emotional consequences 
6.1 Demonstration of the behaviour 
6.2 Social comparison 
6.3 Information about others’ approval 
7.1 Prompts/cues 
9.1 Credible source 







9.3 Comparative imagining of future outcomes 
15.3 Focus on past success 
Emotion Automatic Motivation Persuasion 
Modelling  
Enablement 





6. Comparison of behaviour 
 
 




5.1 Information about health consequences 
5.2 Salience of consequences 
5.3 Information about social and environmental consequences 
5.5 Anticipated regret 
5.6 Information about emotional consequences 
6.1 Demonstration of the behaviour 
6.2 Social comparison 
6.3 Information about others’ approval 
9.1 Credible source 
9.2 Pros and cons 
9.3 Comparative imagining of future outcomes 
15.3 Focus on past success 
Social influences Social Opportunity Modelling 
Enablement 
Environmental restructuring 
5. Natural consequences 
 
6. Comparison of behaviour 
7. Associations 




5.2 Salience of consequences 
5.5 Anticipated regret 
6.1 Demonstration of the behaviour 
7.1 Prompts/cues 
9.2 Pros and cons 
9.3 Comparative imagining of future outcomes 
12.1 Restructuring the physical environment 









Table 13 Potential intervention strategies to reduce vaccine hesitancy [11] 
BCT Label Intervention functions Potential Intervention Strategies 
5.1 Information about health 
consequences 
Education, Persuasion Explain that not vaccinating can increase susceptibility to future HPV infection 
Present the likelihood of HPV exposure and infection: HPV affects 80% of people at some point in life 
Provide information on the consequences of chronic HPV infection (anogenital warts, neoplasia, cervical, anogenital, head 
and neck cancers) 
5.2 Salience of consequences Persuasion, Enablement Provide information on the potential interventions that could be required with chronic HPV infection (colposcopy, laser 
treatment, cold coagulation, surgery, radiotherapy, chemotherapy)  
5.3 Information about social and 
environmental consequences 
Education, Persuasion Inform the parent that the majority of girls (70%) receive the HPV vaccine  
Educate on the importance of herd immunity  
5.5 Anticipated regret Enablement Ask the parent to assess the degree of regret they will feel if they do not vaccinate their daughter and she were to develop 
HPV-related disease 
5.6 Information about emotional 
consequences 
Education, Persuasion Explain that accepting the HPV vaccine for their daughter will offer a level of comfort, knowing that she is somewhat 
protected from chronic HPV infection  
6.1 Demonstration of the 
behaviour 
Modelling Present a vaccinated adolescent or a parent who consented to vaccination, discussing their experience with the vaccine 
Present an unvaccinated adolescent or a parent who did not consent to vaccination, discussing how they regretted their 
decision 
6.2 Social comparison Persuasion Inform that the majority of parents (70%) consent to vaccinate 
6.3 Information about others’ 
approval 
Education, Persuasion Inform that the majority of parents (70%) consent to vaccinate 
7.1 Prompts/cues Education, 
Environmental 
restructuring 
Information leaflets or stickers at locations that will be seen by parents (GP surgery, pharmacy, and other healthcare 
environment, or school notice board, sports facilities) 
Targeted media campaign (television, radio, social media) 
9.1 Credible source Persuasion Encourage HCP (GP, nurse) to engage in conversation about the HPV vaccine 
Encourage HCP (GP, nurse) to provide personalised guidance on the vaccine i.e. “if I were in your position, I would consent” 
Inform the parent that all national and international scientific and regulatory bodies recommend the HPV vaccine (e.g. 
World Health Organisation (WHO), Centres for Disease Control and Prevention (CDC), European Centre for Disease 
Prevention and Control (ECDC)) 
9.2 Pros and cons Enablement Advise the parent to list and compare the advantages and disadvantages of their vaccine decision 
9.3 Comparative imagining of 
future outcomes 









Offer unvaccinated girls repeated opportunity to be vaccinated 







To our knowledge, this is the first published study to use an understanding 
of the HPV vaccine decision-making process, to systematically define 
intervention functions and suggest strategies to promote positive decision-
making for the HPV vaccine and thereby increase acceptance of this 
vaccine. Recommendations are based on the identified factors that 
influence the HPV vaccine decision in Ireland and a systematic approach of 
analysing these factors in the context of behaviour change theory. All 
recommendations should be considered for future public health 
vaccination campaigns and intervention studies, as no single recommended 
BCT or intervention strategy will address all identified factors. 
Five BCW intervention functions were found to meet the APEASE criteria. 
Incentivisation, coercion, training and restriction were not found to be 
appropriate in this context. Incentivisation creates an expectation of 
reward [204]. Provision of financial incentives for vaccination has been 
used with varying effect in different countries for early childhood vaccines 
[391]. In a UK RCT, a combination of financial incentive and reminder text 
messaging increased completion of HPV immunisation [392]. However, 
uptake remained lower than the national target thereby questioning the 
cost-effectiveness and acceptability of incentivisation in regions such as 
Ireland where vaccination is provided free of charge.  
Coercion creates an expectation of punishment or cost [204]. In the US, 





entry HPV vaccine mandates [393]. In contrast, while the HPV vaccine is 
recommended in 31 European countries, vaccination remains voluntary 
[394]. There remains debate on the effectiveness of vaccine mandates and 
it is unclear whether mandatory vaccination may lead to opposing 
attitudes and reduced vaccine uptake [395, 396]. In addition, research has 
demonstrated that coercion, through vaccine mandates, is often viewed as 
unfavourable and unacceptable by parents [397]. In Ireland, similar to 
other European countries, vaccines are recommended by the Irish 
authorities, but are not compulsory: parents are entitled to withhold 
consent and forego vaccination. Legislating for compulsory vaccination 
could potentially be challenged as unconstitutional in Ireland.  
Behaviour change based on restriction involves an increase in the target 
behaviour by reducing the opportunity to engage in competing behaviours 
[204]. This function would not be applicable or feasible in an intervention 
to increase vaccine acceptance: it is not possible to reduce the opportunity 
to engage in the competing behaviour i.e. vaccine refusal. Finally, training 
involves imparting skills [204]. While this function may be suitable in the 
design of an intervention involving vaccinators, it’s inclusion in an 
intervention involving parents would be inappropriate. 
Interviewees revealed that the female parent was the primary healthcare 
decision-maker for the family: a well-recognised phenomenon [398]. It may 
be suggested that future interventions to reduce HPV vaccine hesitancy 
should target this demographic. However, the over-identification of HPV as 





HPV vaccine [399]. Therefore, interventions should seek to normalise HPV 
vaccines as an important aspect for all (information about health 
consequences). Gender-neutral vaccination programmes have been 
introduced in Scotland and Australia, as the awareness of the burden of 
HPV-related cancers in men has increased [400]. Another important 
consideration is the additional protection provided by a gender neutral 
programme to vulnerable groups (e.g. men who have sex with men) [143]. 
In Ireland, the Health Information and Quality Authority (HIQA) has 
completed a health technology assessment in relation to gender neutral 
HPV vaccination and has recommended the adoption of gender neutral 
nonavalent immunisation programme, which began in September 2019 
[143].  
The essential role of HCP in guiding vaccine decisions was identified 
(credible source). However, it is clear that their potential in this role is not 
yet fully realised. Effective interactions with HCP have the potential to 
alleviate concerns of vaccine supportive parents and to motivate a vaccine 
hesitant parent towards acceptance [33]. A recent systematic review 
reported that HCP recommended vaccination less often if they were 
uncomfortable discussing sexual activity, if they perceived parents to be 
hesitant or believed patients to be low risk [401]. It was shown that parents 
prefer strong, unambiguous recommendations from their HCP [4] and 
apathetic interactions are likely to discourage timely HPV vaccination and 
encourage watchful waiting. Therefore there is a requirement for the 





recommending the HPV vaccine with confidence (credible source, 
prompts/cues). Interviewees also discussed how they had appreciated, and 
been reassured by, their HCP sharing their own personal vaccine decisions, 
a finding that has been evident elsewhere (credible source, social 
comparison) [402]. 
The parents who declined the HPV vaccine for their daughter would be 
considered vaccine hesitant as they had all accepted previous vaccines for 
their child or children [48] (focus on past success). Complacency and 
confidence were important factors in their decision. Parents were 
complacent about their daughter being at risk for HPV infection due to age, 
lifestyle choices and/or a lack of family history of cervical cancer. They felt, 
as parents, that they could protect her from future infection through sex 
education, encouraging safe sex practices and attendance at screening 
programmes. There appeared to be an over-reliance on the national 
cervical screening programme, which was mistaken as a diagnostic tool. 
This was notable considering the CervicalCheck controversy in Ireland that 
had saturated media in the months preceding these interviews, when 
significant flaws in smear test results and communications were identified. 
While cervical screening offers protective benefits and is associated with a 
reduction in the incidence of invasive cancer and mortality [403], an effort 
must be made to increase awareness of complementary prophylactic 
measures, such as HPV vaccination. 
 It also emerged that vaccine-hesitant parents were not confident in the 





observed [404]. Although education through the provision of accurate, 
balanced, scientifically-based evidence on the benefits of vaccination is 
essential, it is not sufficient to close the gap between current levels of 
public confidence and levels of trust required to ensure adequate coverage 
[405]. Therefore, in addition to education, both persuasion and 
enablement will be key components of interventions to address vaccine 
confidence. These components could include: providing information on 
HPV, lifetime risk of HPV infection and the impact of chronic infection 
(information about health consequences, salience of consequences, 
information about emotional consequences), clarifying the rationale for 
pre-pubescent vaccination (information about health consequences), 
explaining the societal benefits of herd immunity (information about social 
and environmental consequences, social comparison, information about 
others’ approval), providing assurances of vaccine safety and efficacy 
(credible source) and asking parents to consider how they would feel 
should they decline vaccination and their daughter subsequently develops 
a HPV-related disease (comparative imaging of future outcomes, pros and 
cons, anticipated regret). Personal stories opposing vaccination are 
widespread and this anecdotal evidence is recognised as being highly 
persuasive, fuelling the spread of misinformation, and influencing existing 
health behaviours and beliefs [406]. To counter this effect, personal stories 
encouraging vaccination and describing the vaccine-preventable disease, 
should be shared, to facilitate the spread of information, and encourage 





vaccine, and cervical cancer, patient advocate, Ms. Laura Brennan, who 
campaigned tirelessly in the years preceding her untimely death in March 
2019.        
Limitations of this study must be acknowledged. The study participants 
were asked to retrospectively reflect on a decision made prior to HPV 
vaccine instability. It is unclear whether these parents would have altered 
their decision in light of circulating misinformation. As a qualitative study, 
the findings may not be readily generalisable to the wider population. 
However the participants were sampled across a relatively large 
geographical area, included parents of children attending both DEIS and 
non-DEIS programme second level schools. Furthermore, the proportion of 
vaccine decliners (30%) is similar to the overall population in Ireland, 
suggesting that the findings are transferable. However, it must also be 
noted that the participants comprised a self-selected sample.  
The key strength of this study is the systematic approach (TDF, COM-B 
model and BCW) that was applied to map the parental HPV vaccine 
decision and to recommend a range of potential intervention strategies. It 
has been shown that using theory to understand the mechanisms of action 
of intervention strategies improves the effectiveness of interventions 
[383]. In addition, the World Health Organisation (WHO) has declared 
vaccine hesitancy as one of the ten global threats to health in 2019 and 
intervention strategies recommended by this study may be applied to 






In summary, this study provided a detailed insight into behavioural factors 
influencing the vaccine decision-making process. We identified that 
complacency and a lack of confidence were the main factors dictating the 
decision to vaccinate in hesitant parents and several intervention strategies 
are suggested to address these factors.  
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6.9 Chapter conclusion and context within thesis  
This chapter described the qualitative interview study, undertaken with 
parents of female adolescents and guided by the research questions 
generated in Chapter 4 and the research findings of Chapter 5. The chapter 
explored the knowledge, attitudes, and beliefs about HPV vaccination, 
thereby further addressing the second objective of this doctoral thesis i.e. 
to elucidate vaccine decision-making and to identify barriers to vaccine 
uptake. The evidence-base generated in Chapter 4 and the primary 
research conducted in Chapters 5 and 6 elucidated the HPV vaccine 
decision-making process in both adolescents and parents, and guided the 
development of an intervention to improve vaccine uptake. This 
theoretically-informed and evidence-based intervention is described in 






Chapter 7 Is the HPV vaccine for me? 
Video-based behavioural 
intervention associated with 






The research presented in this chapter is being prepared for journal submission. 
Author Contributions 
SM was involved in the overall design of the research, designed, created and 
narrated the intervention, completed the application for ethical approval, recruited 
participants, analysed the results, wrote the draft manuscript and was involved in 











There is an urgent need to develop interventions, involving parents and adolescents 
which support positive decision-making towards the HPV vaccine. 
Aim 
The purpose of this study was to design, develop and evaluate a theory and 
evidence-based intervention to improve HPV and HPV vaccine knowledge, and 
intention to vaccinate, among parent-daughter dyads. The objectives of our study 
were to (1) evaluate participants’ baseline HPV and HPV vaccine knowledge; (2) 
assess the impact of the intervention on (i) participants’ HPV knowledge (including 
HPV vaccine knowledge) and (ii) intention to vaccinate; and (3) assess the feasibility 
of the intervention by examining the participant acceptability of the methods used. 
Methods 
A theory and evidence-based online behavioural intervention, “Is the HPV vaccine 
for me?” was developed to improve HPV and HPV vaccine knowledge, and intention 
to vaccinate. The impact and feasibility of the intervention was evaluated in a 
prospective randomised controlled feasibility trial.  
Results 
A total of 49 parent-daughter dyads completed baseline knowledge assessment 
(n=24 control, n=25 intervention), and 35 dyads completed knowledge assessment 
at week 2 (n=17 control, n=18 intervention). The intervention was associated with a 





vaccinate. All intervention participants found the video interesting, while 96% 
found it useful.  
Conclusion 
This intervention was found to be affordable, practicable, effective (cost-effective), 








HPV is responsible for approximately 4.5% of global cancer disease burden, with 
cervical cancer the most common cancer caused by HPV infection [142, 143]. The 
infection is also associated with cancers of the oropharynx, anus or rectum, penis, 
vulva and vagina and is responsible for anogenital warts in men and women [143]. 
Three vaccines are licensed and marketed for use to prevent HPV infections and 
their sequelae [144-146]. These are intended to be administered to adolescents 
before the onset of sexual activity [143]. The safety of the HPV vaccines is well 
established [155, 156]. However, unsubstantiated claims linking the administration 
of these vaccines to the development of a plethora of adverse effects [141, 143, 
154], has led to a significant reduction in vaccine uptake worldwide [167, 169, 170]. 
There is therefore a need to develop interventions that support positive decision-
making towards the HPV vaccine [45, 173-176]. Several interventions have been 
designed to address HPV vaccine hesitancy, frequently targeting parents [181], and 
evaluation is often based on the impact of the intervention on parents’ intention to 
vaccinate, with several studies reporting a statistically significant impact on 
intentions [407-411]. However, it has been recommended that adolescents be 
included in healthcare decision-making [371]. Therefore, in this study, the target 
population of our behavioural intervention is parent-daughter dyads.  
Interventions have been shown to be more effective if they are based on principles 
drawn from evidence and theories of behaviour change [184]. Evidence was 
generated in a comprehensive systematic review [4], and through a series of 





qualitative studies were guided by behaviour change theory, including the 
Theoretical Domains Framework (TDF) [206], the COM-B model [204], the 
Behaviour Change Wheel (BCW) [204], and the Behaviour Change Technique 
Taxonomy version 1 (BCTTv1) [215]. The TDF guided the development of focus 
group and interview topic guides, and was used as a coding framework in data 
analysis [204]. Ten of the 14 TDF domains were selected as the most relevant [206, 
381] (Table 14). 
 
Table 14 Theoretical Domains Framework (TDF) Domains identified through qualitative research [5] 
TDF Domain Parents Adolescents 
Knowledge   
Memory, attention and decision processes   
Social role and identity   
Beliefs about capabilities   
Optimism   
Beliefs about consequences    
Goals    
Emotion   
Environmental context and resources    
Social influences   
 
The ten TDF domains were linked to several components of the COM-B model: 
psychological capability; physical and social opportunity; and reflective and 
automatic motivation. The BCW was then used to identify five relevant intervention 
functions: education; persuasion; environmental restructuring; modelling; and 








Table 15 Behaviour Change Techniques (BCT) identified through qualitative research [5] 
BCT Parents Adolescents 
Information about consequences   
Salience of consequences   
Information about social and environmental consequences   
Anticipated regret   
Information about emotional consequences   
Demonstration of the behaviour   
Social comparison   
Information about others’ approval   
Prompts/cues   
Credible source   
Pros and cons   
Comparative imagining of future outcomes   
Restructuring the physical environment   
Focus on past success   
Identification of self as role-model   
 
7.3 Aim 
The purpose of the current study was to design, develop and evaluate a theory and 
evidence-based intervention to improve HPV and HPV vaccine knowledge, and 
intention to vaccinate, among parent-daughter dyads. The objectives of our study 
were to (1) evaluate participants’ baseline HPV and HPV vaccine knowledge; (2) 
assess the impact of the intervention on (i) participants’ HPV knowledge (including 
HPV vaccine knowledge) and (ii) intention to vaccinate; and (3) assess the feasibility 
of the intervention by examining the participant acceptability of the methods used. 
7.4 Methods 
7.4.1 Ethical approval 
Ethical approval was obtained from the Social Research Ethics Committee, 





7.4.2 Intervention development 
We developed an online behavioural intervention, “Is the HPV vaccine for me?” to 
improve HPV and HPV vaccine knowledge, and intention to vaccinate. The video 
was created using VideoScribe 3.3.1-1 software by Sparkol®, in consultation with a 
Technology-Enabled Learning Co-ordinator. It is six minutes in duration. A narrative 
approach was applied, mapping the adolescent HPV vaccine decision journey (BCT: 
demonstration of the behaviour; social comparison). It is narrated by the primary 
researcher (SM), and definitions and numerical information are complemented by 
graphical illustration. The information provided is evidence-based and theoretically-
informed, bridging the knowledge gaps identified through previous research [5]. It 
addresses the objectives outlined in Table 16, according to the identified BCTs. The 
video finishes with a reminder that the majority of girls in Ireland accept the HPV 
vaccine (BCT: information about social and environmental consequences; social 
comparison; information about others’ approval).  
 
Table 16 Intervention objectives and associated Behaviour Change Techniques (BCTs) [215] 
Intervention objectives BCTs 
Understand how HPV is transmitted Information about health consequences 
Know how common HPV infections are Information about health consequences 
Salience of consequences 
Know that HPV infects both men and women Information about health consequences 
Understand the consequences of long-term HPV infection(s) Information about health consequences 
Salience of consequences 
Anticipated regret 
Information about emotional 
consequences 
Comparative imaging of future outcomes 
Pros and cons 
Understand why the vaccine is administered at the recommended 
age 
Information about health consequences 
Appreciate the safety and efficacy of the vaccine Credible source 
Focus on past success 
Know the vaccine side effects Credible source 






7.4.3 Intervention evaluation 
7.4.3.1 Trial design 
A prospective randomised controlled feasibility trial (RCT), containing an 
intervention group who had access to the video and a control group who did not 
have access to the video, was conducted to evaluate the intervention for parent-
daughter dyads, living in Cork, Ireland. Randomisation occurred at the school level.  
7.4.3.2 Participant recruitment 
Eligible participants were parent-adolescent dyads including a female adolescent, 
pre-HPV vaccination, in her final year of primary school (ISCED level 1) [288], 
typically aged 11-12 years. Recruitment took place over a six-week enrolment 
period from April to May 2019. A list of Cork primary schools was compiled and 
stratified according to DEIS (Delivering Equality of Opportunity in Schools) status 
[390]. The DEIS programme supports children who are at greatest risk of 
educational disadvantage [390]. Using a purposive sampling strategy [386], school 
principals were contacted via email and/or telephone and provided with details of 
the trial. Schools interested in taking part were then randomised by simple 
randomisation [412]. The principals were asked to share study information, via 
email, with eligible participants. This email detailed trial information, expectations 
of participation, and instructions on accessing the trial material. Google Forms was 
used as the data collection platform, recording consent to participate and baseline 
characteristics of the parent: gender; age range; highest education level achieved; 





7.4.3.3 Outcome measures 
1. Evaluate participants’ baseline HPV and HPV vaccine knowledge and intention to 
vaccinate 
A 10-item questionnaire to assess HPV and HPV vaccine knowledge was developed 
(Figure 16). Items assessed knowledge using a “True, False, and Don’t know” 
format. These 10 items were identified as knowledge gaps during previous 
literature review and qualitative research [4, 5]. The questionnaire was developed, 
edited and assessed for face validity and content validity by the multi-disciplinary 
research team but did not undergo external validation. A knowledge score was 
based upon correct responses to items 1-10 of the study questionnaire (Figure 16). 
The knowledge score ranged from 0-10, with one point being rewarded for each 
correct response obtained. No points were rewarded if the participant responded 
as “Don’t know”. Participants were also asked if they intended accepting the HPV 
vaccine for their daughter and had the options of “Yes”, “No”, and “Don’t know”. 






1. HPV is very rare 
O True 
O False 
O Don’t know 
2. 8 out of 10 people will get HPV in their life 
O True 
O False 
O Don’t know 
3. HPV always has visible signs or symptoms 
O True 
O False 
O Don’t know 
4. HPV is spread through the air 
O True 
O False 
O Don’t know 
5. Only women can get HPV 
O True 
O False 
O Don’t know 
6. HPV can cause cancer in more than one part of the body 
O True 
O False 
O Don’t know 
7. You only need the HPV vaccine if someone in your family has had cervical cancer 
O True 
O False 
O Don’t know 
8. The HPV vaccine is most effective if given to 11-12-year olds 
O True 
O False 
O Don’t know 
9. The HPV vaccine has only been given in Ireland 
O True 
O False 
O Don’t know 
10. There are many unwanted, long lasting side effects from the vaccine 
O True 
O False 
O Don’t know 
 
Figure 16 HPV and HPV vaccine knowledge questionnaire 
 
2. Assess the impact of the video on participants’ HPV knowledge and intention to 
vaccinate 
Intervention Group: At the start of the study, (Week 0; W0), those in the 





immediately had the opportunity to view the video. Two weeks later, they repeated 
the baseline knowledge assessment (Week 2; W2). They were also asked whether 
the video had increased the likelihood of accepting the HPV vaccine (“Yes, No, and 
Don’t know”).  
Control Group: They did not have access to the video; however they completed the 
knowledge assessments at W0 and W2. They were provided the opportunity to 
view the video, upon completion at W2.  
3.  Assess participants’ acceptability of the intervention 
At W2, participants in the intervention group were asked to respond (“Yes, No, and 
Don’t know”) to the following statements to assess their acceptability: (1) Did you 
find this video interesting? (2) Did you find this video useful? In addition, feedback 
from participants regarding their impressions of the video and suggestions for 
improvement was obtained through the provision of a free-text box. 
7.3.3.4 Statistical analyses 
Data were analysed using IBM’s Statistical Package for the Social Sciences (SPPS) for 
Windows, Version 22.0 (IBM Corp., Armonk, NY). Continuous variables were 
described by means and SDs for normally distributed data and by medians and IQRs 
for non-parametric data. Categorical variables were described by counts and 
percentages. Associations between categorical variables were investigated using 
Yates’ Continuity Chi-Square tests. Mann-Whitney U tests were used to investigate 
differences between groups for non-parametric continuous variables. P values of 






During the six-week enrolment period, 313 schools were invited to participate 
(n=37 DEIS, n=276 non-DEIS). Eleven schools agreed to participate (n=4 DEIS, n=7 
non-DEIS) and were randomised (n=5 control, n=6 intervention). According to 
information provided by the school principals, 326 parent-daughter dyads were 
eligible to participate. A total of 49 parent-daughter dyads completed baseline 
knowledge assessment at W0 (n=24 control, n=25 intervention), and 35 dyads 
completed knowledge assessment at W2 (n=17 control, n=18 intervention) (Figure 
17). Baseline participant demographics are summarised in Table 17. 
  






Table 17 Baseline participant demographics 
 Control n (%) Intervention n (%) p value 
DEIS
a
  10 (41.7) 9 (36.0) 0.909 
 
Females 24 (100) 25 (100) N/A 
 
Age range 
 20-29 years 
 30-39 years 
 40-49 years 













Highest level of education 
 ISCED
b
 level 1 
 ISCED level 2 
 ISCED level 3 
































Children fully vaccinated 
 Yes 
 No 










Intend to accept HPV vaccine 
 Yes 
 No 













: Delivering Equality of Opportunity in Schools): this programme supports children who are at greatest risk 





ISCED level 1: Primary education, equivalent to 8 years official State education 
ISCED level 2: Lower secondary education: Irish Junior/Inter Certificate, equivalent to 11 years official State 
education   
ISCED level 3: Upper secondary education: Irish Leaving Certificate, equivalent to 14 years official State 
education 
ISCED level ≥4:  Higher Education including post-secondary non-tertiary education, short-cycle tertiary 
education, Bachelor (or equivalent), Master (or equivalent) and Doctoral (or equivalent) 
 
 
All participants were female and declared that, to the best of their knowledge, all 
children in their care were fully vaccinated. There were no statistically significant 





(χ2yates (1)=0.013, p=0.909), age (χ
2
yates (1)=3.463, p= 0.063), education (χ
2
yates 
(1)=0.000, p=0.984), number of children (χ2yates (1)=0.580, p=0.456) or intention to 
accept the HPV vaccine (χ2yates (1)=0.021, p=0.884).  
7.5.1 Outcomes 
1. Participants’ baseline HPV and HPV vaccine knowledge and intention to 
vaccinate 
At W0, the overall median (IQR) baseline knowledge score was 5 (4, 6). There was 
no statistically significant difference in baseline knowledge assessment scores 
between control (median=5, n=24) and intervention (median=5, n=25) groups, 
(U=292, Z=-0.163, p=0.870) (Figure 18 and Table 18). Just over half (51%) of the 
participants indicated that they intended to accept the HPV vaccine, while the 
remaining 49% remained undecided. 
 
 
Figure 18 Knowledge Assessment Scores at W0, comparing Control and Intervention groups.  
The total score for the knowledge assessment is on the X-axis, the number of participants achieving this score is 






2. Impact of the video on participants’ HPV knowledge and intention to vaccinate 
At W2, there was a statistically significant difference in knowledge assessment 
scores between control (n=17) and intervention (n=18) groups, (U=1.5, Z=-5.065, 
p<0.01), as shown in Table 18 and Error! Reference source not found.. When asked 
whether this video had increased the likelihood of accepting the HPV vaccine, 88% 
indicated that it had, 4% indicated that it had not and 8% were unsure.  
 











49 5 (4.75, 6) 5 (4, 7) p=0.870 
W2 knowledge 
assessment 
35 5 (5, 6) 9 (9, 10) p<0.01 
 
 
Figure 19 Knowledge Assessment Scores at W2, comparing Control and Intervention groups 
  
3. Participants’ acceptability of the intervention 





























Knowledge assessment score 








The purpose of this study was to design, develop and evaluate the feasibility of a 
theory, and evidence-based intervention to improve knowledge about HPV and HPV 
vaccines and intention to vaccinate among parent-daughter dyads. It was intended 
that targeting these dyads would promote open dialogue between parent-daughter 
pairs, leading to a scenario where the adolescent was involved and participated in 
the vaccine decision. The chosen mode of delivery was an online video. Digital 
media has several advantages: videos can be entertaining; their medium is familiar; 
and they may be designed as a “takeaway tool” that permits more independent 
application, at the viewer’s own pace [413, 414]. We found that this educational 
intervention significantly increased knowledge of HPV and the HPV vaccine for 
participants who viewed the video compared to a control group. Secondly we found 
that this video increased the likelihood of accepting the HPV vaccine for the 
majority of participants in the intervention group. This study therefore provides 
initial “proof of concept” that an educational intervention designed from a “solid 
foundation” of behaviour change theory can positively influence the HPV vaccine 
decision-making behaviour. 
While several interventions have been designed to address HPV vaccine hesitancy 
[407-411], there are no published examples, using the BCW to develop a de novo 
online intervention, targeted at parent-daughter dyads. The intervention was 
evaluated using the APEASE criteria, a set of criteria used to make context-based 
decisions on intervention content and delivery consisting of affordability, 
practicability, effectiveness and cost-effectiveness, acceptability, side-effects/safety 





case, this video-based intervention was created by the lead author in consultation 
with a Technology-Enabled Learning Co-ordinator, with minimal financial input. This 
video was then hosted free of charge on a YouTube® platform (unlisted). If the 
intervention is adopted in its current form, no further financial investment would 
be required. This intervention is practicable in its mode of delivery. Because the 
video is hosted online, the internet is used as a platform to disseminate the content 
as intended to the target population. According to data collected in 2018 by 
Ireland’s Central Statistics Office (CSO), an estimated 89% of Irish households had 
access to the internet at home, with 57% of individuals seeking health-related 
information online [415]. Research has shown that more people are accessing 
internet-based content by following links on social media than through direct 
searches [416]. Social media is defined as; a group of internet-based applications 
that allow the creation and exchange of user-generated content [417]. Social media 
statistics from June 2018 indicate that up to 66% of Irish individuals (over 15 years) 
are using social networking sites (e.g. Facebook®, Instagram®, LinkedIn®, Twitter®) 
[418]. It has been demonstrated that information shared via social media results in 
greater knowledge transfer than when shared via pamphlets [419]. In addition, it 
has been postulated that social media has direct public health relevance because 
social networks could have an important positive influence on health behaviours 
and outcomes [420, 421]. Therefore, social media platforms have the potential to 
effectively increase knowledge and facilitate behaviour change. The intervention 






In this small feasibility study, the intervention was shown to be effective, with a 
statistically significant increase in knowledge assessment scores. At the outset, 49% 
of participants were undecided about their vaccine decision. However, on 
completion of the study, 88% participants indicated that the video had increased 
the likelihood of accepting the vaccine. While this was a positive finding, it must be 
acknowledged that intention alone does not necessarily predict future vaccine 
uptake [422]. This disparity is known as the intention-behaviour gap and is present 
when people hold favourable immunisation intentions yet fail to act [423, 424]. A 
variety of strategies have been suggested to bridge this gap: keeping these 
favourable immunisation intentions in mind through reminders, prompts and cues; 
and reducing barriers through logistics and heuristics [115]. A key strength of an 
anonymised data collection approach is the minimisation of social desirability bias. 
Social desirability bias refers to the individual’s tendency to respond in a more 
socially desirable manner in certain situations and reflects what one believes will 
lead to approval from others or avoiding their disapproval [425, 426]. If intention to 
vaccinate was assessed through qualitative methods, such as face to face interviews 
by the researcher (SM), whose occupation as a pharmacist was known to the 
participants, the results may not have been reflective of true intentions.  
There were no statistically significant differences between the control and 
intervention groups according to DEIS status, age range, education, number of 
children, child vaccination status, and intention to accept the HPV vaccine. All 
parent participants were female. However, such a gender imbalance is not unusual. 
Research has demonstrated that the female care-giver is more likely to participate 





family [352]. In agreement with previous research, baseline HPV, and HPV vaccine, 
knowledge was low [4].  
While it would have been desirable to evaluate the impact of this intervention on 
actual vaccine uptake, this was not a primary objective of the study and was not 
included in the ethics approval. Instead, the favourable immunisation intentions 
generated by the intervention could be kept in mind through repeated 
dissemination of the video (e.g. online via social media or on television screens 
located at healthcare facilities such as GP surgeries and pharmacies). Due to the 
affordability, practicability and effectiveness of the intervention, it was determined 
to be cost-effective.  
Acceptability has become a key consideration in the design, evaluation and 
implementation of healthcare interventions and is a necessary condition for 
effectiveness [427]. The acceptability of this intervention was evaluated: all of those 
asked found the video interesting, while 96% found it useful. However, only 3.5% of 
invited schools consented to participate. While an effort was made to understand 
the reasons underpinning their lack of participation, the majority of contacted 
schools were non-responsive. Of those eligible to complete the knowledge 
assessment at W0, only 15% did so and this was further reduced to 10.7% at W2. 
This decline in response rate between phases is frequently observed and reported 
[428]. However, a higher response rate was expected due to the personal relevance 
of the research topic [429]. This intervention was delivered in May, this is four 
months before the vaccine will be offered to the participants, to permit timely 
provision of vaccine information [430]. It is possible that the time-lag between 





were not yet prepared to consider their vaccine decision and thus were not 
personally invested in intervention content. 
An intervention may be effective and practicable, but have unwanted side-effects 
or unintended consequences [204]. Research has shown that information provision 
regarding vaccine safety and efficacy can cause unpredictable effects on vaccination 
uptake and may even increase such concerns [431, 432]. A free-text box was 
provided in this study and no participants reported any such concerns. Nor did any 
participants contact SM, whose contact information was provided. However, the 
potential for such an occurrence if the intervention were to be scaled up should be 
considered. 
The use of video as a mode of delivery facilitates equity, as it provides standardised 
content across learners and has been shown to be effective among viewers of lower 
literacy levels [433]. However, the impact of the ‘digital divide’ on the 
implementation of an online intervention must be considered. A proportion of the 
Irish population (11%) do not have internet access at home with 30% of these 
reporting that lack of skills hampered their internet access [415]. Parents (and 
adolescents) currently receive vaccine information in written format, (i.e. 
pamphlets and patient information leaflets (PIL)) and additionally, the website of 
the National Immunisation Office (NIO) is signposted, providing further information 
in a variety of formats, including both video and text. The intervention described 
here is not intended to replace such material, but rather to support and 
complement it, providing information and promoting behaviour change in a manner 






A video-based online behavioural intervention was associated with improved HPV 
(and HPV vaccine) knowledge, and intention to vaccinate, among parent-daughter 
dyads. The intervention was found to be affordable, practicable, effective (cost-
effective), acceptable, safe, and equitable, in this feasibility study. However, it is 
important to acknowledge that vaccination is highly context specific [48]. Therefore 
the impact of this intervention will need to be evaluated in alternative contexts, for 
example different regions in Ireland). In addition, from September 2019, male 
adolescents are included in the HPV vaccination programme [143]. An assessment 
of the impact of our intervention in parent-son dyads is required, making 
alterations as required, and supplementing with further qualitative research, if 
indicated. Should this intervention demonstrate efficacy across multiple contexts, a 
national dissemination of “Is the HPV vaccine for me?” should be launched.   
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7.9 Chapter conclusion and context within thesis 
This chapter described the design, development and quantitative evaluation of a 
theoretically-informed and evidence-based intervention to improve vaccine 
knowledge and intention to vaccinate, thereby addressing the final objective of this 





behaviour change theory, the evidence-base generated in Chapter 4, and the 













This thesis investigated vaccine decision-making and identified barriers to vaccine 
uptake in an Irish setting. In this final chapter I will discuss the thesis as a complete 
body of work and interpret and contextualise the overall findings. The chapter will 
begin with a summary of the key findings, before integrating these findings to 
provide greater insights. This will involve a discussion of the implications of the 
research, taking into consideration previous literature, as well as healthcare 
practice and policy. Following this, the overall strengths and weaknesses of the 
thesis will be described. Finally, recommendations for future work will be provided.  
8.2 Summary of findings 
The first objective of this doctoral research was to review the literature on the 
perception and acceptability of vaccination to provide an evidence-base to inform 
the development of research questions for the primary research studies. Chapter 2 
provided a narrative review of the literature on the perceptions, acceptability and 
suitability of microneedle technology for immunisation in key stakeholder groups 
(i.e. parents, children and HCPs). Drivers for acceptability included: a perceived or 
actual reduction in pain; ease and convenience of administration; potential for self-
administration; and attractive visual appearance. Barriers to acceptability included: 
unfamiliarity; allergic potential; and the inclusion of the term ‘needle’ in the 
product name. It was identified that a paucity of studies on paediatric immunisation 
using microneedle patches have been published and further qualitative research 
was required to explore the perception, acceptability and suitability of 





systematic review and meta-ethnographic synthesis of the qualitative literature on 
the views of parents regarding HPV vaccination. Five key concepts that reflected the 
principal findings of all 33 included studies were determined: is prevention better 
than cure; the fear of the unknown; limited knowledge and understanding; complex 
vaccination decisions; and parental responsibility. Drivers for acceptability included: 
provision of information; HCP endorsement; disease prevention; and child 
protection. Barriers to acceptability included: low perception of risk; link to sexual 
intercourse; safety and efficacy concerns; and lack of information. There was 
significant overlap and data recurrence in the review. However, ‘new’ vaccine 
concerns, in light of HPV vaccine instability, have not been addressed in the 
literature and further qualitative research exploring these concerns was 
recommended.  
The second thesis objective was to address gaps identified in the literature reviews 
and ascertain the knowledge, attitudes and beliefs of key stakeholders to elucidate 
vaccine decision-making and to identify barriers to vaccine uptake in Ireland. 
Chapter 3 presented a qualitative focus group study that investigated the 
knowledge, attitudes and beliefs of parents about microneedle-patch vaccines. Five 
core themes were identified and defined as: concern (including general vaccine 
hesitancy, concerns with current vaccines and immunisation programmes and 
safety and efficacy concerns); suitability of microneedle technology for paediatric 
use (including practicality, child-friendliness and acceptability transfer); potential 
for parental administration (including its advantages and disadvantages and the 
requirement for a delivery indicator); the role of the HCP (as a source of 





uses). Chapter 5 presented a qualitative focus group study that investigated the 
knowledge, attitudes and beliefs of female adolescents (aged 14-16 years, including 
vaccine recipients and non-recipients) about HPV vaccination. Knowledge and 
understanding of HPV, HPV-related diseases and sequelae, and HPV vaccines was 
limited. General vaccine acceptance was high and vaccination was viewed as an 
accepted norm. The responsibility for vaccine decision-making was assigned to the 
parent, and adolescents accepted the parental recommendation with minimal or no 
discussion. Other identified social influences included HCPs, vaccinated peers, and 
group conformity. Adolescents were aware, albeit vaguely, of HPV vaccine 
instability, and discussed how negative media attention (i.e. radio) had resulted in a 
variation in vaccine uptake among family members. While self-efficacy in decision-
making was variable, many adolescents believed that vaccine information should be 
delivered to both vaccinees and their parents. Chapter 6 presented a qualitative 
interview study that investigated the knowledge, attitudes and beliefs of parents of 
female adolescents (aged 14-16 years, including vaccine-acceptors and decliners) 
about HPV vaccination. Once again, general vaccine acceptance was high and 
parents recognised the importance of immunisation. Similar to the adolescents in 
Chapter 5, parents’ knowledge and understanding of HPV, HPV-related diseases and 
sequelae, and HPV vaccines was limited, yet highly variable. Social influences 
included daughters, partners, peers, HCPs, and group conformity. It was identified 
that the burden of healthcare decision-making often lay with the female primary 
care-giver, with male care-givers relying on their partner (or an alternative female) 
for guidance on vaccine decision-making. Parents were aware of HPV vaccine 





documentaries, newspaper articles and online information that reported on alleged 
chronic vaccine side effects. Vaccine-acceptors acknowledged their concerns 
regarding vaccine misinformation but prioritised disease and cancer prevention and 
were reassured by the continued, widespread use of the vaccine and their trust in 
the scientific community. In contrast, vaccine-decliners prioritised the alleged risk 
of vaccine side effects and were reassured inaccurately by a reduced perception of 
HPV and HPV-related disease risk. In Chapters 5 and 6, behaviour change theory 
(TDF, COM-B, and BCW) was applied to suggest interventions strategies to address 
barriers to vaccine uptake.  
The final thesis objective was to design, develop and evaluate a theory and 
evidence-based intervention to improve knowledge and intention to vaccinate. 
Chapter 7 described the design of video-based online behavioural intervention (“Is 
the HPV vaccine for me?”), developed to improve HPV and HPV vaccine knowledge, 
and intention to vaccinate. The intervention was associated with a statistically 
significant improvement in HPV knowledge and intention to vaccinate among 
parent-daughter dyads. In addition, the intervention was found to be affordable, 
practicable, effective (cost-effective), acceptable, safe, and equitable.  
8.3 Interpretation and implications of findings 
The overall aim of this thesis was to explore vaccine decision-making to identify and 
address barriers to vaccine uptake in Ireland. Qualitative methods (e.g. focus 
groups and interviews) collated the opinions of parents of children aged less than 
12 years, parents of adolescents (aged 14-16 years), and female adolescents (aged 





and vaccine-decliners. Quantitative research methods (e.g. survey) assessed 
knowledge and the impact of a theoretically informed intervention to improve 
knowledge and intention to vaccinate (Chapter 7). This combination of research 
methods provided an overview of the vaccine decision-making process and 
identified barriers to vaccine uptake.  
Research in the area of vaccine decision-making is extensive and evolving. Primary 
and secondary studies discussing the barriers to vaccine uptake continue to be 
conducted and published (e.g. [434-437]). These continued research efforts are 
necessary due to the variability of vaccine hesitancy. It is established that vaccine 
hesitancy is context specific, and changes with time, place and the specific nature of 
the vaccine [36, 48, 50]. Therefore, the principal contribution of this thesis has been 
the generation of evidence in an Irish context, with a particular focus on the HPV 
vaccine. The findings from this thesis concur with, and add to, previous studies that 
have described barriers to microneedle-mediated vaccine acceptability [84, 86, 261] 
and HPV vaccine uptake [174, 318, 320-328, 332-341, 344-349].  
8.3.1 Fear as a barrier to vaccine uptake [36] 
8.3.1.1 Needle fear 
It was hypothesised at the thesis outset that needle fear, as a non-monetary 
vaccine cost, is a barrier to vaccine uptake, a hypothesis that has been supported by 
the literature [37, 80, 81, 438]. A systematic review and meta-synthesis has recently 
evaluated the prevalence of needle fear: the majority of children included exhibited 
needle fear, while prevalence estimates for needle fear ranged from 20‐50% in 





been designed to address this problem [82]. Therefore, it was suggested that 
alternative vaccine delivery systems, for example, microneedle patches, could 
remove the barrier of needle fear. However, qualitative research presented in 
Chapter 3, indicated that while microneedle technology offers significant 
advantages over conventional vaccination with a hypodermic syringe (e.g. reduced 
pain and bleeding, increased convenience and ease of administration), the potential 
trauma associated with conventional vaccination methods is not a significant 
deterrent to immunisation [3]. Similarly in the qualitative research presented in 
Chapters 5 and 6, none of the vaccine-decliners included acknowledged needle fear 
as a reason for refusal. This observation is reaffirmed by the fact that participating 
HPV vaccine-decliners had accepted all other vaccines recommended by the 
childhood and school immunisation programmes. Therefore, while it may be a 
contributory factor, needle fear alone is not a significant barrier to vaccine uptake. 
8.3.1.2 Fear of adverse events following immunisation (AEFI) 
An adverse event following immunisation (AEFI) is any untoward medical 
occurrence which follows immunisation and which does not necessarily have a 
causal relationship with the usage of the vaccine [439]. AEFIs are divided into five 
categories: vaccine product-related reaction, vaccine quality defect-related 
reaction, immunisation error-related reaction, immunisation anxiety-related 
reaction, and coincidental event [439]. A vaccine product-related reaction is an AEFI 
that is caused or precipitated by a vaccine due to one or more of the inherent 
properties of the vaccine product e.g. extensive limb swelling following 





is an AEFI that is caused or precipitated by a vaccine that is due to one or more 
quality defects of the vaccine product, including its administration device e.g. 
incomplete inactivation of IPV leading to paralytic polio cases. An immunisation 
error-related reaction is a preventable AEFI caused by inappropriate vaccine 
handling, prescribing or administration e.g. contamination of multi-dose vial leading 
to infection transmission. An immunisation anxiety-related reaction is an AEFI 
arising from anxiety surrounding immunisation e.g. vasovagal syncope during or 
after vaccination. A coincidental event is an AEFI that is caused by something other 
than the vaccine product, immunisation error or immunisation anxiety. Fear of 
several AEFIs was evident throughout this research. Focus group participants were 
concerned that parental administration of microneedle-patch vaccines could be 
associated with reduced efficacy due to inadequate administration training and a 
potential immunisation error-related reaction could occur (Chapter 3). Fear of 
vaccine product-related reactions was also observed in Chapter 3: participants were 
concerned about potential allergenic properties of microneedle-patch vaccines. 
Similarly in Chapters 5 and 6, participants were concerned about unsubstantiated 
HPV vaccine product-related reactions, as described. However, all evidence 
indicates that these reactions were coincidental effects i.e. a temporal association 
rather than a causal link between vaccine administration and the development of 
new onset chronic conditions was established.  
8.3.2 Knowledge as a variable barrier to vaccine uptake 
Lack of knowledge is a documented determinant of vaccine hesitancy [48]. 





necessarily a predictor of vaccine refusal, as limited vaccine-specific knowledge was 
evident across all chapters. Passive conformist vaccine-acceptors were found to 
have limited knowledge, making non-deliberate or automatic vaccine decisions 
based on general vaccine acceptance, a high perception of risk and/or a high level 
of trust in the healthcare system [47]. When there is a realistic perception of 
disease risk and trust in the healthcare system, potential AEFIs are acknowledged, 
but do not negatively impact the vaccine decision. Conversely, where there is a low 
perception of disease risk, and/or a low trust in the healthcare system, the fear of 
these potential AEFIs is more impactful. In Chapter 3, the acceptability of 
microneedle-patch mediated vaccination was explored. In spite of high trust in the 
healthcare system and a true perception of disease risk, unfamiliarity prevailed and 
fear of AEFIs, e.g. allergenic potential, negatively impacted the parental perception 
of the technology. In Chapters 5 and 6, a low perception of disease risk, a low trust 
in the healthcare system and limited knowledge were observed. Therefore 
potential AEFIs exerted a greater effect on the decision-making process. Low 
perception of disease risk is a recognised barrier to vaccine uptake [48]. Sexual 
activity inexperience, participation in screening programmes and a lack of familial 
history of cervical cancer were factors associated with an unrealistically low 
perception of HPV risk, as described in Chapters 4 and 6. Low trust in the healthcare 
system was evident, with vaccine-decliners suggesting that HCPs and governmental, 
and HSE representatives failed to allay vaccine safety concerns. While healthcare 
authorities assess safety concerns and respond to them based on available data, 





creating a risk perception gap [113]. Further to this, individuals tend to focus more 
on avoiding loss (e.g. potential vaccine side effects), than obtaining gain [113].  
8.3.2 Implications for practice 
The crucial role of HCPs in the provision of vaccine information and guidance was 
evident in the findings of this thesis, and throughout the literature [440]. In the face 
of emerging vaccine hesitancy, HCPs still remain the most trusted advisor and 
influencer of vaccine decisions [440]. According to Wellcome Trust’s Global Health 
Monitor, 93% of Irish participants reported that they trusted doctors and nurses, 
85% trusted these HCPs for medical or health advice, and 95% trusted the medical 
or health advice they received [117]. However, research throughout this thesis 
indicates that their potential impact on vaccine hesitancy and vaccine uptake is not 
yet fully realised, with the majority of participants failing to consult their HCP to 
guide their vaccine decision. Research has shown that HCPs often have inadequate 
information or training to address specific vaccine concerns [440]. HCPs who were 
vaccinated themselves, or who vaccinate their own children, were more likely to 
recommend immunisation, providing a reassuring example to concerned patients 
[441, 442]. Information campaigns to increase HCP vaccine knowledge (e.g. 
education courses, talks/meetings, posters, or letters/emails) have been shown to 
increase the likelihood of recommending vaccination [443-445]. Further to 
knowledge provision, communication tools for HCPs have been developed, to 
enable HCPs to engage in difficult discussions with vaccine-hesitant individuals 
[446-449]. Given the context, temporal, and vaccine specificity, of vaccine 





conducted throughout this doctoral thesis, and to evaluate their effectiveness in 
the Irish context.  
The capacity and confidence of HCPs are stretched as they are faced with time 
constraints, increased workload and limited resources. Increasing demands on the 
healthcare system as a direct result of the extension of free GP care to include all 
children under 6 years and all adults over 70 years, combined with an ageing 
population, has had a major impact on the GP workload. In addition there is 
evidence of a significant undersupply of GPs in Ireland [450]. To address this 
shortfall, innovative recruitment and retention strategies are required to 
significantly increase the annual intake into GP postgraduate specialist training 
[450]. To alleviate the pressures in primary care, the role of vaccinating pharmacists 
could be expanded to include paediatric and adolescent immunisation. In October 
2011, legislation was introduced which enabled pharmacists to administer the 
influenza vaccine, and vaccine uptake in the community pharmacy setting has 
increased exponentially [451]. Pharmacist-led vaccination services lead to higher 
vaccination rates, and serve members of the public that have not received 
vaccination before [452]. Pharmacy services were expanded in 2015, to include the 
provision Pneumococcal Polysaccharide and Herpes Zoster vaccination. Pharmacists 
are the most accessible HCPs, with 1.5 million visits by the public to local 
pharmacies per week [452]. With the infrastructure already in situ within 
pharmacies, further expansion of the vaccination services provided by pharmacists 
would permit HCPs, such as GPs to focus on those patients with more complex 





8.3.3 Implications for policy 
Vaccine hesitancy is a concern for the public, HCPs and policy-makers alike. Policy-
makers play a crucial role in influencing whether and to what degree research 
findings influence health services and public health [453]. Research has identified 
the importance of building and strengthening trust in, and within, institutions, with 
a particular focus on the critical support relationship needed between policy-
makers and HCPs, to ultimately build public trust [446, 454]. In tandem with the 
development of CPD programmes to provide HCPs with information to adequately 
address vaccine concerns, existing programmes and policies should be modified to 
train HCPs to engage more confidently with vaccine-hesitant patients. The “Making 
Every Contact Count” programme was established by the HSE in 2016. This online e-
learning platform aims to capitalise on the opportunities that occur daily for HCPs, 
to support chronic disease prevention, and self-management of existing diseases.  
The programme provides a foundation in behaviour change theory and techniques, 
including the underlying principles of a patient-centred approach, and 
demonstrates how to carry out a brief intervention through a suite of realistic video 
scenarios [455]. The programme currently includes modules on smoking, alcohol 
and drugs, healthy eating and active living. Should a module on vaccines be 
included in the programme, HCPs will be prompted and encouraged to discuss 
upcoming vaccines with parents and adolescents, and address concerns expressed 
by vaccine-hesitant individuals.  
The Medicinal Products (Prescription and Control of Supply) (Amendment No.2) 
Regulations 2015 and the Medicinal Products (Prescription and Control of Supply) 





seasonal influenza, pneumococcal polysaccharide and herpes zoster vaccines by 
pharmacists [456, 457]. In light of sub-optimal vaccine uptake rates and the 
overstretched primary care sector, expansion of vaccination services offered by 
pharmacists could be beneficial. A proactive response by the Pharmaceutical 
Society of Ireland (PSI) and the HSE is required to drive legislation for further 
amendments to the aforementioned Regulations, and to negotiate an acceptable 
reimbursement contract for pharmacies. 
Research has demonstrated that presenting pro-vaccination information to adults 
may actually encourage anti-vaccine sentiment, suggesting that, in some, these 
beliefs may be deeply held by adulthood, and therefore parenthood [432, 458]. 
Therefore, there is potentially an opportunity for policymakers to focus educational 
efforts on vaccination in childhood [459]. While schools facilitate the provision of 
immunisation programmes by the HSE, there is a need to include age-appropriate 
vaccine education in the primary and secondary school curricula, to instil positive 
views on vaccination. In 2015, the Department of Education and Skills in Ireland 
launched The Digital Strategy for Schools 2015-2020, providing a rationale and an 
action plan for integrating Information and Communications Technology (ICT) into 
teaching, learning and assessment practices [460]. Several digital resources for 
children’s education on vaccination have already been developed, including comic 
books, videos and games [459]. These resources should complement efforts to 
introduce vaccination education into school curricula, offering education via 
multiple modalities.  
This thesis describes the design, development and evaluation of a theoretically-





vaccinate by parents (Chapter 7). This intervention was based on the findings of a 
comprehensive systematic review [4] and a series of qualitative research studies 
and was found to be affordable, practicable, effective (cost-effective), acceptable, 
safe, and equitable in a feasibility study. Although there is significant evidence that 
theoretically-informed behavioural interventions are effective in changing 
behaviour across multiple contexts, populations and behaviours, such evidence is 
seldom translated to population-level change [188]. This is largely due to the fact 
that behavioural interventions are relatively short-lived, under-funded, or fail, due 
to poor implementation, up-scaling, or translation [461, 462]. Therefore, an effort 
must be made to actively engage with stakeholders including the NIO, and the HSE, 
and outline the human and economic advantages of preventive strategies like 
behavioural interventions, instead of a treatment-focused model of healthcare 
provision [463]. It has been reported that for policy-makers, it is difficult to gain 
access to academic research findings, academic timelines often fail to align with the 
policy process, and preferred forms of evidence differ from academics [464, 465]. It 
is essential for academics to engage in knowledge exchange with policy-makers, 
taking a systematic approach to sharing tacit knowledge. Developing a policy brief is 
an effective strategy for rapidly providing scientific evidence to policy-makers [466]. 
A policy brief is a two page (front and back of a single sheet) document that uses 
graphics and text to summarise the key results of scientific research, and links those 
results to specific policy recommendations [467]. Constructing a policy brief 
compiling the evidence generated throughout the course of this doctoral thesis 
could facilitate effective policy-maker engagement. Finally, due to the geographical 





with local government in these low uptake areas. Local authorities will have a 
vested interest in promoting public health in their constituencies and are more 
likely to engage in academic collaboration.  
8.4 Strengths and limitations 
The individual primary research studies (Chapters 3, 5-7) were designed based on 
the findings of comprehensive reviews of the literature [1, 2, 4]. Systematic reviews 
are the gold standard to search for, collate, critique and summarise the best 
available evidence [468, 469], and are seen as the pillar of evidence-based 
healthcare [362, 470, 471]. The research presented in Chapter 4 adhered to best 
practice recommendations for the conduct and reporting of systematic reviews and 
meta-ethnographic syntheses [317, 468, 472]. The findings of these reviews defined 
the current evidence on the perception and acceptability of vaccination and 
allowed the identification of key gaps in the literature. Subsequently, the research 
studies undertaken were designed to address the aims and objectives of the thesis 
overall, whilst ensuring that these key deficits in the literature were addressed.  
A key strength of this thesis is the mixed methods approach. Chapter 1 provided a 
brief overview of the strengths and weaknesses of quantitative and qualitative 
research methods and the advantages of using a mixed methods approach. The 
findings of the individual quantitative and qualitative components of this thesis are 
complementary. The findings from one study helped in the explanations of 
observations from previous studies and led to the generation of research questions 





has generated deeper insights than could have been elucidated from either method 
in isolation.  
This thesis is the first to formally explore vaccine decision-making to identify and 
address barriers to vaccine uptake in an Irish setting. A major contribution of this 
thesis was the qualitative investigation of the views of adolescents. Research on 
vaccine decision-making has primarily focused on exploring the views of parents 
and HCPs and the voice of the adolescent; the intended vaccinee has been 
neglected in the literature. This thesis highlights the imperative for engagement 
with this cohort.  
A key strength of this thesis is the use of behaviour change theory (TDF, COM-B, 
and BCW) and the systematic approach applied. The TDF provides a theoretical 
basis for understanding and changing behaviour [204]. The framework simplifies 33 
theories and 128 constructs into 14 validated domains, underpinned by 
psychological theory [206]. The capability, opportunity, motivation model of 
behaviour (COM-B) distils the TDF into three domains, that interact to predict 
behaviour and include the individual’s capability, motivation and opportunities for 
the behaviour [204]. The COM-B model guides the choice of intervention functions 
or strategies most likely to achieve behavioural change and forms the central 
component of the Behaviour Change Wheel (BCW) [210]. Within 19 frameworks for 
classifying behaviour change interventions, intervention functions and policy 
categories were discerned to construct the BCW [210]. Additionally, the 
intervention functions have been linked to a taxonomy of 93 Behaviour Change 
Techniques (BCTs), organised into 16 groups [215]. Theory was incorporated from 





and delivery of the intervention (Chapter 7). There is substantive evidence 
supporting the efficacy and effectiveness of theory-based interventions targeting 
behaviour change. This evidence justifies the validity of the research and increases 
its potential impact. While this intervention is vaccine specific, the systematic 
approach permits it’s modification in the design of interventions to promote uptake 
of alternative vaccines. 
The quality and rigour of the research conducted as part of this doctoral thesis is 
evidenced in the number of peer-reviewed academic publications and conference 
presentations achieved. This highlights that the research is of value, of scientific 
merit, of interest to academic and healthcare colleagues. Therefore, dissemination 
of the important findings of this research is already underway. The publication 
strategy targeted a series of multidisciplinary journals with a diverse audience 
including healthcare providers, academics, public health practitioners and policy-
makers [1-4]. Open access publication encouraged broader dissemination [2]. An 
effort will be made to further broadcast the crucial findings of this research to 
parents, vaccinees, HCPs working in clinical practice, public health practitioners and 
policy-makers, to minimise the translation gap. Strategies for research 
dissemination include social media campaigns, podcast and/or blog creation, 
attendance at community meetings and/or seminars, and the development of 
policy briefs, as previously discussed [473, 474].  
An additional strength of this thesis is the topical nature of the research described. 
The issue of vaccine hesitancy is gaining increasing traction and recognition 
amongst HCPs, academics, public health practitioners and policy-makers, amplified 





This thesis provides crucial evidence which can serve as the basis for future 
research.  
Whilst there are numerous strengths associated with this research, a number of 
limitations must also be acknowledged. This research was conducted in the Cork 
and Kerry region, in the south of Ireland and therefore limited to a small 
geographical and limited demographic area. This could be seen to limit the 
generalisability (quantitative) and transferability (qualitative) of the study findings. 
While the healthcare structure and immunisation programme in Cork and Kerry are 
akin to those in place nationally, substantial variation in vaccine uptake is observed 
by area. Therefore, this variation requires further investigation at local level.  
Potential sources of bias associated with each research study were considered and 
attempts were made to minimise the impact of these biases. Bias can be introduced 
at any stage of the research process including selection bias, data collection bias 
and analysis bias. Purposive sampling strategies minimised selection bias, because 
the sample is constantly refined to meet the aims of the study. Furthermore, 
additional participants were continuously recruited into the studies during data 
analysis, until data saturation was reached. However research participants self-
selected, potentially affecting representativeness. Using a topic guide in focus 
group and interview studies minimised the potential for data collection bias. 
Strategies to reduce analysis bias were also used and included: constant 
comparison across focus group and interview transcripts; acknowledging deviant 
cases and outliers; and independent coding and analysis of transcripts by multiple 





8.5 Recommendations for future work 
This thesis has provided an exploration of vaccine decision-making, identifying 
barriers to vaccine uptake in an Irish setting and highlights the implications of this 
research for practice and policy. Therefore, it represents an ideal starting point for 
further research to address these barriers. Further research should investigate the 
following areas: 
1. Exploration of the views of vaccinators (e.g. GPs, GP surgery practice nurses, 
community health doctors, public health nurses, and pharmacists)  
The crucial role of HCPs in the provision of vaccine information and guidance of 
decision-making was repeatedly identified throughout this thesis. However, this 
role is not yet realised. An effort must be made to explore the views of frontline 
vaccinators, to identify their perceived barriers to vaccine uptake, and the 
challenges encountered during immunisation programmes. In addition, before 
the vaccination services in pharmacies are expanded, the views of pharmacists 
on this expansion should be explored. The education needs of vaccinators 
should be assessed, to permit the development of suitable CPD programmes. 
Exploration of the views of vaccinators should take the form of qualitative 
investigations, supplemented by larger, quantitative research, to elucidate 
national views. 
2. Exploration of the views of policy-makers  
The translation of evidence-based research will not translate into effective 
policy without collaboration with policy-makers. Qualitative research with 
policy-makers could identify: potential obstacles to the introduction of vaccine 





individuals or groups who play a major role in decision-making or an influential 
role in the introduction of vaccine policy [475]. As before, large scale 
quantitative approaches are likely to follow initial qualitative methods.  
3. Research on vaccine hesitancy in the Irish context  
Further research on vaccine hesitancy in the Irish context is warranted. The 
framework for such research could be based on the approaches taken in this 
thesis. Furthermore, large scale quantitative study, using validated tools to 
elucidate the prevalence of vaccine hesitancy, and the individual characteristics 
that are associated with hesitancy could further strengthen our understanding 
of the facilitator and barriers of vaccine uptake. Examples of these tools include  
the Global Vaccine Confidence Index [182], the Vaccine Confidence Scale [183], 
and the Parent Attitudes About Childhood Vaccines survey [51]. This would 
facilitate the targeting of interventions to support those most affected. 
4. Exploration of the views of male adolescents and parents of male adolescents 
A gender-neutral HPV vaccination programme was initiated in Ireland in 
September 2019. This thesis focussed on exploring the views of female 
adolescents and parents of female adolescents. It is unknown whether the 
barriers to vaccine uptake identified throughout this doctoral research are 
specific to female vaccination. Therefore qualitative research, in accordance 
with methods already described, is warranted to explore the views of male 
adolescents and their parents. 
5. Assess the impact of the intervention in a variety of contexts  
The context-specificity is well established. Therefore, while our intervention to 





small sample of parent-daughter dyads, its impact will need to be evaluated in 
alternative contexts (e.g. different demographics). Given the geographic 
variation of HPV vaccine uptake in Ireland, it would be beneficial to evaluate the 
impact of the intervention in areas reported low rates e.g. Kerry [172].  
6. Assess the impact of the intervention in parent-son dyads 
With the recent inclusion of male adolescents in the HPV vaccination 
programme, there is a need to assess the impact of the intervention in parent-
son dyads, in accordance with procedures outlined in Chapter 7. 
7. Systematic review to guide intervention scale-up 
Potential operational frameworks for intervention scale-up should be identified 
by a systematic review. This could provide evidence-based guidance to policy-
makers and funding-agencies.  
8. National dissemination of intervention 
With guidance from identified stakeholders (i.e. qualitative research 
participants, vaccinators, and policy-makers), the intervention could be 
disseminated nationally. Potential dissemination strategies include sharing the 
video on social media, broadcasting the video on television, or embedding the 
video on influential websites e.g. the NIO [476].  
By conducting the aforementioned research steps, a comprehensive overview of 
vaccine decision-making will be provided and the barriers to vaccine uptake 
perceived by all key stakeholders will be elucidated i.e. policy-makers, vaccinators, 
and members of the public. These systematic barriers may then be addressed, to 












Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Research: Primary  
Data collection and analysis: Qualitative  
Participants: Parent, guardian, caregiver 
Intervention: Female adolescent* HPV 
vaccination 
Research: Secondary e.g. review articles 
Data collection and analysis: Quantitative 
Participants: Non-parent, guardian, caregiver 
Intervention: Male adolescent HPV vaccination, Adult HPV 
vaccination 
 






Sample search strategy  
 
Papillomavirus vaccines (MeSH) OR HPV vaccin* OR human papillomavirus vaccin* 
AND 
perception* OR view OR views OR viewpoint OR accepta* OR knowledge OR belief* OR attitude* 
(AB Abstract) 
OR 
perception* OR view OR views OR viewpoint OR accepta* OR knowledge OR belief* OR attitude* 
(TI Title) 
 
Sample MEDLINE search strategy, conducted on 14th November 2016. 
Search strategy for other databases: as for MEDLINE using index terms and 





Appendix 4.3  
ENTREQ Statement 
1 Aim To determine the views of parents regarding adolescent human 
papillomavirus (HPV) vaccination. 
2 Synthesis methodology Meta-ethnography was chosen as the synthesis methodology as it 
employs a process of comparison and cross-interpretation between 
studies while preserving the context of the primary data, providing a 
higher level of analysis, generating new research questions and 
duplicating duplication of research. 
3 Approach to searching A comprehensive search strategy was developed to retrieve all available 
articles related to the research question. 
4 Inclusion criteria Inclusion and exclusion criteria are outlined in Appendix 4.1. 
5 Data sources Electronic databases: MEDLINE, CINAHL and EMBASE, from inception to 
December 2016. 
Grey literature: Google Scholar. 
Hand searching: Reference lists of included citations. 
6 Electronic search strategy Electronic search strategy outlined in Appendix 4.2. 
7 Study screening methods The titles and abstracts of retrieved citations were assessed by one 
reviewer (SM). Full articles were retrieved for all potentially relevant 
articles. These articles were reviewed by three reviewers (SM, LS and AF) 
and were included if they fulfilled the inclusion criteria. Any disagreement 
regarding the eligibility of particular studies was resolved through 
discussion with a fourth reviewer (AM). 
8 Study characteristics Study characteristics outlined in Appendix 4.4. 
9 Study selection results The study selection process in outlined in Figure 13. 
10 Rationale for appraisal The rationale for appraisal was to assess the quality of the included 
studies. 
11 Appraisal items The CASP tool was used to appraise the included studies. 
12 Appraisal process The appraisal was conducted independently by three reviewers and 
consensus reached through discussion. 
13 Appraisal results Appraisal results are summarised in Appendix 4.5. 
14 Data extraction Three reviewers (SM, LS and AF) carefully and repeatedly read the 
included studies and independently identified the key concepts from 
information detailed in the results and discussion sections of the studies. 
These included both first-order (views of participants) and second-order 
interpretations (views of authors). In tandem with this process, SM 
recorded individual study characteristics. These included study 
objective(s); sample size; participant demographics; vaccine availability; 
methodology; country in which research was conducted and year of 
publication, 
15 Software QSR International’s NVivo V.11 
16 Number of reviewers Three reviewers (SM, LS and AF) were involved in reading all included 
studies and constructing the key concepts. Four reviewers (SM, LS, AF and 
AM) were involved in the translation and synthesis steps.  
17 Coding Line by line coding to search for concepts. 
18 Study comparison The data was compared and contrasted across primary studies, to identify 
similarities and differences. Five key concepts that reflected the principal 
findings of all studies were determined. 
19 Derivation of themes The process of deriving the themes and sub-themes was inductive, 





20 Quotations Direct quotes from study participants and the interpretations of the 
authors are provided in Appendix 4.7. 
21 Synthesis output The translations in each key concept were synthesised to develop novel 
third-order interpretations. These third order interpretations were linked 
using a ‘line of argument’ to develop a conceptual model which 
represents parental views regarding adolescent HPV vaccination (Figure 






Individual study characteristics 












To describe Latina mothers’ acceptance of the HPV 
vaccine for their daughters and explore their knowledge 
base regarding HPV-related issues 
Mothers of daughter(s) 7-









To explore the decision-making process among parents 
of girls eligible for HPV vaccination 
Parents of daughter(s) 
eligible for vaccination  
(n=48) 
  Interview Thematic Peru 2012 
Cooper 
Robbins [320] 
To explore knowledge about HPV and HPV vaccination 
post-implementation of the national school-based HPV 
vaccination programme 
Parents of daughter(s) 12-
16 years  
(n=38) 
  Interview Thematic Australia 2010 
Cover  
[321] 
To explore reasons for HPV vaccine acceptance or non-
acceptance and to ascertain the process by which 
parents make their decision 
Parents of daughter(s) 








Thematic Vietnam 2012 
Craciun  
[322] 
To explore the experience of Romanian mothers with 
the HPV vaccine, to identify their perceptions and 
attitudes towards the HPV vaccine and to understand 
their reasons for accepting or rejecting HPV vaccination 
for their daughters 
Parents of daughter(s) in 







Thematic  Romania 2012 
Dela Cruz  
[323] 
To identify HPV vaccination barriers, motivators, and 
brochure preferences among parents of teens in Hawaii 
Parents of daughter(s) 11-
18 years  
(n=20) 






To investigate the reasons why mothers accepted or 
declined HPV vaccination for their daughters 
Mothers of daughter(s) 
11-17 years  
(n=52) 







To address HPV vaccine barriers and facilitators 
Parents of daughter(s) 
who are age-eligible for 
the HPV vaccine 
(Cambodian descent) 
(n=37) 
  Focus group Thematic USA 2010 
Friedman  
[326] 
To identify HPV vaccine communication and 
mobilization needs, to understand HPV vaccine-related 
perceptions and concerns of male and female caregivers 
in four rural communities in western Kenya 
Caregiver of daughter(s) 
9-12 years  
(n=56) 




To examine actual HPV vaccination decision-making 
processes 
 
Mothers of daughter(s) 
13-27 years  
(n=10) 
  Interview Grounded theory USA 2015 
Gordon  
[174] 
To explore attitudes to HPV vaccination in British Jewish 
mothers who had recently made a decision about 
vaccinating their daughter in the context of the national 
vaccination programme 
Parents of daughter(s) 12-
13 years 
(n=20) 
  Interview Framework analysis UK 2011 
Gottvall  
[328] 
To explore how  parents reason when they accept HPV 
vaccination for their young daughter and their views on 
HPV-related information 
Parents of daughter(s) 11-
12 years  
(n=27) 






To explore the factors influencing mothers’ decisions to 
vaccinate 11-12 year old daughters against HPV, 
including understanding of and attitudes about HPV 
vaccination, interactions with others about HPV 
vaccination, and media/marketing exposure and 
mothers’ and daughters’ perspectives about  HPV 
vaccine related decision-making 
Mothers/primary female 
guardians of daughter(s) 
11-12 years  
(n=32) 
  Interview Framework analysis USA 2012 
Haesebaert 
[330] 
To assess mothers’ acceptance of HPV vaccination for 
their 14-18 year old daughters and determinants of that 
acceptability 
Parents of daughter(s) 14-
18 years  
(n=32) 
  Interview Content analysis France 2012 
Hamlish  
[331] 
To examine in-depth motivations and barriers to HPV 
vaccination among African-American mothers and their 
Mothers of daughter(s) 9-
18 years 





vaccine-eligible adolescent daughters (n=19) 
Harries  
[332] 
To explore key challenges and opinions towards HPV 
vaccination introduction in South Africa 
Parents of daughter(s) 
eligible for HPV 
vaccination  
(n=43) 






To understand decision-making at the point of care 
Mothers of daughter(s) 
11-18 years  
(n=20) 






To explore attitudes to HPV vaccination among black 
and Asian mothers living in Britain 
Parents of daughter(s) 
<16 years  
(n=20) 




To assess Hispanic mothers’ and girls’ perceptions about 
cervical cancer, HPV and the HPV vaccine 
Parents of daughter(s) 11-
17 years  
(n=24) 
  Focus group Grounded theory USA 2013 
Mupandawana 
[336] 
To explore factors influencing UK based African parents’ 
acceptance or decline of the HPV vaccine, whether 
fathers and mothers share similar views pertaining to 
vaccination and any interfamily tensions resulting from 
differing views 
Parents of daughter(s) 8-
14 years  
(n=10) 
  Interview Thematic analysis UK 2016 
Niccolai  
[337] 
To explore parents’ attitudes and beliefs about STI and 
cancer prevention in the context of HPV vaccination 
Parents of daughter(s) 10-
18 years  
(n=38) 






To investigate the feasibility and acceptance of a school-
based HPV programme 
Parents of daughter(s)  
(n=32) 
  Focus group Grounded theory USA 2015 
Olshen  
[339] 
To improve understanding of parental acceptance of the 
HPV vaccine 
Parents of daughter(s) 10-




Content analysis USA 2005 
Paul  
[340] 
To assess STI-related knowledge and HPV specific 
vaccine awareness and acceptability 
Parents of daughter(s) 
<18 years  
(n=36) 
X Interview Coding matrix India 2014 
Perkins  
[341] 
To identify the rationale by parents/guardians and 
providers for delaying or administering HPV vaccination 
to girls 
Parents/guardians of 
daughter(s) 11-17 years  
(n=124) 







To explore low-income, minority parents’ attitudes, 
intentions, and actions with regards to HPV vaccination 
for their daughters 
Parents of daughter(s) 11-
18 years  
(n=76) 
  Interview 





To learn what people knew about cervical cancer and 
HPV vaccination, whether they would find HPV 
vaccination acceptable, and how they viewed vaccine 
delivery and consent procedures 
Parents of daughter(s) 11-











To describe attitudes and social and environmental 
factors that affect African American parents’ intent to 
vaccinate their daughters against HPV 
Parents of daughter(s) 9-
17 years  
(n=30) 




To determine the knowledge, attitudes and beliefs 





  Focus group Grounded theory USA 2013 
Siu 
[346] 
To investigate the perceptions of Hong Kong mothers in 
regard to vaccinating their daughters against HPV 
Mothers of daughter(s) 9-
17 years  
(n=35) 






To identify recently immigrated Haitian mothers’ beliefs 
about HPV vaccination and cultural factors that 
influence their willingness and resistance to having their 
daughters vaccinated 
Mothers of daughter(s) 
11-18 years (Haitian 
descent)  
(n=31) 
  Interview Thematic analysis USA 2013 
Waller 
[348] 
To explore mothers’ attitudes towards vaccination 
Parents of daughter(s) 8-
14 years  
(n=24) 
X Focus group Framework  analysis UK 2006 
Wong 
[349] 
To assess the mother’s knowledge and attitudes toward 
HPV vaccination 
Parents of daughter(s) 
eligible for vaccination  
(n=47) 













































     ?     High 
Craciun  
[322] 
   ?  ? ?    Moderate 
Dela Cruz  
[323] 
     ?     High 
Dempsey 
[324] 










     ?     High 
Getrich 
[327] 
     ?     High 
Gordon  
[174] 
       ?   High 
Gottvall  
[328] 







     ?     High 
Haesebaert [330]      ?     High 
Hamlish  
[331] 
     ?     High 
Harries  
[332] 
     ?     High 
Hughes  
[333] 
     ?     High 
Marlow  
[334] 
          High 
Morales-Campos 
[335] 
     ?     High 
Mupandawana 
[336] 
          High 
Niccolai  
[337] 
          High 
Nodulman  
[338] 
     ?     High 
Olshen  
[339] 
  ? ?  ?     Moderate 
Paul  
[340] 










     ?     High 
Remes 
[343] 





          High 














     ?     High 
Waller 
[348] 
     ?     High 
Wong 
[349] 










Occurrence of concepts and sub-themes 










































































































































































































          
 
        
 
    
 
    
 
       
    
    
General vaccine 
acceptance  
      
    
  
 
      
    
  
    
    
 
    
    
    
Financial savings 
 
    
    
  
                         
Lack of access to 
treatments  
  
      
  
                        
Vaccine hesitancy 




      
  
 
    





Trust in HPV vaccine 
           
    
                    
HPV vaccine use 
elsewhere    
  
       
  
     
  
               
Access to HPV /vaccine 
        
  
 
    
   
  

















































































































































































































                
 
    
    
  
Safety and efficacy                                  
Side effects                                  
Experimental vaccine                                  
Conspiracy theory                                  
Watchful waiting                                  
Engage in risky 
behaviour 
                                 
Fears of HPV and cancer                                  
Anticipated regret                                  
Unknown partner sexual 
history/activity  















































































































































































































Limited knowledge                                  
Insufficient 
knowledge to 
make a decision 
                                 
Lack of 
understanding 
                                 
Young age                                  
Limit health 
literacy 




























































































































































































































                
 




   
Poor provision of 
information 
                                 
Perception of risk                                  
Low perception of risk                                  
HCP endorsement                                  
Opinion of healthcare 
system 





                                 
Impact of media                                  
Impact of peers                                  
Impact of family                                  
Personal experience 
of HPV and HPV 
related illnesses 
                                 
Market as a cancer 
vaccine 
                                 












































































































































































































Protection                                  
Societal responsibility                                  
Defer responsibility                                  
Control over 
healthcare decisions 
                                 
Encourage sexual 
activity 
                                 
Difficult conversation 
topic 
                                 
Requirement for 
parental consent 






First (italicised) and second (non-italicised)-order interpretations 
First author 
 Is prevention better than cure? The fear of the unknown Limited knowledge and 
understanding 
Complex decision-making process Parental responsibility 
Bair  
[318] 
 The main theme provided by 25 





“I would vaccinate her but not 
until it is tested on other 
persons and proven that the 
vaccine functions correctly and 
that there are not any types of 
risks.” 
“I do not know anything. I am 
undecided because I would like to 
be more informed about vaccine, 
to get more information.” 
Most mothers viewed their children as 
susceptible to HPV in their teenage years. 
“We are giving them 





 Vaccines are a well-recognised and 
accepted form of prevention. 
“I heard somewhere that you 




Some parents mentioned that 
they did not have enough 
information to make the 
decision. 
The decision-making was influenced by the 
context-particularly the way in which 
vaccination was offered, the follow-up by 
the health personnel, the commitment 
shown by the teaching staff. 
“If your husband didn’t 
agree? They didn’t give her 
the vaccine, because if 
something happened to her 
it was my responsibility.” 
Cooper Robbins 
[320] 
 “It’s lumped in, it’s another 
vaccination in the blue book-you do 
this at age 2, at age 5 you do this, I’ve 
never questioned the blue book.” 
“It says it only helps prevent 
four HPV diseases and there’s a 
hundred or more, so it doesn’t 
seem very effective.” 
 
The core theme, lack of 
knowledge represents the 
confusion experienced by 
participants, resulted from 
limited understanding about a 
complex topic. 
  Some parents explained 
their lack of knowledge by 
the tendency to defer 




 “Immunisation is the best way of 




Vaccine safety and side effects, 
suspicion and misconceptions 
about the HPV vaccine, and 
concerns related to the age of 
the girl and her risk of cervical 
cancer. 
 “I was advised by my doctor so I took the girl 
to get vaccinated. It is because I saw many 




  The vaccine was represented as 
an experiment serving the 
commercial interest of 
pharmaceutical companies. 
 
Most did not understand how 
the vaccine works and how it is 
linked to cervical cancer 
prevention. 
If the doctor is trusted in general, than 
his/her recommendation of the vaccine will 
play an important role in the vaccination 
decision. 
As mothers they felt 
responsible for their 
children’s health and take 





Dela Cruz  
[323] 
  “I’m planning on vaccination 
them but maybe I think like a 
lot of other parents that I’m 
seeing, ‘Well, it’s kinda early’” 
 The physician’s recommendation to 
vaccinate and willingness to educate parents 
about the vaccine are very important to a 




 …wanting to protect against or 
prevent cervical cancer. 
“I don’t want her to fall into a 
category where she gets this 
done and then ten years down 
the line they find that it reacts a 
different way” 
 
Concerns were related to a 
feeling that they personally 
lacked the knowledge needed to 
make an informed decision about 
HPV vaccination for their 
daughter, or that the medical 
establishment in general lacked 
sufficient knowledge about HPV 
vaccines to ensure safety. 
Among mothers accepting the vaccine, the 
most commonly identified reasons for this 
decision were…perceiving that their 
daughter was at high risk for acquiring 
HPV…personal experience with HPV 
infection or HPV-related diseases…strong 
physician recommendation for HPV 
vaccination. 
 
“I figured now is the best 
time because it’s a time 
that I can make the 
decision for her and I 
wanted to make sure she 
was protected before there 
was any chance of her 
becoming sexually active” 
Do 
[325] 
 “Prevention is better than treatment. 
It costs less and saves time” 
 
“It is new. What if you get the 
shot and die” 
 
We found that very few of our 
Cambodian focus group 
participants were aware [of HPV 
infection and vaccination]. 
“I am concerned about those who work, 
have children, and do not have health 
insurance. Their income is little, and having 
to get their daughters vaccinated may cause 
financial hardship” 
…indicated that this was 
the type of topic that they 





Participants identified cultural beliefs 
as potential challenges to 
vaccination, particularly among the 
elderly, traditional herbalists and 
some men/fathers, who distrust 
vaccines or do not belief in 
preventive health services. 
“There are people in the 
community who are fond of 
spreading rumours. They may 
inform the parents that their 
children are only being used for 
research purposes and the 
vaccine would be no use to their 
children” 
Widespread ignorance about 
cervical cancer and the vaccine 
emerged as primary barriers to 
vaccination.  
Community mobilisation and sensitisation 
were seen as critical for raising cervical 
cancer awareness; prompting demand for 
vaccination; and helping overcome stigma. 
The vaccine was seen as a 
way to protect children 
from a disease associated 




 “Do I want my kid to have a vaccine? 
Are vaccines good?” 
 “I heard that it prevents…I don’t 
know…but it does help with 
different cancers and stuff” 
 
 
…concern about their daughters’ sexual 
health was raised because of behaviours of 
their older siblings, such as drug use and 
teenage pregnancy, as well as their own 
experience with sexually transmitted 
infections, childhood sexual abuse, early 




“Now at least I know she’s 
protected from that. There 
are so many illnesses 
because of sex that you 









 Most mothers described the 
importance of vaccines being safe, 
effective and necessary to protect 
against common or severe diseases, 
but vaccinating their children was 
generally seen as ‘part of the 
routine’. 
Most of the mothers who 
declined vaccination were also 
concerned about the safety of 
HPV vaccination given that it 
was relatively “new” and 
“untested”. 
I don’t think it can be caught and 
therefore I don’t feel that I have a 
communal responsibility to 
accept the vaccine, whereas I 
would do if it was something that 
is based on a majority having it in 
order for it to be successful and 
work” 
“I was just about to say yes, and then there 
was the scare, that a girl died in the 
Midlands and that’s what stopped me” 
 
 
…although they hoped their 
daughters would lead a 
particular lifestyle, they 
were not able to ‘control’ 
or ‘predict’ their behaviour, 
and it was therefore better 
to protect them. 
Gottvall  
[328] 
 Many had accepted the other 
vaccines offered in the child 
vaccination programme and were 
positive to vaccines in general. 
 
“…if I say no to the vaccine and 
she gets sick, I would never be 
able to forgive myself” 
 
 
Many parents felt they had 
limited knowledge about the 
vaccine. 
“I thought it was a pretty hard decision. I 
thought that I got quite insufficient 




Most parents had their 
daughter vaccinated 
against HPV for her future 
health, but some also felt a 
responsibility to vaccinate 




 The most commonly noted health 
benefit of HPV vaccination was its 
potential to prevent cervical cancer. 
“I think that if you don’t 
vaccinate ‘em now and then 
they’re 30 years old and end up 
with cervical cancer, then you 
would so regret not giving her 
that chance to prevent it” 
Some of these beliefs about 
vaccine safety and efficacy…were 
inaccurate: one mother stated 
that once she “got the 
knowledge that it protected them 
for life”, she was in agreement. 
Exposure to media and marketing about HPV 
vaccines played a key role in mothers’ 
decisions to vaccinate in the following ways: 
by raising their awareness of HPV and HPV 
vaccines, reassuring them if the benefits of 
vaccination, triggering discussions with their 
daughters, and prompting them to seek out 
more information about HPV and HPV 
vaccination. 
“I know that HPV is a pretty 
common STD. The vaccine 
is available. I believe in 
protecting my kids 
whenever possible” 
Haesebaert [330] 
 …vaccination offered the opportunity 
of preventing a severe and potentially 
fatal disease, namely CC (cervical 
cancer), in their daughters. 
Undecided and opposed 
mothers justified their position 
by the fact that we have little 
experience of the vaccine to 
look back on and by fear of side 
effects with what is a new 
vaccine. 
…few mothers had a detailed 
recollection of the information 
provided. 
The key role played by physicians is 
illustrated…”He told me not to vaccinate my 
daughter”. 
14.1% preferred to rely on 
their physician’s decision 
and waited to know his 
opinion and 7.0% preferred 




 Mothers demonstrated an emotional 
conviction to prevent the trauma and 
pain of CD (cervical dysplasia)/CC 
(cervical cancer). 
Mothers’ disease narratives 
focussed on CD/CC as the 
source of trauma, uncertainty, 
anxiety, fear and pain. 
Limited health literacy and 
knowledge of HPV make 
mothers vulnerable to doubt, 
despite a strong conviction to 
immunize their daughters. 
Mothers waited for a clear, unambiguous 
message from their doctor; a message that 
resembled the certainty doctors expressed 
for other vaccines. 
Mothers regarded HPV 
immunisation as a window 
of opportunity to protect 
their daughters and reduce 







 “Prevention is better than cure” “Many a time we use vaccines 
that are not the same standard 
as first world countries…Are 
they going to give us a cheaper 
vaccine with more side effects 
which we only see in 30 years?” 
Overall knowledge of cervical 
cancer was either poor or 
anecdotal and the causal 
relationship between HPV and 
cervical cancer was unknown 
amongst all participants. 
“The children in our community are very 
sexual active because they are already 




  “I probably just want to know 
more about it and what the 
risks are…it’s new to me…so I 
need more education on it” 
“I just don’t think they need to 
right now, at 13…it’s young” 
“I don’t think she need [HPV vaccine] at this 
time. I guess it’s for girls that’s having 
sex…and I know my daughter and she’s not 
into that right now” 
“She doesn’t  really have a 





When asked to talk about vaccine 
decision-making process for their 
children, most of the mothers 
described it as ‘automatic’ and 
something they just did without too 
much thought. 
“It’s something new and 
people, well I for one am fearful 
of something new.” 
 
Many of the mothers from both 
black and Asian backgrounds 
found it difficult to understand 
the reasons for giving HPV 
vaccination at 12/13 years of age.  
…mothers said they spoke to other family 
members and friends about vaccinations, in 
particular those who already had made 
vaccination decisions for their own children 
as opposed to friends who did not have 
children because they would be “just as 
inexperienced.” 
“…but we live in this 
country, you don’t know 
what environment we live 




 …perceived protection and 
prevention as the main benefit of the 
vaccine. 
“Because science is just 
invention…but my daughter is 
not going to be a rabbit for 
invention.”  
Mothers…who had heard of HPV 
and the vaccine had limited 
knowledge about HPV. 
“So I told him [the doctor] that he could not 
give her an injection just because they told 
me so. I wanted information…to know why 
and for what I was giving her that injection. 
And since they did not give it to me, I didn’t 
vaccinate her.” 
“…a way that I, as a mother 
can protect my daughter is 
vaccinating her. I say, I am 
going to protect her more 
than just talking.”  
Mupandawana 
[336] 
 Previous vaccination rumours and 
scandals such as the MMR also 
influenced vaccine decline. 
“Let them vaccinate their own 
children first, then after 20 
years if nothing happens, we 
will also vaccinate our own.” 
…even though they had received 
the information, it was as though 
there wasn’t much 
understanding of the 
information, as most of the 
parents continued to believe that 
only promiscuous and sexually 
active girls should be vaccinated. 
It was evident from most of the participants 
that the fathers were the ultimate decision-
makers in most issues pertaining to the 
family and especially the children. 
“People must know that if 
they do this thing [consent 
to vaccination], they are 
giving their daughters a 





 “Because neither one of them are 
good. They’re both bad. It, it kills two 
birds with one stone [cancer and 
STIs]” 
 
…one chose to defer 
vaccinations for her daughters. 
“I’ve heard of it; I’ve heard the 
name but I don’t know what it 
is…I’ve heard people talk about it, 
but I don’t know how it gets 
passed on or what it is.” 
Parents…discussed personal or family 
experiences with cancer as motivations to 
vaccinate their children. 
…they viewed vaccination 








 “It prevents HPV supposedly.” Many of the parents of girls did 
not believe that the vaccine 
had been studied sufficiently 
and/or they wanted to know 
more about the vaccine before 
they allowed their daughters to 
be vaccinated. 
“I am so confused.” Some parents did not think the vaccine was 
necessary because, according to them, their 
daughters were too young to be thinking 




 Parents held favourable views about 
vaccines their children currently 
receive. 
Parents were concerned about 
major side effects. 
“What is it? If I have HPV, what 
will I have, an infection?” 
Physician recommendations weighed heavily 
on parental views of vaccines. 
“I can’t imagine how I 
would explain to this kid 
what this vaccination is…” 
Paul  
[340] 
 Parents understood that vaccines 
were important “to have good health, 
to keep children healthy, and prevent 
disease.” 
…most common barriers to 
vaccination were…side effects… 
None of the participants knew 
about the HPV vaccine. 
Most parents were willing to vaccinate their 
children against HPV, especially with a 




 “It is important for her to get the HPV 
vaccine ‘cause it can prevent cervical 
cancer. I just wanted my daughter to 
have every chance not to get HPV.” 
“I’d rather my child die of 
cervical cancer than her die of 
me giving her a vaccine.” 
Several parents did not 
understand the rationale for 
giving HPV vaccination in 
advance of sexual debut. 
“When [the doctor] said it to me it wasn’t 
like, your daughter should have this, it was 
like this is an option. It’s like, do you want 
tea or coffee.” 
“Just thinking, in the long 
run, anything that would 
protect from any cancer 
down   the road just 
seemed to make sense.” 
Perkins 
[342] 
 “If it’s going to help prevent them 
from getting cervical cancer, why 
shouldn’t they get it?” 
“Probably in a few years’ time I 
will think differently about [HPV 
vaccine]. By then kids who have 
received it, they would have 
monitored, and they would 
know if there are any long-term 
effects, you know, and the 
reactions to those 
vaccinations.” 
…only 53% knew that HPV was a 
sexually transmitted infection, 
and only 39% knew that HPV 
caused genital warts. 
“She is going to be sexual at some point and 
I would rather have her protected than get 
infections or diseases.” 
…parents struggled with 
how to protect their 
daughters from HPV while 
still asserting that they 




 Almost all adults said they would 
allow their daughters to be 
vaccinated since “prevention is better 
than cure.” 
They feared side effects; 
especially whether the vaccine 
would have a potential effect 





“The disease you are talking 
about; we are completely in the 
dark about it.” 
 
“I know the government cannot do 








  “If there is a 50/50 chance that 
it [HPV] would leave my child 
handicapped or something, that 
would turn me off.” 
Parents expressed reluctance to 
vaccinate girls as young as nine 
years old. 
Men and women agreed that the final 
decision about HPV vaccination for their 
daughter’s was most often made by 
mothers, with father consultation as the 
mother perceived necessary. 
Most parents felt that the 
child could express feelings 
and concerns about 
vaccination, but ultimately 





  “If you got the shot you might 
get it [cancer].” 
Participants had low levels of 
knowledge and misconceptions 
about details of HPV. 
Resource issues within the clinic were 
identified…parents noted providers not 
recommending the vaccine or lengthy 




 “Vaccines are made from viruses. 
Therefore, I believe it is not good to 
have too many vaccinations. After all, 
a vaccine is a foreign material, and 
this material can make your body 
weak.” 
The HPV vaccine was a new 
vaccine to all participants. They 
expressed doubt and hesitation 
about its safety. 
Most of the participants had little 
understanding or knowledge 
about HPV and its potential 
danger to women’s health. 
“I have never thought about taking my 
daughter to be vaccinated. It is too early for 
her.” 
Participants worried that 
vaccinating their daughters 
could convey the message 
that they were allowed and 




  “People are always testing-
testing on us [Haitians].” 
 
“I have no heard of this.” 
 
The mothers stated they would prefer 
receiving HPV vaccine information from their 
physician…physicians would provide them 
with accurate information and would 
understand their personal and cultural 
values regarding their daughters’ sexual 
health. 
Many of the women were 
concerned that discussing 
HPV with their daughters 
meant having to address 
sexual health issues. 
Waller 
[348] 
 “…but if there’s a vaccine that’s going 
to prevent them from getting 
anything that I wouldn’t want them 
to get or they wouldn’t want to have, 
then yeah, definitely.” 
 
The main concern raised about 
vaccination was the possibility 
of side effects, both immediate 
reactions and longer-term 
problems. 
None of the women had heard of 
HPV before taking part in the 
focus group. 
Some women felt that the need for 
vaccination against STIs would depend on 
the individual characteristics of the child. 
One woman thought she might be more 
concerned if her daughters were “messing 
around with the local boys.” 
“You also don’t want 
children to become 
complacent and think ‘Well, 
I’ve been vaccinated, I’ll 
just go out now and I’ll…’” 
Wong 
[349] 
 “Prevention is better that cure.” “Since the vaccine is new, we 
want to know how well it has 
been tested, is it really 
effective? Since it is 
recommended to girls at such a 
young age, is it really safe? 
How many people have taken 
The link between HPV and 
cervical abnormalities was poorly 
understood even among those 
who had heard of HPV. 
“It depends on upbringing of the children.” 
 
They were more likely to vaccinate their 
children at early age if their daughters show 
signs of high-risk sexual behaviour; 
otherwise they preferred to hold 
immunisations. 
“You won’t understand a 
mother’s feeling…as a 
mother; I will give this 
vaccine to my daughter 
simply because she is my 
chid, so that she is 





this vaccine in our country?” 
 
There were controversies over 
whether the vaccine has been 
researched enough to know its 
long term safety and efficacy. 
disease.” 
 
Most of them wanted to do 
the best they could to 











What are your opinions of the HPV vaccine? 
Would you like to share your opinions? 
We are looking for teenage girls (14-16 years) to take part in a focus group 
Your participation would involve one session lasting approximately 90 minutes 
For more information about this study, or to volunteer for this study, please contact: 
Sarah Marshall 
Phone: 0851309228 or Email: s.marshall@umail.ucc.ie 
This study has received ethical approval from the Social Research Ethics Committee, UCC 






Informed Consent for Research Participants 
Purpose of the study 
I am a community pharmacist currently undertaking a PhD in Clinical Pharmacy in UCC. The research is 
concerned with determining the opinions of female adolescents on vaccines, with a particular focus on the 
adolescent human papillomavirus (HPV) vaccine. 
What will the study involve? 
The study will involve participation in one focus group lasting 90 minutes. The focus group will be made up 
of approximately six participants. 
Why have you been asked to take part? 
Your daughter has been asked to take part as she is a teenage girl (14-16 years). We are hoping to 
examine knowledge, attitudes and beliefs surrounding vaccines from an adolescent point of view. 
Do you have to take part? 
Participation is voluntary. If you provide permission to participate, you will be asked to sign the attached 
consent form. You may withdraw at any stage, including mid-session and up to two weeks after data has 
been collected, even if you have given consent to participate. If you wish to withdraw, you may contact 
me directly via phone (0851309228) or email (s.marshall@umail.ucc.ie). At this stage, any identifiable data 
will be immediately destroyed. 
Will your participation in the study be kept confidential? 
Your daughter is being asked to take part in a focus group. For this reason complete confidentiality and 
anonymity is not possible as information is shared with other individuals in the group, with me and with 
my research supervisors. However, I will ensure that no clues to your daughter’s identity will be published 
in the thesis. Any extracts that are quoted in the thesis will remain anonymous.  
What will happen to the information which you give? 
The focus groups will be audio-recorded. I will transcribe and anonymise the recordings. The transcript will 
be reviewed and verified by my supervisors, at which point the recording will be destroyed. The written 
data will remain confidential for the duration of the study. On completion of the thesis, the data will be 
retained for a further ten years before it will be destroyed. 
What will happen to the results? 
The results will be used to design an intervention to reduce vaccine hesitancy in adolescents. They will 
also be presented in the thesis, which will be available to future students. They may be published in a 
research journal.  
What are the possible disadvantages of taking part? 
I do not envisage any disadvantages to your taking part. If you agree to allow your daughter to participate, 
her contribution is voluntary and she will not be pressurised to speak. Should you or your daughter have 
any issues after completion of the focus group, I would encourage you to contact me in confidence to 
discuss your distress. 
Who has reviewed this study? 
The University College Cork Social Research Ethics Committee has reviewed and approved this study. 
Any further queries? 
If you need any further information, you can contact me, Sarah Marshall via phone (0851309228) or email 
(s.marshall@umail.ucc.ie)  
 







Informed Consent Form 
 
I.......................give permission for my daughter……………….to participate in Sarah Marshall’s research study. 
The purpose of this study has been explained to me in writing. 
I am participating voluntarily. 
I give permission for focus group participation to be tape-recorded. 
I understand that I can withdraw from the study, without repercussions, at any time, whether before it 
starts or while I am participating. 
I understand that I can withdraw permission to use the data within two weeks of the focus group, in which 
case the material will be deleted. 
I understand that anonymity will be ensured in the write-up by disguising my identity. 
I understand that disguised extracts from my interview may be quoted in the thesis and any subsequent 
publications if I give permission below: 
Please tick one box 
 □ I agree to quotation/publication of extracts from my focus group                      
 □ I do not agree to quotation/publication of extracts from my focus group       
   
 
Signed ……………………………………………                                                      Date …………………… 
 
















What do you think about vaccines? 
Do you usually follow vaccine recommendations?   
What do you know about HPV? 
What do you know about the HPV vaccine? 
What do you think happens if you get the HPV vaccine?    
What do you think happens if you do not get the HPV vaccine? 
How important do you think it is to get the HPV vaccine? 
I want you to remember what it was like when you were offered the HPV vaccine… 
How did you feel when you were asked to get the HPV vaccine? 
How easy or difficult is it to understand HPV vaccine recommendations? 
Do you think you were capable of making your own vaccine decision? 
Did you listen to the opinions of others when you were making your HPV vaccine decision? If so, who were 
these people? 
How important were their opinions and did they affect your vaccine decision? 
What information is needed when you are making a vaccine decision? 
Where do you look for this information?  
If internet is mentioned: what websites do you use? 
Did you find it difficult to determine how reliable this HPV vaccine information was? 
How difficult was it for you to find HPV vaccine information? 
Imagine a friend of yours is undecided about getting the HPV vaccine, what would you say to her? 
HPV vaccination rates in Ireland are quite low… 
What is stopping girls from getting vaccinated? 






Consolidated Criteria for Reporting Qualitative Studies (COREQ) checklist [380] 
Domain 1:  





Personal Characteristics   
1. Interviewer/Facilitator SM Methods 
2. Credentials MPharm, MPSI Title Page  
3. Occupation 
Pharmacist  
Clinical pharmacy researcher 
Methods 
4. Gender Female Methods 
5. Experience and training Experience in conducting qualitative research Methods 
Relationship with participants   
6. Relationship established SM was not known to the participants Discussion 
7. Participant knowledge of 
interviewer 
Participants were aware that Author 1 was a 
pharmacist 
Discussion 
8. Interviewer characteristics 
Pharmacist and clinical pharmacy researcher, with 





Theoretical framework   
9. Methodological orientation 
and theory 
Focus groups using the TDF, BCW and BCTTv1 Methods 
Participant selection   
10. Sampling Purposive sampling Methods 
11. Method of approach 
Recruited school Principals invited eligible participants 
to participate 
Methods 
12. Sample size 50 adolescents participated in 10 focus groups Results 
13. Non-participation 12.66% recruitment rate Results 
Setting   
14. Setting of data collection School grounds Results 
15. Presence of non-participants Only SM and participants were present N/A 
16. Description of sample Appendix 5.6 Appendix 5.6 
Data collection   
17. Interview guide TDF-based topic guide, with a semi-structured design Appendix 5.4 
18. Repeat interviews Repeat interviews were not conducted N/A 
19. Audio/visual recording Focus groups were audio-recorded Methods 
20. Field notes No field notes were taken N/A 
21. Duration Focus groups had a mean duration of 36 minutes  Results 
22. Data saturation 
Focus groups were conducted until no new themes 
emerged 
Methods 
23. Transcripts returned Transcripts were not returned N/A 
Domain 3: 
Analysis and Findings 
  
Data analysis   
24. Number of data coders SM, LS, AF Methods 
25. Description of the coding 
tree 
Transcripts were analysed by inductive thematic 
analysis, with constant comparison methods applied 
throughout.  
Methods 
26. Derivation of themes The codes were attributed to the domains of the TDF Methods 





28. Participant checking Participants did not provide feedback on findings N/A 
Reporting   
29. Quotations presented Quotations are presented Results 
30. Data and findings consistent 
There was consistency between data presented and 
the findings 
Results 
31. Clarity of major themes The codes were attributed to the domains of the TDF 
Methods and 
Results 



















Focus Group Participants (n) Age (years) Vaccination Status Pobal HP Description (2016) County 
1 3 15 1 Vaccinated  
2 Not vaccinated 
Marginally below average Cork 
2 8 15-16 Vaccinated Marginally below average Kerry 
3 7 15-16 Vaccinated Disadvantaged Cork 
4 5 15 Vaccinated Marginally below average Cork 
5 4 16 Vaccinated Marginally below average Cork 
6 4 15-16 Vaccinated Marginally above average Cork 
7 5 15-16 Vaccinated Marginally above average Cork 
8 5 15-16 Vaccinated Marginally above average Cork 
9 4 15-16 Vaccinated Affluent Cork 







TDF-based interview topic guide 
 
What do you think about vaccines? 
Do you usually follow vaccine recommendations?   
What do you know about HPV? 
What do you know about the HPV vaccine? 
What do you think happens if someone gets the HPV vaccine?    
What do you think happens if someone does not get the HPV vaccine? 
How important do you think it is to get the HPV vaccine? 
How did you feel when you were offered the HPV vaccine for your daughter? 
How easy or difficult was it to understand HPV vaccine recommendations? 
Did you listen to the opinions of others when you were making the HPV vaccine decision for your daughter? If 
so, who were these people? 
How important were their opinions and did they affect your vaccine decision? 
What information was needed when you were making the vaccine decision? 
Where did you look for this information? (If internet is mentioned: what websites did you use?) 
Did you find it difficult to determine how reliable HPV vaccine information was? 
How difficult was it for you to find HPV vaccine information? 
Imagine a friend of yours is undecided about getting the HPV vaccine, what would you say to her? 
What is stopping girls from getting vaccinated? 
How do you think the Health Service Executive (HSE)* should deal with the low vaccination rates? 
 
*Health Service Executive (HSE): responsible for the implementation of the primary childhood, school 







Purposive sampling strategy and recruitment 
A list of second level schools (n=67) and education centres (n=12) in the Cork/Kerry 
region of Ireland was compiled. This included those enrolled in the Delivering 
Equality of Opportunity in Schools (DEIS) programme. This programme supports 
children who are at greatest risk of educational disadvantage. School principals 
were contacted by telephone or email and provided with details of the study. The 
principal then approached individual parents to identify potential participants. 
Inclusion criteria included self-declared satisfactory English language and parent or 
caregiver/guardian of a female adolescent aged 14-16 years. It was highlighted to 
parents that participation was voluntary and no incentive to participation was 
offered. When a parent expressed an interest in participating, the primary 
researcher followed up with a telephone call or email to arrange a convenient time 






Consolidated Criteria for Reporting Qualitative Studies (COREQ) checklist [389].  
Domain 1:  
Research team and reflexivity 
 Location in 
manuscript 
(Section) 
Personal Characteristics   
33. Interviewer/Facilitator SM Methods 
34. Credentials MPharm, MPSI Title Page (journal 
submission) 
35. Occupation Pharmacist  
Clinical pharmacy researcher 
Methods 
36. Gender Female Methods 
37. Experience and training Experience in conducting qualitative research Methods 
Relationship with participants   
38. Relationship established SM was not known to the participants Methods 
39. Participant knowledge of 
interviewer 
Participants were aware that SM was a pharmacist Methods 
40. Interviewer characteristics Pharmacist and clinical pharmacy researcher, with 





Theoretical framework   
41. Methodological orientation 
and theory 
Semi-structured interviews using the TDF  Methods 
Participant selection   
42. Sampling Purposive sampling Methods and 
Appendix 6.2 
43. Method of approach Recruited school principals informed eligible 
participants 
Methods 
44. Sample size n=13 Results 
45. Non-participation N/A  
Setting   
46. Setting of data collection Location convenient for the participant Methods 
47. Presence of non-participants Only SM and participant were present Methods 
48. Description of sample Appendix 6.4 Appendix 6.4 
Data collection   
49. Interview guide TDF-based interview topic guide Appendix 6.1 
50. Repeat interviews Repeat interviews were not conducted Methods 
51. Audio/visual recording Interviews were audio-recorded Methods 
52. Field notes Field notes were recorded by SM Methods 
53. Duration Duration ranged from 10 to 43 minutes (average 
duration of 21 minutes) 
Results 
54. Data saturation Francis method was used to determine when data 
saturation had been reached 
Methods 
55. Transcripts returned Transcripts were not returned Methods 
Domain 3: 
Analysis and Findings 
  
Data analysis   
56. Number of data coders 
 





57. Description of the coding 
tree 
Transcripts were analysed by inductive thematic 
analysis, with constant comparison methods applied 
throughout.  
Methods 
58. Derivation of themes The codes were attributed to the domains of the TDF Methods 
59. Software QSR International’s NVivo V.11 Methods 
60. Participant checking Participants did not provide feedback on findings N/A 
Reporting   
61. Quotations presented Quotations are presented Results 
62. Data and findings consistent There was consistency between data presented and 
the findings 
Results 
63. Clarity of major themes The codes were attributed to the domains of the TDF Results 







Characteristics of interview participants (n=13) 














P1 F 40-49 14 ISCED level 3 2 Declined 
P2 F 50-59 15 ISCED level 3 2 Accepted 
P3 M 40-49 15 ISCED level 3 2 Accepted 
P4 F 40-49 16 ISCED level ≥4 2 Accepted 
P5 F 40-49 14 ISCED level 3 2 Declined 
P6 F 40-49 14 ISCED level ≥4 4 Accepted 
P7 F 30-39 15 ISCED level 2 2 Accepted 
P8 M 50-59 15 ISCED level 3 2 Accepted 
P9 M 40-49 15 ISCED level 3 2 Accepted 
P10 F 50-59 14 ISCED level ≥4 > 4 Declined 
P11 F 40-49 16 ISCED level ≥4 2 Accepted 
P12 F 40-49 15 ISCED level 3 1 Accepted 
P13 F 40-49 14 ISCED level ≥4 2 Declined 
 
*Highest education level 
 ISCED level 1: Primary education, equivalent to 8 years official State education 
 ISCED level 2: Lower secondary education: Irish Junior/Inter Certificate, equivalent to 11 years official State 
education   
 ISCED level 3: Upper secondary education: Irish Leaving Certificate, equivalent to 14 years official State 
education 
 ISCED level ≥4:  Higher Education including post-secondary non-tertiary education, short-cycle tertiary 
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